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ABSTRACT 
PURPOSE: Prior to genetic characterization, “breast cancer” was considered a uni-
form diagnosis and was treated in a standardized and uniform way. The discovery of 
the disease’s heterogeneity in recent years led to the subsequent development of a 
multitude of new drugs and drug combinations. Since every breast cancer patient 
has to be considered unique, with each tumor behaving in a distinctive manner, 
treatment selection should be just as singular. This is why a diagnostic tool to acc u-
rately predict the treatment efficacy of each tumor would be a key factor in this deci-
sion-making process. Ideally, this assay should replicate each component involved in 
tumor treatment and progression with a minimum of confounding factors.  
A three-dimensional breast cancer cell culture model was proposed and introduced, 
generated from patient biopsy material that includes cancer cells as well as the sur-
rounding tumor microenvironment on an individual patient level.  
The aim of this prospective study was to predict treatment response in breast cancer 
patients receiving neoadjuvant chemotherapy by using the in vitro breast cancer 
spheroid model. We propose that the predictive potential of such an in vitro model 
system may simplify in the decision, which drugs or drug combination are most help-
ful in the treatment of patients on an individual basis.  
PATIENTS AND METHODS: Three-dimensional spheroids were generated from 
fresh tumor biopsies of 78 primary breast cancer patients eligible for neoadjuvant 
drug treatment. Cell survival following 96 h in vitro exposure to the clinically equiva-
lent therapeutic agents was measured using a standard metabolic assay. Treatment 
results were correlated with pathological complete response (pCR, i.e. ypT0 ypN0) 
determined following the completion of chemotherapy. The sensitivity and specificity 
of the collected variables was quantified using receiver operator characteristic (ROC) 
analysis and compared according to the accuracy of predicting pCR.  
RESULTS: A mean cell survival of 21.8% was found in the breast cancer spheroid 
model for 22 patients with pCR. The mean cell survival in vitro was 63.8% in 56 pa-
tients without pCR (p =.001). The area under the ROC curve to predict pCR was 
0.86 (95% CI: 0.77 to 0.96) for cell survival in vitro compared to 0.80 (95% CI: 0.70 
to 0.90) for a combined model of conventional factors (hormone- and HER2 receptor, 
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and age). A cutoff at 35% cell survival in the spheroid model was proposed. Out of 
the 32 patients with values below this threshold, 20 patients (62.5%) and one patient 
(1.8%) with a cell survival of >35% achieved pCR respectively; sensitivity 95.5% 
(95% CI: 0.86 to 1.00); specificity 80.4% (95% CI: 0.70 to 0.91). In addition, extent of 
residual disease (ypT) was significantly associated with increased cell survival (p < 
.001).  
CONCLUSION: The high rate of patients without pCR means that roughly two thirds 
of the patients may have undergone suboptimal chemotherapy and emphasizes the 
need for a pre-screen in vitro model to improve chemotherapy success. The breast 
cancer spheroid model proved to be a highly sensitive and specific predictor for pCR 
after neoadjuvant chemotherapy in breast cancer patients. 
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ZUSAMMENFASSUNG 
EINLEITUNG: Vor der genetischen Charakterisierung wurde Brustkrebs als einheitli-
che Erkrankung betrachtet, die mithilfe von ungerichteten, standardisierten  Metho-
den behandelt worden ist. Dies schien nach dem  damaligen Verständnis der beste 
Ansatz zu sein, um die bestmöglichen Heilungschancen zu erzielen. Die Erforschung 
der zugrundeliegenden Heterogenität und die daraus folgende Entwicklung einer 
Vielzahl neuartiger Medikamente und Kombinationstherapien, legte zudem nahe, die 
therapeutische Herangehensweise zu überdenken. Jede Patientin ist einzigartig und 
jeder Tumor verhält und entwickelt sich nach einem individuellen Muster. Demzufol-
ge sollten die diagnostischen Tests zur Vorhersage des Ansprechens einer Therapie 
ebenso auf einer individuellen Basis beruhen.  Im Idealfall sollte ein Test die einze l-
nen Komponenten und Systeme der Tumorentwicklung, mit einem Mindestmaß an 
konfundierenden Faktoren, möglichst vollständig wiederspiegeln und beinhalten  
Dreidimensionale Zell-Kultur-Modelle bestehenden aus Patienten-eigenem Gewebe 
repräsentieren die heterogenen Zellpopulationen und einzelne Komponenten des 
Tumormicroenvironment wieder. Im Gegenteil zu einem Model aus einem zweidi-
mensionalen Monolayer Assay wird hierbei die ursprüngliche Tumorachitektur ohne 
den Einfluss des murinen Microenvironment beibehalten.  
Ziel dieser prospektiven Diagnostik-Studie war die Untersuchung der Prädiktivität 
eines in vitro Brustkrebs-Sphäroid-Models bei neoadjuvant behandelten primären 
Brustkrebs-Patientinnen.  
PATIENTEN UND METHODIK: Von 78 primären Brustkrebs-Patientinnen, die auf-
grund von klinischen Faktoren potentiell für eine neoadjuvante Chemotherapie ge-
eignet erschienen, wurden aus entnommenen Biopsien zur Diagnosestellung 3D 
Sphäroide generiert. Nach einer Inkubationszeit von 48 Stunden mit der geplanten 
Kombination zytostatischer Wirkstoffe und entsprechender Lösungsmittelkontrolle, 
wurde die metabolische Restaktivität mittels eines standardisiertem ATP oder MTS 
Assay gemessen. Die gewonnenen Werte wurden anschließend mit klinischen und 
histologischen Faktoren (pathologische Komplettremission, ypT0/ypN0) nach erfolg-
reichem Behandlungsende und anschließender Operation, miteinander verglichen.  
Zusammenfassung [German] 
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ERGEBNISSE: Der Vergleich von 22 Patientinnen mit und 56 ohne pCR, zeigte eine 
mittlere metabolische Restaktivität von 21.8% im Gegensatz zu einem Mittelwert von 
63.8% bei Patientinnen mit verbleibendem vitalen Tumorgewebe (p =.001).  Der er-
mittelte area under the curve Wert in einer ROC Analyse ergab 0.86 (95% CI: 0.77 – 
0.96) für die metabolische Restaktivität im Sphäroid-Modell. Im Vergleich dazu be-
trag die AUC eines multifaktoriellen Models aus konventionellen klinischen Faktoren 
bestehend aus Hormon- und HER2-Rezeptorstatus, sowie Alter bei Erstdiagnose 
0.80 (95% CI: 0.70 – 0.90).   
Aus den gesammelten Daten wurde ein Trennwert von 35 % metabolische Restakti-
vität ermittelt um individuelle Patienten mit vollständigem und unvollständigem Be-
handlungserfolg zu differenzieren. Insgesamt 32 Patientinnen erreichten einen Wert 
unter diesem Trennwert, 20 Patientinnen (62.5%) aus dieser Subgruppe zeigten 
ebenfalls eine Komplettremission. Eine Probe mit einem Wert oberhalb 35% zeigte 
ebenfalls pCR, was eine Sensitivität von  95.5% (0.86 – 1.00) und Spezifität von 
80.4% (95% CI: 0.70 – 0.91) des Sphäroid-Modells ergab. Analyse der zusätzlichen 
Ausgangsfaktoren ergab eine ebenfalls signifikante Korrelation der Daten des Sphä-
roid-Modells und des Umfangs der residualem Tumoranteile (ypT, p < .001). 
SCHLUSSFOLGERUNG: Das Sphäroid-Modell erwies sich als hoch spezifischer 
und sensibler Prädiktor für pCR bei neoadjuvant behandelten Brustkrebs-
Patientinnen. Zum einen werden die individuellen Eigenschaften eines Tumors be-
rücksichtigt und zum anderen stimmen die ermittelten in vitro Behandlungswirksam-
keit mit den klinischen Ergebnissen überein. 
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INTRODUCTION 
Due to an increasingly aging population, the number of women diagnosed with 
breast cancer has continually increased, especially in western countries where it re-
mains the most common type of cancer to afflict women [1, 2]. Mortality rates in 
women are second only to lung cancer, with especially high rates found in develop-
ing countries [3]. Overall prognosis has, however, continually improved as a result of 
emerging treatment options, and a more in depth understanding of the underlying 
tumor biology. Today, a diagnosis of breast cancer is no longer considered the death 
sentence it once was, and is increasingly viewed as a chronic illness for the majority 
of patients. Epidemiological data have reported 5-year survival rates between 93 – 
100%. However, there remain to be patients with rapid tumor progression and poor 
long-term prognosis. For example the 5-year survival rate of advanced or metasta-
sized breast cancer currently lies around 22% [4, 5]. Identifying these susceptible 
patient subgroups and selecting the most effective drug treatment is a main goal of 
current research today. In order to do this several aspects of the disease and its 
treatment must be identified and considered as detailed in the following sections.  
Characterizing tumors of the breast 
The breast consists of several layers of tissues and structures, the main components 
are fatty and glandular tissue. Different phases of development (childhood, puberty, 
pre- and post-menopause) and pregnancy are associated with differences in tissue 
consistency and makeup due to changes in hormone production [6]. Figure 1A-C 
show confocal images of normal breast tissue taken from a postmenopausal woman 
[7]. Malignant tumors originating in the breast most commonly stem from the epithe-
lium of the glandular tissues, consisting of lobules or ducts. Invasive ductal carcino-
ma is the predominant histological type of breast cancer and is collectively referred 
to as “invasive breast cancer of no special type” (NST)  [8, 9]. The lobular histology, 
found in approximately 10% of cases, is distinctly different in comparison to tumors 
with NST histology and has an overall worse prognosis. Differences were observed 
in metastatic pattern (primary visceral metastasis), lower rate of pathologic complete 
response, and a higher incidence of multifocal and contralateral tumors [10-12]. Fig-
ure 1D-F show microscopic images of sections taken from an invasive lobular carci-
noma. Both ductal and lobular neoplasms can also occur as precursor lesions (duc-
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tal carcinoma in situ DCIS, lobular carcinoma in situ LCIS), which are considered a 
risk factor in developing invasive cancer [13, 14].  Less frequent histological types 
are classified according to WHO criteria [15]. In one and the same tumor, a hetero-
geneous pattern of histological subtypes may be found [16-18].  
 
Figure 1: Confocal images of normal breast tissue A-C antibody staining using collagen IV (red) and DAPI (green). A) 20x 
magnif ication B) 40x magnif ication of a lobule with adjacent ducts. Connective tissue is seen in the surrounding area and fatty 
tissue is not stained at all. C) 20x magnif ication of a duct leading to lobules. Green stained cells in the surrounding area are 
f ibroblasts. D-F show  tissue from a lobular carcinoma stained using DAPI (green) and tenascin (red). D) Control section nega-
tive for tenascin showing tissue without invasive components. E) Positive red stain indicating cancerous stroma surrounding a 
lobule. F) Typical cell formation for lobular carcinoma aligned in single-row  at 20x magnif ication.  
 
The initial histopathological analysis is done using microscopic tissue sections from 
small core or fine-needle biopsies, or surgical tissues which are stained using 
hematoxylin and eosin. Additional immunohistochemistry markers may be further 
used to distinguish between benign and malignant lesions (e.g. myoepithelial mark-
ers), as well as determining the histologic type (e.g. E-cadherin).  
During the microscopic analysis of the cancerous tissue the grade of differentiation is 
also determined. Long-term studies have shown that the grade of differentiation is 
highly associated with overall survival (OS). Well differentiated (G1) tumors show a 
D E F
A B C
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better prognosis compared to poorly differentiated ones (G3) [19]. In breast cancer 
the majority of tumors is moderately (G2) or poorly differentiated [20, 21].   
The tumor biology is characterized via the steroid hormone receptors (HR) status, 
consisting of the estrogen (ER) and the progesterone receptor (PR). Both receptors 
are part of the subfamily 3 of the nuclear receptors, more specifically ERs are part of 
the ER-like, and PR of the 3-ketosteroid receptors groups. One or both are overex-
pressed in approximately 70% of tumors [22]. George Beatson first made the asso-
ciation between ER overexpression and cancer in the 19th century following obser-
vations of changes in tissue composition in lactating livestock. He later went on to 
successfully treat breast cancer patients by removing the tubules and ovaries [23]. 
Analyses of the prognostic implications showed that patients with ER positive (ER+) 
tumors have a lower rate of recurrence compared to patients with ER negative (ER-) 
tumors, independent of other clinical factors associated with prognosis [24, 25].  
ER and PR are both expressed as two subtypes ɑ and β, which may combine to 
form homo- and heterodimers. Both ER subtypes seem to have an opposing effect 
on carcinogenesis. The ERɑ receptor is associated with resistance to antihormonal 
treatment and estrogen-induced proliferation, while ERβ has been shown to limit pro-
liferation and invasiveness of cancer cells through its influence on ERɑ regulated 
genes [26]. For each ERɑ and β subtype, several isoforms have been identified. In a 
recent publication a low ERβ1 and high ERβ2 expression was associated with higher 
risk of recurrence in patients with ERɑ positive tumors following endocrine therapy 
[27].  
The expression of the PR is induced by estrogen and characterizes an intact ER sig-
naling pathway. PR may also effect ERɑ action, although the exact modes of co-
regulation, as well as the implications for endocrine therapy are  not yet fully clear 
[28, 29]. PR positive (PR+) tumors, similar to ER+ tumors, show a better prognosis 
than negative tumors (PR-). Tumors that are both ER+/PR+ have a better response 
to endocrine therapy and patients an overall improved prognosis [30].  
The hormone dependency found in the majority of tumors has resulted in the devel-
opment of effective antihormonal or endocrine treatment. The cutoff to distinguish 
between hormone receptor positive (HR+) and negative (HR-) tumors is set at 1% 
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immunoreactive cells, and a decision for an endocrine drug strategy is made accord-
ingly [31].  
An additional subset of 15-30% of patients is characterized by HER2 receptor over-
expression (HER2+), a condition that results in an especially aggressive type of 
breast cancer [32, 33]. The HER2 receptor, also referred to as receptor tyrosine-
protein kinase Erb-B2, is composed of an extracellular and a transmembrane region 
with a cytoplasmic tyrosine kinase domain. The HER2 receptor, as well as others of 
the same protein family (HER1, HER3, and HER4) is overexpressed in several solid 
tumors such as ovarian and gastric cancer, as well as neurodegenerative diseases 
[34]. However, out of these four ErbB-receptors only HER2 remains in a constant 
state of activation [35]. Several pathways are activated by HER2 receptor signaling, 
including the mitogen-activated protein kinase (MAPK), phosphatidylinositol-4, 5-
bisphosphate 3-kinase (PI3K, through binding with HER3), and signal transducer 
and activator of transcription (STAT) pathways. Cellular growth and differentiation 
are also stimulated [36, 37].  
Through mRNA characterization two additional HER2+ breast cancer subtypes 
where recently identified: the HER2 enriched and luminal subtypes, each with a 
prevalence of 50% [38]. The HER2 receptor has proven to be a valuable target for 
specifically designed drugs, and its discovery marks a major milestone in cancer 
treatment (i.e. trastuzumab, pertuzumab, TDM-1, etc., see section below) [39].  
Test results for receptor overexpression via protein expression analysis are grouped 
according to number of receptors per cell, percentage of positive cells, and the de-
gree of membrane staining. Tumors are scored 0, 1+, 2+, or 3+ with a score of 3+ 
indicating a medical need for anti-HER2 therapy, whereas a score of 0 or 1+ does 
not (HER2-). Additionally tests using in situ hybridization methods, mainly FISH,  are 
required for a score of 2+ in order to quantify the number of HER2 genes per tumor 
cell [40]. Some researchers argue that patients with a score of 1+/2+ might profit 
from anti-HER2 therapy as well, especially in patients with a score of 2+ regardless 
of the results from FISH analysis [41]. 
Ki67 is a nuclear protein that has only recently been included in the initial assess-
ment of the tumors, and is currently under discussion as a biomarker for tumor pro-
liferation. This protein can be found in dividing cells during the active phase of the 
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cell cycle but not during the G0 phase. The percentage of positive stained cells 0 – 
100%) is sometimes referred to as the Ki67 labelling index. A threshold to differenti-
ate between low, medium, and high proliferating tumors has been proposed, but cur-
rent guidelines recommend that Ki67 should best be used as a continuous variable. 
Luminal A and B (both HR+ and HER2 negative) are breast cancer subtypes that are 
separated through a low (luminal A), or high (luminal B) Ki67 index. Nearly all con-
ducted studies have shown some prognostic and predictive relevancy of Ki67 [25, 
42]. However, Ki67 is only predictive of treatment outcome in the neoadjuvant chem-
otherapy setting, not for survival following adjuvant therapy. The cause may be an 
underlying heterogeneity in tumor biology in the previously conducted studies. It has 
been proposed that on one hand some highly proliferative tumors respond well to 
treatment, thus leading to a good prognosis.  On the other hand, highly proliferative 
tumors with a poor response to neoadjuvant therapy lead to a bad prognosis. Tu-
mors with a low Ki67 expression tend to be associated with a good prognosis.  This 
observed interaction between treatment response and proliferation serves as an ex-
planation for the observed differences in the prognosis for individual patient sub-
groups. While a statistical relevance for Ki67 continues to be found in many clinical 
trials, there is still an ongoing discussion regarding the ideal clinical implementation 
of this biomarker. Problems such as intraobserver variability and intratumeral heter-
ogeneity have prevented Ki67 from being fully validated.  In addition, the immuno-
histochemistry procedure (MIB-1 antibody) used to quantify Ki67 has not been 
standardized [42, 43].  
The molecular characterization of tumors was first proposed with the discovery 
BRCA1 and BRCA2 genes in the 1990s and some two decades later BRCA3 [44]. 
These genes were identified while studying families where breast cancer was 
passed onto female family members with a higher frequency compared to idiopathic 
cases. In their normal function, the BRCA genes are implicated in the repair mecha-
nism of damaged DNA. The genes lose their original tumor suppressor function in 
the mutated form, leading to the development of invasive breast cancer in around 5-
10% (BRCA1 and 2) and 0.3% (BRCA3) of cases. The likelihood for the develop-
ment of ovarian cancer is also increased 10 to 30 fold in women who carry these 
mutations. Sporadic tumors with triple negative tumor biology (HR- and HER2-) 
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share characteristics with these hereditary tumors and are referred to as  
“BRCAness” [45]. 
Aside from the germline BRCA mutations, a genetic characterization by the Human 
Cancer Genome Atlas has revealed somatic mutations associated with breast can-
cer [46, 47]. Some of the up-regulated genes in invasive ductal cancer are TP53, 
PIK3CA, GATA3, and MAP3KI [46]. Based on these finding, a cluster of four molecu-
lar subtypes was proposed by Perou et al.: Luminal A (ER+ and/or PR+, HER2-, low 
Ki67); Luminal B (ER+ and/or PR+, HER2+ or HER2- with high Ki67); Basal-like (ER, 
PR-, HER2-); HER2 enriched (ER, PR-, HER2+) [48]. The luminal A subtype has 
shown the highest prevalence with 30-70% of all cases, luminal B and basal-like 
rank second with respectively 10-20% and 15-20% each. The HER2 enriched sub-
type is the least frequent with only 5-15% of all cases. The prognosis for these sub-
types varies with luminal A and B having the highest 10-year OS rate of circa 90% 
and 88% respectively. Basal-like which share some similarities with serous ovarian 
cancer have the lowest survival rate of 75%, slightly below the HER2 enriched sub-
type (77%) [49-52].  
The clinical and genetic characteristics of triple negative tumors (ER-, PR-, and 
HER2-) largely overlap with the above described basal-like molecular subtype. How-
ever, both groups are not identical and only 71% of triple negative tumors are also 
basal-like [53]. A recent cluster analysis of genetic data has suggested an additional 
subdivision of triple negative tumors into basal-like 1, basal-like 2, 
immunomodulatory, mesenchymal, mesenchymal stemm-like, and luminal androgen 
receptor [54].  
Proteomic analysis, mainly done using immunohistochemistry (IHC) or 
mass-spectrometry may offer valuable insight into the differences in protein expres-
sion and/or additional modification (phosphorylation, acetylation, ubiquitination, etc.) 
between different breast cancer subtypes, as well as intrapatient differences be-
tween normal and malignant tissue [55]. The same applies for data obtained on the 
small-molecule composition (metabolomics) or the analysis of mRNA 
(transcriptomics) [56, 57]. The combination of several methods of characterization 
into one systems approach (proteomics, metabolomics, transcriptomics, and ge-
nomics) is currently a very promising area of interdisciplinary research. Through an 
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increasingly smaller subcategorization of breast cancer patients, these newer meth-
ods could lead to increasingly refined drug targets and treatment strategies. Howev-
er, these methods are currently not fully validated for reproducible biomarker/patient 
subgroup identification. Reliability also remains a critical issue, especially when new 
antibodies are used. The massive amounts of data collected in these analyses pre-
sent major statistical and bioinformatics challenges.  
Chemotherapy 
Early treatment mainly relied on radical and oftentimes crippling surgical techniques 
to treat breast cancer. Today, treatment may include surgery, radiation, and/or drug 
treatment [58, 59]. Due to years of extensive clinical and basic research, three ap-
proaches to drug treatment have evolved: cytotoxic chemotherapy, endocrine thera-
py, and targeted therapy.  
The accidental discovery of the cytostatic effects of mustine, an analogue of mustard 
gas, was the first use of a chemical compound in treating cancer. In the following 
years other alkylating drugs (cyclophosphamide), as well as folate antagonists 
(methotrexate) were discovered to have an antineoplastic effect. Additional sub-
stance groups are antimetabolites, anti-microtubules, topoisomerase inhibitors, as 
well as drugs with antibiotic effect [60, 61]. The efficacy of the applied drug or com-
bination of drugs often depends on the disease stage, tumor biology, or prior cyto-
static treatment [62-64]. In addition, the mode (oral vs intravenous) and timing (num-
ber/length of the applied treatment cycles) may vary. 
Treatment may be administered with curative or palliative intention. The central aim 
of palliative treatment is to improve the quality of life for the patient by minimalizing 
secondary tumor symptoms such as pain and discomfort. Breast cancer patients with 
potentially curable disease receive chemotherapy either in the adjuvant (following 
surgery) or in the neoadjuvant setting (prior to surgery) with proven equivalent out-
come regarding disease-free survival (DFS) and OS [65, 66]. The EORTC trial 
showed similar results using FEC combination treatment 
(5-FU+Epirubicin+Cyclophosphamide) [67]. Neoadjuvant therapy was initially rec-
ommended for patients with large and locally advanced, as well as inflammatory 
breast cancer considered inoperable at diagnosis. Using a neoadjuvant approach the 
number of cases with breast conserving surgery instead of mastectomy has vastly 
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improved. Another advantage is a direct in vivo observation of the cytostatic effect of 
the applied substances through tissue or imaging analysis during the course of the 
treatment. When the disease and treatment setting allow, a tissue sample may be 
obtained before, shortly after beginning, and following treatment completion for a 
longitudinal analysis of molecular and protein data. For example, a study conducted 
in 2007 found a significant correlation between consistently high levels of Ki67 during 
neoadjuvant endocrine treatment and poorer prognosis [68]. Other factors such as 
GATA3 mutation and reduced DUSP4 expression were likewise discovered to be 
associated with resistance to endocrine and standard chemotherapy [69, 70].  
Primary endpoint for neoadjuvant therapy is pathologic complete response  (pCR), a 
potential surrogate marker for survival. The current overall rate of pCR lies around 
20-30% [71, 72]. In a clinical trial pCR and/or survival endpoints may be recorded. 
Survival can be measured as the time between the end of treatment until death from 
any cause (OS), or until the disease or symptoms of the disease return 
(DFS)/worsen (progression-free survival, PFS). Pathologic complete response is de-
fined as no remaining tumor (ypT + ypN0) or non-invasive lesions (ypT0/is + ypN0) 
in breast and lymph nodes. The association with event-free survival (EFS) and OS is 
less clear when positive lymph nodes (ypT0/is + ypN0/+) or microinvasive tumor re-
siduals (ypTis/mic + ypN0/+) are included. However, using pCR as a surrogate for 
survival remains controversial since a significant correlation on an individual patient-
level has only been found for luminal B/HER2-, HER2-enriched, and triple negative 
disease. A trial-based level of correlation between the two parameters has not yet 
been verified [49, 71].  
Most chemical based cytostatic drugs target the frequently observed high rate of pro-
liferation characteristic for tumor cells by interfering with the cell cycle, thus leading 
to a stagnation of tumor growth. Depending on the drug or drugs being administered 
side effects such as cardiotoxicity, alopecia, inflammation of the intestines, anemia, 
and immune weakness may occur. Cardiotoxicity is most frequent in patients receiv-
ing antibiotic chemotherapy drugs called anthracyclines, especially doxorubicin [73, 
74]. PEGylated liposomal-encapsulated (Caelyx®) and non-pegylated liposomal dox-
orubicin (Myocet®) were developed to reduce these side effects. Significantly im-
proved rates of treatment-induced cardiotoxicity were found for both substances, 
although a high rate of hand-foot syndrome was observed in patients receiving 
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Caelyx®. The combination of Myocet®, paclitaxel, and trastuzumab was found to 
achieve a pCR rate of 40% in women with HER2+ tumors, with few observed side-
effects [75].  
Anthracyclines are produced by genetically altered Streptomyces through fermenta-
tion. Compounds from this substance group have four different modes of action 
against tumor cells: through a) DNA intercalation, which prevents the replication of 
DNA and RNA, b) stabilization of the topoisomerase II complex, which is responsible 
for separating the DNA double helix during replication and causing the breakdown of 
DNA, or c) the production of free oxygen radicals [74]. In breast cancer, 
anthracycline-based combination treatment, mainly including epirubicin or doxorubi-
cin, are a central component of nearly every chemotherapy regimen [76]. Results 
obtained in the NSABP B-18 study showed that adjuvant or neoadjuvant application 
of anthracycline-based chemotherapy is equivalent regarding prognosis [65, 66]. In 
addition, the ADEBAR Study showed that a higher dose of anthracycline (i.e. 
epirubicin) does not increase the rate of observed toxicity [77, 78].  
The compound doxorubicin also belongs to the topoisomerase inhibitors and is fre-
quently combined with cyclophosphamide, an alkylating agent [79]. These com-
pounds act by directly binding an alkyl group of the DNA and by crosslinking DNA 
strands, thereby interrupting DNA synthesis via P53 [80, 81]. Cyclophosphamide is 
considered a pro-drug and is enzymatically processed into phosphoramide mustard. 
Initially, cyclophosphamide was part of the combination treatment cyclophospha-
mide-methotrexate-fluorouracil (CMF) which remained the standard treatment for 
breast cancer until the publication of the NSABP B-15 study in which the combina-
tion doxorubicin + cyclophosphamide was found to be equally effective [82].  Con-
sidering the increased risk of leukemia following prolonged treatment with cyclo-
phosphamide, the anthracycline-based regimen was subsequently preferred due to 
the shorter application period (63 days vs 6 months) [83].  
The platinum-based compounds carboplatin or cisplatin are referred to as alkylating-
like agents. These compounds form a covalent bond with the DNA, thereby causing 
DNA strands to crosslink and impairing DNA conformation and synthesis [84, 85]. In 
recent trials carboplatin was found to be effective in the treatment of metastatic and 
locally advanced triple negative breast cancer [86, 87]. Cisplatin is currently being 
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studied for its efficacy in the treatment of hereditary breast cancer, based upon 
promising data obtained from in vitro and in vivo models, as well as small clinical 
trials [88]. Especially BRCA1 mutation carriers achieved good results [89, 90]. Com-
parison between the two platinum compounds, showed a slightly higher rate of pCR 
for carboplatin.  In a meta-analysis, anthracycline-taxane based neoadjuvant chemo-
therapy including any platinum compound resulted in a pooled pCR rate of 48.4%. In 
the triple negative group, the overall rate of pCR was twice as high compared to oth-
er tumor subtypes. While promising, an optimal chemotherapy regime for platinum 
compounds remains under discussion [91]. 
Unlike the previously mentioned groups of chemotherapy drugs, antimetabolites are 
specific for the S-phase phase of the cell cycle.  DNA synthesis takes place during 
this phase and the antimebolitic drugs act as competing substitutes for naturally 
available substances such as purine and pyrimidine. The drug 5 -fluorouracil (5-FU) 
for example acts on RNA synthesis by inhibiting the thymidylate synthase thereby 
causing DNA damage [92].  It remains one of the most commonly used drugs in the 
treatment of several solid tumors, either as single-agent or combination therapy. 
However, current German therapy guidelines no longer recommended it for the pri-
mary treatment for breast cancer due to results from the GIM-2 study which showed 
that the addition of 5-FU does not improve the overall efficacy of anthracycline- or 
taxane-based therapy [63, 93]. Recently conducted studies comparing FEC to 
anthracycline-taxane treatment (i.e. EC – Doc) showed equivalent results for OS, 
and hematologic and serious adverse events were more frequent in the FEC study 
arm [77]. In contrast, another study found more toxicities for the anthracycline-taxane 
combination, although treatment efficacy was also higher [94]. The addition of a 
taxane was shown to increase efficacy to FEC combination treatment [95, 96]. 5-
fluorouracil or its prodrug capecitabine may be an alternative for patients intolerant to 
taxane-based treatment. Capecitabine is taken orally and is converted to 5-FU 
through enzymatic processing. In metastatic breast cancer capecitabine is currently 
mainly prescribed as single-agent chemotherapy, and less frequently in combination 
with docetaxel, the microtubule inhibitors ixabepilone and eribulin, or the multi-kinase 
inhibitor sorafenib where it has shown a high response rate and good tolerability. It is 
also recommended for patients resistant to, or heavily pretreated with first-/second-
line taxane and/or anthracycline chemotherapy [97, 98]. 
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Gemcitabine is also an antimetabolite and induces apoptosis by replacing the nucleic 
acid base cytidine [99, 100]. It is mainly used in the treatment of metastatic disease 
where it has shown mixed results when combined with standard chemotherapy [101-
103]. Studies with high risk primary breast cancer patients have also not any im-
provement in pCR through the addition of gemcitabine to anthracycline-taxane based 
chemotherapy [104, 105].  
Another mode of action in anticancer treatment targets the microtubule function, 
more specifically the assembly and disassembly during the S-phase of the cell cycle. 
Two different drugs used in the treatment of breast cancer fall under this category, 
the taxanes and the vinca alkaloids. The precursor substance for the taxanes 
paclitaxel and docetaxel are extracted from the needles of the yew tree, and chemi-
cally altered to their final pharmacologic form [106]. Taxanes work by stabilizing mi-
crotubule formation, thus blocking disassembly and obstructing the cell cycle [107, 
108]. Multiple clinical trials have demonstrated the high and equivalent efficacy of 
both paclitaxel and docetaxel. Combinations including one of the two include DocAC 
[109], FEC-Doc [94, 110], and EC- Doc [111, 112] both in the neoadjuvant and adju-
vant setting. The addition of a taxane to anthracycline-based chemotherapy was 
shown to both improve the rate of breast conserving surgery (BCS) and pCR [113, 
114]. Currently, the anthracycline-taxane based chemotherapy remains the standard 
of care, although there are still ongoing trials to determine the ideal treatment timing 
and sequence [115, 116]. A modified form of paclitaxel, nanoparticle albumin-bound 
(nab-) paclitaxel, has also been subject of several clinical trials for the treatment of 
metastatic disease. The goal behind the development of this compound was to re-
duce neurological side-effects by eliminating the solvent chromophore EL, as well as 
increasing drug availability through improved systemic distribution [117]. Several tri-
als have found a clinical benefit and improvement in the rate of pCR for albumin-
bound paclitaxel compared to regular taxanes [118-120]. 
Vinca alkaloids also act through competitive binding to tubulin, the building blocks of 
the microtubules, subsequently preventing the formation of the mitotic spindle. From 
this group of substances, vinorelbin is most commonly used for pretreated metastatic 
cancer [121, 122]. Older patients may tolerate treatment with vinorelbin better than 
taxane or anthracycline-based treatment. However, in monotherapy vinorelbin was 
found to be less effective compared to taxanes. Compared to 5-FU/capecitabine and 
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other combination treatments an equivalent response was observed in the 
neoadjuvant, as well as the adjuvant treatment setting [121].  
Although efficacy to these untargeted cytostatic drugs (meaning, proliferation is a 
sufficient but not exclusive criteria of cancer cells) is high, some patients may never-
theless show tumor progression due to drug resistance. In metastatic disease, the 
success rate of second-line chemotherapy is as low as 20-30% following disease 
progression after first-line treatment [123]. Tumors may be intrinsically resistant or 
develop an acquired resistance to a specific compound. In some cases an acquired 
resistance may extend to include other compounds with different modes of action, 
referred to as cross-resistance. The main mechanism implicated in resistant tumors 
is via increased drug efflux. Multi-resistant tumors have an upregulation of ATP-
binding cassette (ABC)-membrane transporter proteins (i.e. P-glycoprotein, multi-
drug-resistant protein 1, breast cancer resistance protein) in the plasma membrane, 
which leads to reduced intracellular drug concentrations. Other mechanisms leading 
to drug resistance are mutations, alterations, or overexpression of tubulin isotypes or 
tubulin-associated proteins (resistance to taxanes), changes in topoisomerase II 
(anthracycline resistance), cytoplasmic drug-metabolizing enzymes (cyclophospha-
mide resistance), or aldehyde dehydrogenase isoform expression (taxane re-
sistance). On a molecular level the changes in the tumor-suppressor gene p53 (re-
sistance to doxorubicin), resistance to apoptosis through the survivin gene, and ab-
normal mismatch repair mechanisms were all associated with drug resistance [124, 
125]. Currently different strategies of overcoming drug resistance are being studied 
such as resistance-reversing drugs, new drugs with altered targets, or resistance 
predicting biomarkers [126].  
Overcoming resistance and improving treatment outcome may also be achieved us-
ing dose-dense or dose-intensified chemotherapy. In dose-dense regimens, stand-
ard compounds are given at a higher dose, while dose-intense regimens are given at 
a higher dose and shorter between cycle intervals. Promising results have been 
found for patients with a high risk profile (lymph node metastasis ≥ 4), both in the 
adjuvant and neoadjuvant treatment setting [127]. However, the optimal dosing 
scheme is still being discussed. The frequency of observed toxic side-effects was 
also increased. In order to limit the subsequent myelotoxicity and neutropenia in-
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duced by the increased chemotherapy dose, granulocyte colony-stimulating factor is 
simultaneously administered [128].  
Endocrine treatment 
Some types of cancers such as breast, prostate, as well as endometrial cancers can 
be treated using a whole other strategy, by exploiting the tumor’s hormone depend-
ency [129]. There are three treatment strategies which target HR+ tumors: inhibition 
of hormone synthesis, competitive antagonists, and hormone substitutes [26, 130]. 
The choice of treatment depends on the disease stage and the menopausal status of 
the patients [131, 132]. In pre-menopausal women the estrogen and progesterone 
production by the ovaries can be suppressed through an analog of the gonadotro-
pin-releasing hormones (GnRH) which acts on the pituitary gland [133]. The aroma-
tase inhibitors (AIs) inhibit hormone production through the aid of an enzyme called 
aromatase in other tissues as well. This enzyme catalyzes the transformation of an-
drogens into estrogen. Letrozole, anastrozole, and exemestane are among the sub-
stances that are used to inhibit the function of aromatase [64, 131].  
The second class of anti-hormone drugs is the competitive antagonists, such as the 
selective ER modulators (SERMs) and the antiandrogens. However, only the SERMs 
are relevant for the treatment of breast cancer. Tamoxifen is the most commonly 
prescribed of these drugs and can be used in the treatment of both early, locally ad-
vanced, and the metastatic cancers. Tamoxifen binds to the ER and inhibits the sub-
sequent signaling pathway [134-136].  In general, this type of therapy may be admin-
istered as neoadjuvant, or more commonly as adjuvant maintenance therapy. In the 
neoadjuvant setting, an increase in objective response rates and BCS, especially in 
older, postmenopausal women was found [137].  
In a few cases when all other substances have failed to be effective or are contrai n-
dicated, estrogen or progesterone can be administe red as a supplement. This may 
lead to a down-regulation of ERs through a negative feedback mechanism. This 
treatment is, however, outdated and not frequently used [138-140].  
The positive response rate to endocrine therapy lies around 75% [141]. Current data 
on resistance mechanisms suggest a hyper activation of the 
PI3K/PTEN/AKT/mTORC1 (PTEN, phosphatase and tensin homolog, mTORC1, 
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mammalian target of rapamycin complex 1, AKT, protein kinase B) and MAPK path-
ways mediated through growth-factor stimulation (HER2, insulin-like growth factor 1 
receptor, fibroblast growth factor receptor 1). Resistance to tamoxifen is also induced 
through an altered or decreased expression of ERα or changes in the enzymes that 
metabolize the drug (CYP2D6). Overexpression of the cofactor AIB1 and subse-
quent binding to the ERα transcription complex may also lead to tamoxifen-
stimulated tumor growth. Similar drug efflux mechanisms are active in the resistance 
to untargeted chemical compounds and are also implicated in endocrine resistance 
(Pgp, MDR1) [142, 143]. In recurrent tumors loss of HR overexpression was also 
observed [144, 145]. A combination of mTOR inhibitors (everolimus, see also below) 
and endocrine therapy drugs (tamoxifen, aromatase inhibitors) may be used to treat 
patients with HR+/HER2- primary and metastatic tumors resistant to endocrine ther-
apy [146-148]. 
Targeted drugs 
A third major group of drugs, monoclonal antibodies and small molecule drugs target 
specific properties that only cancer cells exhibit, thereby increasing efficacy and de-
creasing unwanted side effects.  
Compounds with low molecular weight, otherwise known as small molecule drugs, 
target tyrosine or serine/threonine kinases. Unlike the larger antibody-based drugs, 
small molecule compounds may function by intervening in both intracellular and ex-
tracellular processes. However, the half-life of these drugs is also shorter compared 
to antibody drugs [149]. The two main drugs which are part of current breast cancer 
treatment are lapatinib and everolimus. Lapatinib is a tyrosine kinase inhibitor target-
ed against HER2 overexpression and acts through the inhibition of the EGFR path-
way [150, 151]. In clinical trials, lapatinib combined with standard chemotherapy was 
found to be effective both for primary and metastatic disease, both as a single, and a 
dual HER2 blockade with trastuzumab. The treatment effect on survival remains less 
clear with results from follow-up from neoadjuvant and adjuvant trials showing only 
small or no improvement [152, 153].  
Everolimus, on the other hand, works by blocking the mammalian target of 
rapamycin (mTOR) and is used to treat tumors that are HER2- or exhibit an acquired 
resistance to anti-HER2 drugs. It is also used for several other solid tumor manifes-
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tations such as renal and pancreatic carcinoma. The drug binds to the FKBP12 re-
ceptor, and inhibits downstream signaling pathways involved in cell proliferation 
through subsequent interaction with mTORC1 protein complex. Research suggests 
that everolimus may reverse resistance to endocrine and anti-HER2 therapy as men-
tioned above [154, 155]. The recommended treatment setting for everolimus is lim-
ited due to an increase in adverse events and mortality observed among clinical trial 
participants, and currently the drug is only approved for patients with metastatic or 
advanced disease [156, 157]. 
Poly (ADP-ribose) polymerase (PARP) inhibitors interfere in the DNA repair path-
ways and work by preventing homologous recombination following binding through 
the replication fork and double-strand break. This inhibition is especially effective in 
BRCA-mutated tumors where this mechanism is impaired, thereby leading to cell 
death of mutation carrying cells. For this reason PARP inhibitors are a promising a l-
ternative for BRCA mutation carriers and BRCA-associated tumors. Currently, 
olaparib and similar PARP inhibitors (veliparib, niraparib, talazoparib, rucaparib, and 
CEP-9722) are being studied in phase III clinical trials to assess their efficacy and 
toxicity in breast and other solid tumors [158].  
Compared to small molecule drugs monoclonal antibodies such as trastuzumab, 
bevacizumab, and the more recently developed pertuzumab, have been more suc-
cessful. Trastuzumab and pertuzumab are both humanized monoclonal antibodies 
that bind to the HER2 antigen presented on the surface of cancer cells. Cell growth 
is prevented through the interference with the signaling pathway, the internalization 
and subsequent degradation of the receptor heterodimer, prevention of dimerization, 
downregulation of HER2 expression, induction of cell cycle arrest, and inhibition of 
irregular HER2 cleavage [159]. A second mode of action of trastuzumab is mediated 
through the innate and adaptive immune system [160]. The drug is given either sim-
ultaneous to regular chemotherapy, and/or as maintenance therapy for one year af-
ter surgery in the neoadjuvant or adjuvant setting for HER2 positive (HER2+) early, 
locally advanced, and metastatic disease [161].  
Targeting of the HER2 receptor can be done with a single compound or dual target-
ing using trastuzumab, pertuzumab, the small molecule compound lapatinib, as well 
as antibody-drug conjugates [162-164]. Due to the affected signaling pathways a 
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dual inhibition of the HER2 receptor leads to an accelerated intracellular degradation 
[37]. The reasoning behind a dual blockade is to prevent tumor resistance through 
parallel targeting of two different cellular mechanisms. Lapatinib for example, targets 
both HER1 and HER2 as an ATP competitor, thereby preventing PI3K/AKT and 
MAPK signal transduction [165]. Pertuzumab on the other hand prevents the HER2 
receptor from binding to other receptors from the HER family. Both drugs have been 
found to be equally effective given concomitant with standard chemotherapy. This 
dual approach is especially effective for tumors which are also HR-.   
This treatment option has caused the rate of pCR among women with HER2+ tumors 
to rise up to 53.2% [166] through single-agent inhibition, and up to 66.2% using dual 
inhibition [167-170]. Supplementing trastuzumab to neoadjuvant chemotherapy re-
sulted in an increase in pCR regardless of the applied chemotherapy regimen (FEC 
[167], CMF [171], EC – Doc [172]). The observed OS rate was also improved from 
75.2 to 84%, DFS likewise by 40% [173, 174]. A main concern regarding this combi-
nation treatment is the simultaneous application of anthracyclines and trastuzumab, 
especially regarding cardiotoxicity. For this reason trastuzumab is mainly given sim-
ultaneous to taxane therapy. The study of the underlying cellular pathways in cardiac 
dysfunction induced by trastuzumab has however shown that these effects are not 
persisting, unlike those brought on by anthracycline application [175]. 
A full and long-lasting response to HER2 inhibition is achieved in circa 30% of pa-
tients [176-178]. Potential biomarkers to predict resistance to anti-HER2 treatment 
via lower rates of pCR are alterations in the oncogene PI3KCA (mutation, loss, am-
plification, copy number gain, increased expression, and PTEN loss) [179]. Mecha-
nisms of resistance are via p95HER2 (shortened HER2 receptor, extracellular bind-
ing site for trastuzumab missing), IGFR (through interaction with HER2), abnormal c-
MET (signaling pathway leading to resistance still unclear), Src (implicated in intri n-
sic and acquired resistance, phosphorylated form), signaling with the ER, and low 
immune response (low levels tumor-infiltrating lymphocytes, TILs, low PD-L1). Identi-
fied resistance mechanisms may represent potential druggable targets to overcome 
resistance. For example, inhibitors to the heat shock protein Hsp90 are currently be-
ing investigated in clinical trials (ganetespib, tanespimycin) [180-182]. 
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A conjugate of trastuzumab and emtansine (T-DMI), an anti-microtubule agent, has 
recently been approved for patients with metastatic tumors resistant to regular 
trastuzumab formulation. Via intracellular delivery of emtansine, T-DMI was found to 
increase OS in patients previously treated with trastuzumab and taxane [183]. 
Through the intracellular mode of action, the safety-profile was also improved [184].  
Compared to a reversible block from the previously described drugs, new agents that 
irreversibly block the HER2 receptor such as afatinib and neratinib may increase the 
anti-HER2 treatment efficacy even further [185, 186]. However, a recently conducted 
study was ended prematurely due to a high rate of observed adverse events in the 
afatinib study arm [187].  
Bevacizumab is humanized monoclonal antibody that is used to treat the remaining 
cases that are HER2-. The target is the vascular endothelial growth factor A (VEGF-
A), a protein that is associated with angiogenesis and vasculogenesis. Both factors 
have been implicated to play a major role in tumor growth [188-191]. The ability of a 
tumor to attract existing blood vessels or form new blood vessels has been identified 
as a major factor in the differentiation of normal to malignant cells [191]. 
Bevacizumab is currently being used in the treatment of primary and advanced can-
cers with a HR+ or triple negative tumor biology. An improvement in progression-free 
survival was especially evident in metastatic disease [192]. Results regarding OS 
and pCR were less clear, with the GeparQuinto trial reporting especially favorable 
results for HR+ tumors while Bear et al reported greater benefit for HR- disease [193, 
194]. However, the approval of the drug had been under great scrutiny due to an 
unfavorable risk/benefit ratio in clinical trials. The approval for the drug was revoked 
2010 in the United States by the Food and Drug Administration for the treatment of 
breast cancer, the European Agency has upheld their initial approval [195].  
Predictive and prognostic biomarkers 
In breast cancer treatment decision-guiding algorithms are based on the results of a 
long history, and a multitude of clinical trials summarized in national and international 
guidelines. These are successfully applied in the treatment selection process by an 
interdisciplinary team of treating physicians for the systemic management of the dis-
ease [196]. Routine clinical and pathological criteria such as TNM criteria, HR and 
HER2 status, grading, histology, and age are important factors in identifying basic 
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breast cancer subtypes. For the majority of patients, treatment stratification based on 
these cri teria will be sufficient, but in certain cases and circumstances a more indi-
vidualized approach is essential. This includes patients not responding to treatment, 
recurrent or metastatic disease, as well as those with a high risk of recurrence. Also, 
in some cases a certain treatment cannot be administered because of a persisting 
medical condition, drug intolerance, or other conflicting comorbidities. Here a similar-
ly effective treatment option needs to be identified. For these reasons, preclinical and 
clinical diagnostic methods, biomarkers, or factors predicting individual treatment 
efficacy and overall prognosis remain an important aim of translational medicine 
[197]. This is especially important considering the overwhelming multitude of availa-
ble and emerging treatment options as described in the previous sections. 
Per definition, diagnostic factors, assays, or biomarkers are variables that consist of 
a single measurement or a combined score obtained from the joint analysis of se v-
eral measurements. Regardless of the type of variable, the results may be predictive 
for survival (prognostic) and/or treatment outcome (predictive). The difference be-
tween the predictive and prognostic biomarkers is the association with the applied 
treatment: A marker is predictive if the difference between its presence/absence 
marks a higher effect for one of the treatment arms, it is prognostic if its presence or 
absence is the same for both arms equally [198]. Biomarkers may also detect and 
diagnose a disease, as well as provide surveillance data. A proposed biomarker is 
categorized using levels of evidence (LOE) ranging from strong I to weak V. In order 
to obtain a LOE I the biomarker must be validated in a randomized controlled trial 
using prospective data [199, 200]. The validity of the biomarker describes the 
agreement of the measured data with the actual clinical outcome (i.e. clinical valida-
tion), also important factors are the reliability or analytical validation of the data con-
sistent across repeated measurements [201].  
Established clinical predictive factors that are associated with a higher rate of pCR 
following neoadjuvant chemotherapy are high tumor grade (G3), young age at diag-
nosis [202], HER2+ [72, 203], and HR- status [71]. Young age at diagnosis is also 
prognostically favorable, along with other factors such as negative lymph node sta-
tus, low tumor grade, HR+ and HER2+ status, pCR, and early response to 
neoadjuvant treatment [204, 205]. These have been extensively studied and are eas-
ily measured, due to their implementation into routine clinical practice. 
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Emerging factors that may function as potential biomarkers and drug targets include 
dysregulation of cyclin D1 [206], topoisomerase IIα [207], circulating tumor cells or 
tumor cell-derived DNA [208, 209], as well as the ERβ [210, 211].  All of these mark-
ers were found to have prognostic relevancy, however research data is not conclu-
sive and the mode of implementation into clinical routine remains unclear at this 
time.   
Ki67 and the serine protease urokinase plasminogen activator and its associated 
serpin inhibitor plasminogen activator inhibitor-1 (uPA/PAI-1) on the other hand, are 
already part of most routine histopathological analysis. As described above, Ki67 is a 
potential surrogate marker for cellular proliferation that has been highly associated 
both as a predictive and prognostic factor in all breast cancer subtypes. The com-
bined assessment of uPA/PAI-1 has been validated as LOE I in lymph node negative 
breast cancer as a prognostic and predictive marker [212]. The uPA system is found 
to be upregulated in several types of cancer and is associated with an increased ce l-
lular migration and lessened adhesion via changes in the extracellular matrix (ECM). 
The disrupted ECM thus initiates local and distant invasion through cancerous cells 
and therefore a high uPA score is a marker for higher risk of recurrence [213]. For 
early intermediate risk ER+/G2 breast cancer patients, the assessment of uPA/PAI-1 
was proven to aid in risk stratification regarding the necessity for adjuvant chemo-
therapy [214]. While being very cost-efficient drawbacks include the requirement of 
fresh/frozen tissue samples. Validation and standardization of the assay using fixed 
tissue samples remains a key issue, a reason why the clinical implementation of this 
assay has only slowly caught on. 
Molecular profile assays, imaging methods, as well as immune-related factors are 
other central research areas [215-220]. As described in the section on the character-
ization, molecular profiles obtained through cDNA microarray analysis provide data 
on patient risk stratification by identifying the tumor subtype. Patients are character-
ized by their risk of relapse with or without systemic chemotherapy, thereby avoiding 
potential overtreatment. The commercially available molecular profiles are PAM50, 
MammaPrint, and OncotypeDX. The difference between these tests are the underly-
ing genes that are used as classifiers, whereas OncotypeDX uses a set of 21 genes 
for its profile, PAM50 uses 50, and MammaPrint 70 genes. MammaPrint was the first 
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test of its kind available to patients, and is also the only test currently approved by 
the FDA.  
The OncotypeDX has been successfully validated for ER+/LN- primary breast cancer 
patients, and classifies patients into low/intermediate/high risk for relapse. Systemic 
chemotherapy is considered unnecessary for patients with a low risk profi le. The 
identified risk profiles are also associated with differences in response to 
neoadjuvant chemotherapy [221]. However, the clinical relevancy of the large 
amount of generated data is not yet fully understood and the implications for inter-
mediate- and high-risk profiles remain less clear. Also, the currently available tests 
are costly and only analyze exons are analyzed, lacking information on the underly-
ing driver mutations [222].  
A closely related subgroup classification may be done using the routine 
histopathological tissue assessment. The combined score is referred to as IHC4 and 
combines HR and HER2 status, as well as a tumor grade. In contrast to cDNA mi-
croarray, IHC-based analysis is scored manually using semi-quantitative methods, 
results are therefore more difficult to standardize and less reliable.  On the other 
hand this approach is already part of the routine histological analysis, making it a 
feasible and cost-efficient option even in developing countries. A comparison of the 
IHC4 assay with the equivalent microarray assay PAM50 resulted in a similar cate-
gorization with the exception of the HER2-/LN- patient subgroup [223].  
The available tests have in common that they distinguish between patients who 
should receive chemotherapy and patients who should not [47, 224, 225]. Similarly, 
circulating tumor cells have proven to be of prognostic value  [226], however, a pre-
dictive value has not been shown [227, 228].  
Preclinical research models 
Only a small percentage of drug candidates screened successfully in preclinical re-
search studies are subsequently approved for patient treatment, oftentimes due to 
issues regarding safety and clinical efficacy [229, 230]. This high attrition rate sug-
gests that current preclinical strategies are not fully representative of the characteris-
tics exhibited by patient tumors. A refined preclinical strategy through improved 
models may reduce costs and expedite the time until market approval.  
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Preclinical research models and tools consisting of in vivo animal and in vitro cell 
culture models are an essential component in identifying new and promising drug 
targets, underlying pathways, and predicting short-/long-term treatment efficacy. An-
imal models were first developed during the 1930s in parallel with the development 
of the first chemotherapy drugs, the most widely used animal being tumor-bearing 
mice. In comparison to other available animal models the genetic makeup of the 
mouse is more closely related to humans than non-vertebrae, amphibian or fish 
models. The advantage of the mouse is its small size and efficient breeding methods 
compared to larger mammals. All pharmacological and physiological effects of a 
candidate drug can be studied, including its toxicology. The entire organism is repre-
sented, which is why in vivo models make up a central component in the current 
drug approval process [231, 232]. In breast cancer research mouse models for both 
primary and metastatic disease stages have been successfully implemented, and 
were fundamental in developing important drugs such as tamoxifen [233]. A widely-
used model for breast cancer progression and metastasis is the MMTV-PyMT model 
[234]. In general, treatment efficacy in mouse models can be analyzed using defined 
biomarkers, imaging methods such as PET-CT, NMR, and ultrasound. Alternatively 
surrogates for survival can also be assessed [235]. Individual processes such as 
tumor dissemination, for example, may be simulated by injecting tumor cells directly 
into the circulatory system of the animal [236].   
Mouse models may be classified according to spontaneous or induced tumor growth 
[60, 237]. For example skin tumors may be induced through the application of car-
cinogenic substances such as 7,12-dimethylbenzo[a]anthracen (DMBA) and croton 
oil [238]. Inoculation with microorganisms, such as infection with H. pylori allow the 
study of gastric tumorigenesis [239].  
Genetically engineered mouse models (GEM) are bred carrying specific loss or gain 
of function mutations in a single or multiple tumor suppressor gene(s) or onco-
gene(s) (i.e. TP53, BRCA), thus leading to the development of tumors. Through the 
controlled manipulation deregulated pathways contributing to tumorigenesis and its 
effects on treatment efficacy and survival may be studied without the confounding 
influence of outside carcinogenic factors [240, 241]. Unlike xenograft models, GEM 
models maintain a competent immune system.  
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Alternatively, cancer cells may be injected, transplanted subcutaneously or 
orthotopically into the animal. These xenographic and patient-derived xenograft 
(PDX) models uti lize nude or NOD-SCID mice with an immature immune system so 
the transplanted tissue will not be rejected by the host animal. Components of the 
patient’s hematopoietic immune cells may also be transplanted resulting in so called 
“Avatars” [242]. In another approach the mammary fat pads of the mouse may be 
cleared and injected with human fibroblasts, epithelial and stromal cells to mimic the 
human tumor microenvironment [236, 243]. Both organ site-specific orthotopic and 
heterotrophic tumors where tumor cells are subcutaneously implanted into the flank 
of the animal, develop within several weeks or months following implantation. The 
successful implantation rate lies around 75% [244, 245]. Through transfer from one 
animal to the next a tumor may be cultivated and expanded for an extended period 
of time. Studies using patient tissue from breast, colon, pancreatic and lung cancer 
have shown that results may be predictive for treatment efficacy in the clinic. Several 
aspects of the individual patient tumors such as tumor histology and phenotype, 
gene expression profiles, SNPs, and copy number variants are retained in PDX 
models [243-245]. PDX models more closely represent the multiple and heterogene-
ous mutations of the majority of human tumors whereas GEM models are more re-
lated to tumorigenesis associated with genetic predispositions, thus making the PDX 
approach more relevant for preclinical drug selection [246].   
The main problem of PDX models is the sensitivity of the immunodeficient mice, 
making the breeding and caretaking costly and time-consuming [242, 247-249]. In 
addition, some criticize that these in general mouse models do not accurately mimic 
the tumorigenesis and heterogeneity of human tumors due to inherent inter-species 
distinctions [250]. For example, telomerase activity and metastatic behavior are two 
points that show marked differences [246].  The murine, or rather loss of the human 
tumor microenvironment represents a significantly confounding factor even when this 
component is supplemented using patient material [251].  
These may be the underlying reasons why preclinical drug efficacy studies using the 
PDX model have not been as successful as initially predicted [252]. Problematic re-
mains the high-throughput practicability and clinical implementation. It should also be 
noted that not all patient tumors are successfully implanted, with a higher success 
rate observed for more aggressive tumors. Following successful implantation the 
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time span for tumor development in the mouse (several weeks) exceeds the time 
between a patient’s diagnosis and the start of chemotherapy [253].  Although models 
for breast cancer have been well established and validated there are currently no 
models available for other solid neoplasms such as ovarian, brain, kidney, and ma-
lignant melanoma [254]. 
A vast amount of research has been done using established breast cancer cell lines. 
These are isolated from excised primary or metastatic tissue, pleural cavity fluid or 
ascites of cancer patients. The primary tumor cells become immortalized using in 
vitro techniques or due to intrinsic mutations [255]. All cells of a specific cell line are 
clones and therefore behave similarly when exposed to comparable conditions and 
compounds, making it a simple and inexpensive method for preclinical drug selec-
tion, as well as to study various aspects of cancer biology [256, 257]. The most wide-
ly used cell lines in breast cancer research are the MCF-7 [258], T-47D [259], and 
MDA-MB-231 [260] cell lines. All three cell lines were obtained from the pleural effu-
sion of patients with metastatic disease [261]. Cell lines may be used in adherent 
single-layer culture or suspension culture conditions. Data comparing the cell lines 
with the primary tumors or tumors of similar characteristics shows that phenotype, 
hormone receptor status, genomic aberrations, and changes in protein expression 
may remain stable even after prolonged culture [262-264].  
However, others have shown that this is not true for all characteristics. In some in-
stances experimental data obtained from the same cell line may even differ between 
laboratories [265]. Various cell lines cultured in one laboratory may have more in 
common with each other than with the same cell lines stored in another facility due to 
location-specific cell culture conditions. Treatment efficacy results obtained from cell 
lines do not consistently translate to clinical treatment outcome. Likewise, a  compari-
son of the pathways involved in multi-drug resistance showed that results were i n-
consistent with clinical data [266].  
The reason behind this may be long-term cell culture which favors cells that are 
more adapted to these conditions. Upon transfer from the patient to the laboratory, 
cellular heterogeneity, genetic complexity, and extracellular and stromal signaling 
are reduced through the removal of the supporting tumor microenvironment [267]. In 
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addition, due to repeated passaging of the cells genetic aberrations accumulate 
thereby causing the cells to lose some of their original tumor characteristics   [268].  
Compared to freshly isolated primary tumor ce lls cell lines also show a higher level 
of genome amplification. The reason behind this might be the tissue source, which is 
mainly metastatic pleural effusions or tumors with triple negative tumor biology [269, 
270]. In comparison to other cancer cells, breast cancer cells are particularly difficult 
to maintain due to the slow rate of proliferation and contamination with normal cells 
and fibroblasts. Only around 100 cell lines are permanently available and the majori-
ty of research data is based on the three most commonly used lines. Another com-
plicating factor is tumor necrosis, reducing the net yield of isolated cells obtained 
from surgical tissue. There are currently only a small number of cell lines obtained 
from early stage, primary breast tumors, HCC1937 remains the only cell line with a 
BRCA1 mutation. For the luminal A and B breast cancer subtypes there is a lack of 
representative cell lines [271-273]. This leads to the suggestion that human breast 
cancer cell lines may only represent a small spectrum of the heterogeneity found in 
patient tumors both in phenotype and genotype [268].  
Regardless of whether cell lines or primary cancer cells are used, a main criticism of 
standard 2-dimensional (2D) cell culture has been the absence of the tumor micro-
environment, which may have an important influence on tumor development, pro-
gression, and drug efficacy [274, 275]. The tumor vasculature, stromal and immune 
cells, signaling molecules such as growth factors and cytokines, as well as the extra-
cellular matrix (ECM) are all key factors in the perpetual interaction between the 
growing tumor and the surrounding tumor microenvironment [276]. Several of the 
body’s defense mechanisms must be overcome or modulated in order for a tumor to 
grow in size and spread to distant sites, such as formation of blood vessels, degra-
dation of the surrounding ECM and its components, and transitioning from an endo-
thelial to mesenchymal phenotype. The underlying signals originate from the tumor 
microenvironment [277].  
Through the increasing tumor mass the amount of available oxygen is also de-
creased, thereby creating a hypoxic environment which is associated with greater 
genetic instability and increase in angiogenesis.  Due to the lack of available oxygen 
the Warburg effect causes tumor cells to produce lactate leading to an acidic envi-
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ronment, although the cancer cells themselves retain a neutral pH. These changes 
may lead to the dysfunctional behavior of epithelial cells or vice versa [278, 279]. 
The hypoxic environment has also been implicated in the commissioning of tumor-
associated macrophages (TAMs) and mesenchymal stem cells; thereby acting im-
munosuppressive [280, 281]. 
Compared to benign breast tissue that contains normal stromal fibroblasts, specific 
cancer associated fibroblasts (CAFs) are found in malignant breast tumors. These 
CAFs are involved in tumor progression by secreting growth factors and 
chemokines, through protease secretion cancer cells may infiltrate the surrounding 
benign tissue [282, 283]. The origin of these CAFs has not yet been definitely deter-
mined; however the current hypothesis states that they may evolve from local fibro-
blasts, mesenchymal stem cells, and/or epithelial cells. CAFs and other fibroblasts 
(myofibroblasts and adipocytes) are involved in tumor growth, angiogenesis, promo t-
ing endothelial-mesenchymal transition (EMT), remodeling or destroying the ECM, 
and via the reverse Warburg effect feeding lactate to cancer cells [284].  
In addition, through the production of myelogenous cells such as TAMs and tumor-
infiltrating lymphocytes (TILs) act as opposing forces in tumor progression. TAMs 
lack cytotoxic efficacy and are linked to a mild chronic inflammation often found in 
solid cancer. Regarding treatment efficacy, TAMs may be either beneficial or harm-
ful. A chemoresistance to several compounds has been observed through the induc-
tion of TAM-induced survival pathways. Signaling involves cytokines (e.g. TNF, IL-1, 
IL-10, and IL-17), cathepsins, growth factors, and the recruitment of additional mac-
rophages. Especially the M2 TAM subcategory is associated with an anti -
inflammatory and immune suppressive phenotype, leading to a reduced response to 
chemotherapy (e.g. anthracyclines, platinum compounds, and taxanes). Conversely, 
a shift toward a M1 macrophage subtype is considered beneficial for treatment effi-
cacy, suggesting a potential target for new targeted drugs [285-287].  
TAMs also hide cancer cells through the secretion of IL -10, promote angiogenesis 
through VEGF + NOS, support tumor growth (EGF), and remodel ECM. An increase 
in TAMs is associated with a worse prognosis. TAMs have also been found to sup-
press T-cell activity, thereby actively suppressing an immune response against the 
tumor.  
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An increase in TILs found in the surrounding stroma and/or intratumoral compar t-
ments is considered beneficial regarding overall prognosis in triple negative and 
HER2-positive breast cancer [288, 289]. Furthermore, TILs are considered a predic-
tive marker for neoadjuvant therapy in breast cancer, with high levels significantly 
associated with an increased likelihood for pCR [216, 290]. 
Cancer cells and the TME restrict the accumulation of TILs through the secretion of 
exosomes (FasL and TRAIL), potentially CAFs, TAMs and myeloid-derived suppres-
sor cells (MDSCs) are also involved. Apart from suppressing accumulation, survival, 
reproduction and stromal migration are also restricted. This is mediated through the 
tumor vasculature, chemokines, induction of apoptosis through Fas-L, IDO, and PD-
L1.   
These factors all represent potential targets for therapy which is the reason they are 
essential components of a preclinical assay system which ought to represent the 
entire tissue not just individual cancer cells. Single-cell suspension and cell mono-
layer assays using cell lines or patient-tissue derived cells [291-294] cannot fully re-
capitulate these factors. Assays based on this type of cell culture are currently not 
sufficiently validated for clinical implementation [295].  
In comparison, data suggests that 3-dimensional (3D) spheroid models have the ad-
vantage of incorporating components of the tumor microenvironment, as well as oth-
er critical factors such as cell-cell and cell-matrix interaction, while maintaining the 
original tumor architecture with similar physiochemical gradients [296]. In compari-
son to standard 2D monolayer cell culture, 3D models offer the advantage of a more 
tissue-like complexity and heterogeneity, tissue-like cellular polarity and interactions. 
The 3D architecture also results in the formation of a penetration barrier. Cancer 
cells grown in 3D have demonstrated similar behavior, structure, and organization 
compared to in vivo tissue, making it an ideal model to study treatment efficacy 
[297]. Several approaches have been studied in regard to predicting drug response 
in vitro [298, 299]. Spontaneous or induced spheroid formation has been observed in 
cancer cells derived from colon [300-302], gastric [303], lung [304, 305], and breast 
patient tissue [306-308].  In addition there are several cell lines which form spheroids 
or aggregates in suspension culture such as MCF-7, T-47D, and BT20 among others 
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from different tumor types. The aggregation is initiated by the secretion of extracellu-
lar matrix components by the cells themselves [303, 309].  
This can be achieved with the aid of several methods, such as with the aid of a sca f-
fold, matrigel, hydrogel, microfluidics, cell-derived matrix, extracellular matrix-free 
spheroid culture, or self-aggregating cells, which exhibit a natural tendency to form 
close contact with neighboring cells. The type of method used to generate the 3D 
cell culture as well as the subsequent mode for culturing the engineered construct 
depend on the aim of the research being done [310, 311]. 
The main 3D cell culture models that are currently being applied in cancer research 
are organotypic explant cultures, tumor on a chip, and multicellular spheroids in 
mono- or co-culture with other cells such as fibroblasts.   
In organotypic explant cultures the human or animal tissue in its 3D form remains 
intact and is the most basic and least technically challenging type of 3D cancer cell 
culture. Small biopsy or minced surgical patient tissue samples are cultured on top of 
or embedded in a collagen matrix for a specific length of time to test drug efficacy. 
While preserving the original tumor architecture of the patient tissue is a key ad-
vantage of this culture method, while on the other hand interfering with standardiza-
tion due to interpatient heterogeneity [255, 312]. 
The tumor on a chip approach combines a microfluidic system where µm-sized sphe-
roids or tissue slices are cultured for extended periods of time in a replicated model 
of the human tumor microenvironment. Using interconnected channels, compounds 
or circulating tumor cells can be applied to the tumor samples and the biochemical 
composition of the resulting fluid may be assessed in regard to drug transport, target 
receptor binding, and overall cellular response [313]. Taking this approach one step 
further allows the incorporation of one or more additional organ-specific compart-
ments. Thereby simultaneously modelling drug efficacy and toxicity [314, 315].  The 
substance in- and efflux can be minutely controlled to study the effect of different 
flow properties. Changes in tissue composition may be visualized using among oth-
ers real-time confocal imaging, viability assays, on-chip cytometry [316, 317]. How-
ever, while technologically interesting this type of system currently lacks in vivo and 
clinical validation regarding treatment efficacy outcome.  
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The nomenclature for multicellular 3D spheroid models varies greatly as summarized 
by Weiswald et al [318]. As suggested in this review the available methods may fur-
ther be categorized into four groups: multicellular tumor spheroids (MCTS), 
tumorspheres, tissue-derived tumor spheres, and organotypic multicellular sphe-
roids. Cells derived from non-malignant tissue or cell lines are also capable of form-
ing a 3D structure in culture and these are termed organoids. Whereas MCTS are 
mainly generated from cancer cell lines, the other three methods may be applied to 
cells obtained from patient or xenograft tissue. Tumorspheres may be obtained using 
small numbers of cells which are allowed to proliferate in stem cell medium until a 
sphere-like structure is formed in vitro. The methodology for both organotypic multi-
cellular spheroids and tissue-derived tumor spheres begins with the mechanical dis-
association of the obtained tissue sample. This is followed by enzymatic digestion 
which leads to a single-cell suspension.  The length of the subsequent culture and 
cell type composition effects the size and compaction of the generated spheroids. 
Generally a more prolonged culture leads to spheroids larger in diameter with a more 
compact morphology. In a scaffold-based natural or synthetic hydrogel, and hydro-
gel-coated plates approach in spheroid culture, the external factors may be manip u-
lated to study cell-cell and cell-matrix interaction as well as cellular migration. While 
post-experimental harvesting of the spheroids is facilitated, the handling of the hy-
drogel requires some practice in order to obtain uniform experimental settings and 
the confined space may limit outward growth and increase necrosis.  
Using a spinner or rotating flask, a large number of spheroids can be generated sim-
ultaneously. Due to the continuous stirring or rotating movement, the cells cannot 
attach to the surface of the culture vessel and all elements of the culture medium are 
evenly distributed. The cells in culture, however, show a tendency to drift toward the 
sides of the vessel where they form spheroids. 
Methods without a scaffold consist of the hanging drop [319], or liquid overlay tech-
nique [320], as well as using ultra-low attachment plates. All three methods have in 
common that cells are self-aggregating and the generated spheroids are less com-
pactly organized compared to scaffold-based methods, which may be attributed to a 
differential production of fibronectin [321, 322]. Regardless of the method used to 
generate spheroids, there are several methods available for characterization, such 
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as microscopic and imaging analysis, direct viability assessment through flow 
cytometry or via a surrogate measurement in biochemical assays [297, 323, 324].   
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 Aim and objective 
Preclinical models that correctly predict treatment outcome on an individual patient 
basis remain an unmet need in the current drug development process. Contrary to 
the 2D cell culture models 3D patient-derived spheroids reflect the tumor biology 
much more accurately and incorporate several aspects of the tumor microenviron-
ment absent in other models and assays [300, 301, 325-328]. The spheroid-based 
assay proposed herein, was assessed as a diagnostic tool to aid in therapeutic deci-
sion-making for primary breast cancer patients receiving neoadjuvant chemotherapy. 
The objective of the SpheroNEO study detailed in this manuscript was to test wheth-
er in vitro treatment efficacy results obtained in the breast cancer spheroid model are 
associated with pCR in primary breast cancer patients undergoing neoadjuvant ther-
apy.
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PATIENTS AND METHODS 
Machines and laboratory equipment 
 
Refrigerators: 
 
 
a) KTe 1740 
Liebherr, Bulle, CH 
b) Liebherr Profi Line 
  
 
Incubators: 
 
 
a) CO2 Incubator Series CB210 (53L) 
 
Binder GmbH, Tuttlingen, DE 
 
 
 
 
Laminar Flow: 
 
a) Laminar Flow Gelaire® Flow Laboratories – Model BSB-6A 
b) Laminar Flow BDK-SKV 1200 
BDK Luft- und Reinraumtechnik GmbH, Sonnen-
buehl-Genkingen, DE 
  
 
Microscope: 
 
 
a) Zeiss Axiovert 10  Carl Zeiss AG, Oberkochen, DE 
b) Zeiss Axiovert 25 CFL  
 
 
c) Olympus IX50  
 
 
Olympus Deutschland GmbH, Hamburg, DE 
 
 
 
Pipettes: 
 
 
a) Eppendorf Research ® 0.5 – 10 μl  
Eppendorf AG; Hamburg, DE 
b) Eppendorf Research ® 2 – 20 μl  
c) Eppendorf Research ® 20 – 200 μl  
d) Eppendorf Research ® 200 – 1000 μl 
  
 
e) Multichannel pipette Acura ® 851 5 - 50 μl  
f) Multichannel pipette Acura ® 855 20 - 200 μl 
   
Socorex, Ecubien, CH 
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Pipetboy:  
 
 
a) Accu-jet ® 
 
Brand GmbH & Co KG, Wertheim, DE 
 
b) Pipetus ®  
  
 
Hirschmann Laborgeräte GmbH & Co KG, Eberstadt, DE 
 
 
 
Centrifuges: 
 
a) Hettich centrifuge Rotixa / RP – Model 4200 
 
Andreas Hettich GmbH & Co. KG, Tuttlingen, DE 
 
 
b) Eppendorf centrifuge type 5415 C  
Eppendorf AG; Hamburg, DE 
c) Eppendorf centrifuge type 5810R 
 
 
 
 
Photometer: 
 
 
a) FilterMax™F3 – Multi Mode Microplate Reader 
Molecular Devices, LLC, Sunnyvale, CA, USA 
b) Microplate reader VersaMax  
 
 
c) Tecan Elisa-Reader Ultra384  
 
 
Tecan Deutschland GmbH, Crailsheim, DE 
 
 
 
Scales: 
 
 
a) Precision scale Model 2100g 
  
Sartorius, Göttingen, DE 
 
b) Scale model 440 21N  
 
 
Kern & Sohn GmbH, Balingen-Frommern, DE 
 
 
 
Water bath: 
 
 
a) Water bath type 1002 
 
Gesellschaft für Labortechnik mbH, Burgwedel, DE 
 
b) Water bath type OLS200 
 
 
Grant Instruments, Cambridge, UK 
 
c) Water bath type 3047 
 
 
Köttermann GmbH & Co KG, Uetze/Hänigsen, DE 
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Materials: 
 
 
 
a) Neubauer Improved cell counting chamber  
(chamber depth = 0.100 mm) 
  
LO Labor Optik GmbH, Friedrichsdorf, DE 
 
b) Safe – Lock tubes 1.5 ml, 2 ml, 5 ml  
Eppendorf AG; Hamburg, DE c) Ep Dualfilter T.I.P.S. 
d) ep T.I.P.S. Reloads 
  
 
e) Falcon™ conical centrifuge tubes 50 ml 
  
 
Corning Inc., Corning, NY, USA 
f) Centrifuge tubes 15ml  
 
TPP Techno Plastic Products AG, 
Trasadingen, CH 
 
 
g) Disposable reagent reservoir 50ml  
Corning Inc., Corning, NY, USA h) Polystyrene serologic pipettes 2, 5, 10, 25 ml  
i) Sterile, nylon cell strainer 40, 70, 100 μm  
 
 
j) Surgical disposable scalpel nr. 22  
 
 
Braun, Aesculap AG, Tuttlingen, DE 
 
k) Costar® assay plate, 96 well, with lid, flat bottom, sterile, white 
polystyrene 
 
 
Corning Inc., Corning, NY, USA 
 
l) Glass petri dish  
 
 
Manufacturer unknown 
 
m) Pasteur pipettes Volac® 
  
 
Sigma-Aldrich Chemi GmbH, Heidenheim, 
DE  
 
n) Plastic petri dish easy grip Ø 60, 100 mm sterile 
Becton Dickinson GmbH, Heidelberg, DE  
o) Syringe BD Discardit™ II 
 
 
p) Sterile forceps  
 
 
VWR International GmbH, Darmstadt, DE 
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Chemicals and reagents: 
 
 
a) Trypan blue solution 0.4% 
 
Sigma-Aldrich Chemie GmbH, Heidenheim, 
DE   
 
b) DMEM F12 (1:1) L-glutamine, 1.2g/l NaHCO3, with glucose  
Pan-Biotech, Aidenbach, DE 
c) Fetal bovine serum (FBS) 
d) Non-essential amino acids (NEAA) without L-glutamine  
e) Vitamin 100x concentrate 
 
 
f) Denatured Ethanol 80% 
 
 
Pharmacy University Hospital LMU, DE 
 
g) Metronidazol 5 g/l  
 
B. Braun Melsungen AG, Melsungen, DE 
 
h) Amphotericin B 0.25 g/l  
 
 
Biochrom GmbH, Berlin, DE 
 
i) Ampicillin 50 g/l  
Ratiopharm®, Ulm, DE 
j) Gentamycin 40 g/l  
 
 
k) Ciprofloxacin 2 g/l  
 
 
Fresenius Kabi Deutschland GmbH, Bad 
Homburg, DE 
 
l) Dulbecco’s phosphate buffered saline solution, without calcium 
or magnesium 
 
Pan-Biotech, Aidenbach, DE 
 
m) Liberase
TM
 TM (Thermolysin Medium) Research Grade  
 
 
Roche, Basel, CH 
 
n) ATP Reagent CellTiter-Glo® Luminescent – Cell Viability 
Assay   Promega, Mannheim, DE 
o) CellTiter 96® AQueous MTS Reagent Powder  
 
 
p) Phenazine methosulfate 
 
 
Sigma-Aldrich, Steinheim, DE 
 
q) Methocoel (proprietary composition) 
  
 
SpheroTec GmbH, Martinsried, DE 
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Cell culture media 
 
a) Supplemented culture medium/shipping medium (proprietary composition) 
- 500 ml DMEM F12 
- 10% FBS 
- 2.5x/ml NEAA 
- 2.5x/ml Vitamin concentrate 100x 
- Ampicillin 
- Amphotericin B 
- Ciprofloxacin 
- Gentamycin 
- Metronidazole 
 
b) Medium for enzymatic digestion 
- 500 ml DMEM F12 
- 2.5x/ml NEAA 
- 2.5x/ml Vitamin concentrate 100x 
- Liberase TM Research Grade 
 
c) Culture medium 
- 500 ml DMEM F12 
- 10% FBS 
- 2.5x/ml NEAA 
- 2.5x/ml Vitamin concentrate 100x 
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Study design 
 
Figure 2: Study design overview, timeline. Study screening procedure begins during the initial biopsy. Patient informed consent 
is obtained prior to the start of the biopsy procedure. Duration of the individual steps in the course of the clinical treatment is 
dependent on the selected chemotherapy regimen and other clinical and patient factors.   
 
The SpheroNEO study was designed as a prospective, non-interventional cohort 
study. Primary breast cancer patients (N=202) eligible for neoadjuvant chemotherapy 
were consecutively recruited for the study starting from October 2009 until Septem-
ber 2012 (Figure 2).  
In a feasibility assessment prior to the beginning of the study, breast cancer centers 
in Germany were asked to fill out a questionnaire estimating the number of potential 
patients eligible for neoadjuvant treatment. Sixty of the sites addressed for study 
feasibility, 27 responded and 15 were interested in study participation. A total of sev-
en met criteria for sufficient patient numbers and were initiated. An additional 7 sites 
in close association with the coordinating LMU University Hospital were also asked 
to participate without any prior feasibility assessment. All 14 study sites were asked 
to specify their preferred neoadjuvant chemotherapy regimen and to supply a rank-
ing of the most frequently applied treatment schemes. However, during the course of 
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this study this information proved unreliable, and a patient-by-patient recommenda-
tion made by the treating physician the day of the biopsy procedure was more likely 
to correspond to the actual clinical treatment the patient received (data not shown). 
The complete list of all participating breast cancer centers can be found in the a t-
tachment (Table 12). The study was performed in accordance to all applicable GCP 
regulations and approved by all applicable ethics committees (ethics committee ref-
erence Nr. 278/04, Ethikkommission bei der LMU München). Patients were asked to 
participate and recruited to the study following clinical diagnosis either through pal-
pation and/or radiological examination prior to the start of chemotherapy. Biopsy 
samples were obtained simultaneously for the SpheroNEO study and pathological 
confirmation of an invasive tumor. A written consent was obtained from all eligible 
patients prior to the biopsy procedure.  
The in- and exclusion criteria were as follows: 
Inclusion criteria: 
 Standard clinical, radiological, and pathological  treatment 
 Women >18 years old  
 Histological confirmed case of breast cancer  
 Written and oral consent to participate in the study 
 Ability to cooperate and understand the aims of the study 
 Laboratory: Cellular vitality of the study sample > 50 % 
Exclusion criteria: 
 Medical history of breast cancer 
 Previous or simultaneous malignant tumor (exceptions: squamous-cell or ba-
sal-cell carcinoma of the skin or cervical cancer in situ) 
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 Laboratory: Contamination of the spheroids by end of therapy  ≥ 50 % 
 Laboratory: Study sample shipment  > 72 h 
 Laboratory: Less than 4 wells with 10 000 cells each are available in cell cul-
ture for therapy prior to treatment 
Patients with a metastasized disease were also excluded for the final analysis. The 
clinical treatment for each patient was performed according to the standard 
neoadjuvant protocol [329-331] of each study site in accordance to national guideline 
recommendations. The final treatment decision was made by a tumor board consist-
ing of all treating physicians from the respective site following the completion of all 
relevant clinical and pathological examinations. The resulting recommendation for a 
particular treatment combination was communicated to the laboratory and arrived 
together with the tumor biopsy sample. An equivalent in vitro treatment was applied 
accordingly.  
Results obtained in the breast cancer spheroid model were not communicated to the 
treating physician(s) and had no impact on the clinical treatment of the patients. A 
comparison of the treatment efficacy in vitro and clinical outcome, documented in the 
pathological report of the surgical specimen, was performed after all patients had 
completed neoadjuvant drug treatment and underwent the subsequent surgery.  
Breast cancer spheroid model 
The method to generate patient-derived spheroids used here can be referred to as a 
modified liquid overlay technique, which is described in previous publications [320, 
332]. The method is patent-protected, for this reason some details are proprietary.  
A freshly prepared sterile shipping medium was sent to the participating study sites 
each week with an expiration date set to two weeks following production. The tumor 
tissue was immediately transferred into medium after excision and shipped at 4-8°C 
to the laboratory (SpheroTec GmbH, Martinsried, DE) for cell isolation.  
The entire laboratory procedure was performed according to standardized, quali-
ty-controlled (ISO9001:2008) operating procedures. All cell culture steps were per-
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formed in the central laboratory under a laminar flow-hood for semi-sterile conditions. 
Upon arrival, the study samples were transferred into fresh medium and stored at 
4oC for 1.25 – 162.75 min until the start of the cell isolation procedure. Subsequently, 
the tumor samples underwent mechanical and enzymatic digestion using an enzyme 
cocktail (Roche, Penzberg, DE) to generate a single-cell suspension. Cell number 
and viability were quantified using the trypan-blue exclusion test (Sigma Aldrich, 
Heidenheim, DE). The isolated cells were then evenly distributed on a 96-well plate 
together with a proprietary non-scaffold medium substrate. Spheroid formation took 
place in the subsequent 48 h under standard culture conditions (37° C, 5% CO2). 
Following this period of incubation, the morphology was assessed using bright -field 
microscopy.  
The spheroids were treated in vitro with the treatment combination recommended by 
the responsible tumor board of each study site. The peak plasma concentration (ppc) 
was used. The applied ppc was based on a literature search documenting the results 
of phase one and/or pharmacokinetic studies of the same or other tumor types. For 
each experiment/study sample control wells were included using the solvent control 
of the applied substance(s). Both solvent controls and ppc for each substance are 
listed in Table 1 below. In order to control for material artefacts of the utilized plates 
and medium, negative control wells without cells were also included. Values ob-
tained from this blank control were subtracted from measured absolute data.    
Table 1: Overview of the utilized compounds and the corresponding ppc concentration.  
Compound 
1 ppc 
[µg/ml] 
Molecular weight 
[g/mol] 
1 ppc 
[µmol/l] Solvent 
Literature 
source  
Carboplatin 40.843 371.254 110.014 H2O [333] 
Cyclophosphamid 41.000 261.086 157.036 NaCl [334] 
Docetaxel  2.180 807.8792 2.698 EtOH [335] 
Doxorubicin 1.640 543.5193 3.017 NaCl / H2O [336] 
Epirubicin 1.005 543.5193 1.849 NaCl [337] 
5-FU  100.000 130.0772 768.774 H2O [333] 
Paclitaxel  1.530 853.9061 1.792 EtOH [333] 
Trastuzumab  88.000 145531.5 6.047 H2O [338] 
ppc, peak pl asma concentrati on, N aCl, Sodium chloride, EtOH, Ethanol, 5-FU, 5-Fluorouracil.  
 
Following the 96 h drug incubation period, treatment efficacy was determined using a 
standard assay measuring metabolic activity (Promega, Mannheim Germany) to 
quantify cell survival in vitro, MTS (fluorescence) or ATP (luminescence). Both viabil-
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ity assays were performed according to manufacturer’s instructions. Irrespective of 
the applied readout technology, mean cell survival was expressed as percent of 
metabolic activity relative to control wells. Laboratory test results were available after 
eight days.  
Data management and statistics 
Clinical and laboratory data was recorded in a case report form (CRF) and collected 
from all clinical sites at the end of the study. Study documentation was done in part 
by on-site staff and external personnel. A clinical research organization was com-
missioned with monitoring activities and the collection of the completed CRF. The 
clinical and laboratory data was subsequently entered into a relational database 
specifically designed for the trial data (Access 2010). Correct clinical data entry was 
verified by two physicians, and laboratory data was verified by several members of 
the laboratory team. Statistical analysis was done in cooperation with the Institute for 
Medical Informatics, Biometry and Epidemiology (IBE) in Munich. The data was ex-
tracted from the database to a SPSS file and provided to an independent statistician 
for analysis. The patient cohort was analyzed as intention-to-treat, meaning the 
treatment, which each patient initially began was used for the subsequent correlation 
irrespective of change in regimen, incomplete number of cycles, or dose reduction. 
Clinical and laboratory data was described separately for patients with and without 
pCR using appropriate measures of location and dispersion. The discriminatory 
power of the spheroid model and traditional risk factors were analyzed using receiver 
operating characteristic (ROC) curves and the corresponding c statistics (areas un-
der the ROC curves, AUC). The ROC curves were calculated with the logistic re-
gression procedure using the R package penalized. A potential cutoff was calculated 
based on the 95th percentile of the residual activity in women with pCR and the re-
sulting sensitivity and specificity. The respective 95% confidence intervals were con-
sidered for each factor. A calculation of the Youden Index resulted in the same cutoff 
value. Statistical tests for categorical factors were done using Pearson’s chi-square  
or Fisher’s exact tests, ANOVA and t-tests for numerical variables. Strength and type 
of correlation between two numerical factors was done using the Pearson’s product-
moment correlation and Pearson’s r is reported. Associations for ordinal factors were 
tested using the Spearman's rank correlation coefficient. Odds ratios for cell survival 
and frequently used clinical predictors of pCR were calculated using univariate and 
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multiple regression models. Odds ratios in the multiple-regression models were cal-
culated using a forward selection based on Wald tests. Single factor regression 
analysis was done using a linear regression model and the change in R2 was deter-
mined. All hypotheses tested were two-sided on an alpha level of 5%. Analyses were 
performed using the Statistical Analysis System SAS, version 9.2 for Linux (SAS In-
stitute, Cary, NC, USA), R version 2.12.2 (The R Foundation for Statistical Compu-
ting, Vienna, AT), as well as SPSS Statistics version 22.0 (IBM, Armonk, NY, USA).
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Study participant in- and exclusion 
A total of 202 patients were enrolled in the SpheroNEO Study from 14 clinical sites 
associated with the University Hospital of the LMU, as well as other breast cancer 
centers located in the central and southern part of Germany. The mean drop-out rate 
was 65.15% with a range of 25-100% per study site. A total of 15.25 patients were 
enrolled and screened in the study per month, the recruitment per site ranging from 
0.25 to 3.33 patients per month, data is shown in detail in Table 12 of the supple-
mentary material. The study was generally well-received due to its simple manage-
ment for the on-site hospital staff.  
Exclusion criteria for the screened patients as shown in the study flowchart (Figure 
3) are separated into clinical and laboratory criteria. The two main clinical reasons for 
exclusion related to the selection of the treatment regimen. A total of 30 patients did 
not receive neoadjuvant treatment as initially planned, instead underwent surgery 
and/or adjuvant chemotherapy, anti-hormone treatment. Patients with a diagnosis of 
metastatic disease (N=5) were also excluded from the final analysis.  
The second main reason for exclusion (N=21) was the discrepancy between clinical 
and in vitro treatment selection. The initial recommendation for the in vitro treatment 
regimen was communicated upon shipment of the tissue specimen. At this time 
point, the final pathological report as well as the staging examination had not been 
completed and no final treatment decision had been made. In some cases, data ob-
tained through these staging examinations caused the tumor board of the respective 
clinical study site to recommend a different treatment regimen from the one initially 
recommended.  
A prior malignant disease lead to the exclusion of 7 patients , this criteria applied to 
malignant neoplasms which appeared in the patients’ medical history at least 5 five 
years prior to the current diagnosis. A total of 6 patients were considered loss to fol-
low-up; reasons were incomplete clinical documentation, continuation of treatment in 
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the patient’s country of origin, or a patient’s decision to switch medical facilities for 
subsequent treatment. Two samples were obtained from suspicious lesions which 
were diagnosed as benign upon further inspection.  
 
 
Figure 3: Study f lowchart depicting the screening process of the patients in the study cohort. ≠, unequal to, pCR, pathologic 
complete response.  
 
The main reason for laboratory exclusion was low baseline metabolic activity. A 
threshold twice the mean luminescence as measured in the untreated controls was 
considered sufficient for differential results (107.5 cps). Metabolic activity below this 
threshold was found for 32 study samples, which was significantly associated with a 
low sample weight (r(175) =.177, p =.019). The number of necessary biopsy cylin-
ders was not specified in the initial study protocol and varied between patients and 
study sites. Site staff reported problems such as bleeding, patient discomfort, and 
difficulty maintaining a good biopsy trajectory as reasons for low number of addition-
al biopsy cylinders available for the study. A mean of 3.55 cylinders were received 
per study sample with a range of 1-12. A total of 13 patients were excluded due to 
the insufficient number of isolated cells (12 000 total isolated cells per study sample). 
In vitro Diagnostic test results
correlated with pCR (N=78) 
Assessed for eligibility (N=202)
Excluded due to clinical criteria (N=71)
• No neoadjuvant drug therapy (N=30)
• Clinical treatment ≠ in vitro treatment (N=21)
• Previous malignant disease (N=7)
• Clinical data not available (N=6)
• Metastatic disease (N=5)
• No malignant tumor (N=2)
Excluded due to laboratory criteria (N=53)
• Cell metabolic activity under threshold (N=32)
• Insufficient number of epithelial cells (N=13)
• Cell viability <  50% (N=3)
• Technical difficulties (N=3)
• Yeast contamination (N=2)
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Cell viability over all received samples was good with a mean of 85.92% (range 6.10 
– 100%), three patients were excluded with a viability < 50%. In the final analysis the 
threshold of 70% cellular viability as previously specified in the study synopsis was 
determined to be an insufficient determinant for inclusion given the diverse tissue 
composition of the study samples, this led to the subsequent inclusion of two pa-
tients with a cellular viability <70%. One patient was included in the final analysis 
despite low viability at 26.2% since the number of vital cells was sufficient to obtain 
successful assay readout (3.41 *106 total isolated cells). Reason for low viability 
were insufficient shipping conditions and handling of the study samples (transporta-
tion in NaCl solution (N=2), or a long period before transfer to culture medium). 
Yeast contamination of the cultured cells was observed for two samples. Technical 
difficulties led to the exclusion of three study samples. During the initial phase of the 
study the laboratory criteria for a successful assay were defined broadly to compen-
sate for problems in the initial setup of the trial logistics. In the later phase of the 
study, laboratory criteria were amended according to the experience gained from the 
starting phase. The inclusion and exclusion criteria were amended to compensate for 
the information gained during the beginning of the study (Amendment III approved 
10.11.2011) by expanding the age of eligibility to patients older than 18 at diagnosis, 
excluding patients with a tumor diagnosis simultaneous to or ≤ 5 years prior to study 
enrollment, as well as the addition of laboratory inclusion criteria (cellular vitality of 
<70%, study sample shipment duration of <48h).   
The final analysis included 78 patients, who qualified according to both clinic and 
laboratory criteria. The anonymized patient list is found in the supplementary materi-
als with applicable exclusion criteria for all of the screened patients (Table 13). 
Factors influencing successful assay outcome 
A successful assay outcome, defined as valid readout results distinctly discerning 
cell survival from the applied cytostatic treatment to the solvent control, was signifi-
cantly associated with several laboratory factors as shown in Table 2. Out of all 
samples, a total of 129 (63.9%) met all laboratory eligibility criteria. The following 
analysis compares these 129 samples to the remaining 73 that did not meet all crite-
ria. The most prominent factors for assay success were directly or indirectly correlat-
ed with the absolute number of cells isolated from the study samples. The absolute 
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number of isolated cells per mg and metabolic activity of the solvent controls per cell 
was also highly correlated with assay success (successful assay outcome with mean 
0.515 *106 vs 0.097 *106 cells; p =.000; 0.306 vs 0.052 cps/cell, p =.023). Total sam-
ples weight (mean 102.02 vs 44.28 mg, p =.000),  number of biopsy cylinders re-
ceived (mean 3.87 vs 2.94, p =.000), total enzyme used during tissue dissociation 
(mean 1.32 vs 0.98 units, p =.001), cell viability following digestion (87.48% vs  
82.54%, p =.008), number of cells per spheroid (mean 23 977 vs 11 762.55 cells per 
spheroid, p =.000), number of generated spheroids (mean 7.18 vs 4.55, p =.000), 
number of treatment options applied per study sample (mean 1.72 vs 1.20, p =.000), 
and readout method used following treatment in vitro (mean 90.9% MTS vs 67.8% 
ATP, p =.009) were all significantly correlated to a valid assay outcome.    
Regression analysis showed that the absolute number of cells isolated per study 
sample (all biopsy cylinders received per patient) allowed a fairly accurate estimate 
for the number of treatment options which could be tested in the assay (Figure 4A, 
R2=0.264, p =.000). This factor is critical for the comparison of several clinically rele-
vant treatment options in the assay, using the resulting linear equation a minimum of 
2.984 *106 cells are necessary to test four treatment options in the assay. This cell 
number corresponds to a total samples weight of 248.08 mg. As previously men-
tioned, the number of isolated cells also factors highly in the successful readout at 
the end of the assay. Sample characteristics figuring most importantly in the total 
number of isolated cells were total sample weight and weight per received biopsy 
cylinder. A regression analysis of both factors resulted in a highly significant estima-
tion of net cell yield (Figure 4B and 4D, total sample weight, R2=0.764; weight per 
biopsy cylinder, R2=0.166, both p =.000). The number of biopsy cylinders received 
per study sample was also associated with net cell yield but the association was not 
significant (Figure 4C, R2=0.032, p =.053).  
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Figure 4: Factors influencing assay outcome, relation between the absolute number of isolated cells per study sample (N=129 
eligible according to laboratory criteria) and A) number of treatment options, B) total sample w eight, C) the number of biopsy 
cylinders received per patient, and D) w eight per individual biopsy cylinder. The coeff icient of determination as obtained 
through regression analysis is displayed at the top of each graph. 
 
Table 2: Overview of factors influencing assay outcome, overall received study samples and compared according to successful 
assay outcome. 
     Lab criteria fulfilled 
    
  
Yes 
 
 
No 
 
  
 
N 
 
% 
  
N 
 
% 
 
 
N 
 
% 
 
p-value 
All Study samples  202 -  129 63.9  73 36.1  
 
Tissue and logistic cri teria 
  
 
      
No. of biopsy cylinders received         .000 
 Mean 3.55  3.87  2.94  
 Range 1-12  1-12  1-6  
Weight study sample [mg]          .000 
 Mean 82.573  102.02  44.28  
 Range 0.90–1568.00  8.90-1568.00  0.90-176.50  
Biopsy method          .427 
 Core needle biopsy 198 98.0  126 63.6  72 36.4  
 Vacuum-assisted biopsy 2 0.99  2 100  0   
 Excision biopsy 2 0.99  1 50  1 50  
No. of technical replicates         .939 
 Mean 2.19  2.20  2.14  
 Range 1-6  1-6  2-5  
Transport in medium         .153 
 Yes 181 89.6  121 66.9  60 33.1  
 No 9 4.5  5 55.6  4 44.4  
 Not documented 12         
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Transport medium not expired 
  
 
     
 
.460 
 Yes 153 75.7  101 66.0  52 34.0  
 No 21 10.4  16 76.2  5 23.8  
 Not documented 28 13.9        
No. of days TM expired [d]          .768 
 Mean 7.33  8.19  4.60  
 Range 1-61  1-61  1-9  
 
Characteristics cell isolation procedure  
 
    
Time diff. biopsy – begin lab procedure [h]        .447 
 Mean 27.23  25.80  30.05  
 Range   1.25-87  7.25-162.75  
Mechanical isolation [min]         .868 
 Mean 11.57  11.81  11.10  
 Range 2-45  2-45  3-23  
Enzymatic isolation [min]        .711 
 Mean 158.42  156.99  161.30  
 Range 103-285  103-275  107-285  
Total time isolation procedure        .836 
 Mean 169.99  168.80  172.40  
 Range 112-295  112-287  119-295  
Total enzyme added [units]          .001 
 Mean 1.21  1.32  0.98  
 Range 0.65-5.20  0.65-5.20  0.65-2.6  
Total No. of vital cells [*106]         .000 
 Mean 0.383  0.515  0.097  
 Range 0-34.092  0.012-34.092  0-1.420  
Cell viability [%]           .008 
 Mean 85.92  87.48  82.54  
 Range 6.10-100  26.2-100  6.1-100  
No. of cells per spheroid        .000 
 Mean 20206.29  23977.68  11762.55  
 Range 852-187500  2841-187500  852-80000  
No. of cells per spheroid         .000 
 < 10 000 68 33.7  32 47.1  36 52.9  
 10 000 – 20 000 45 22.3  36 80.0  9 20.0  
 > 20 000 69 34.2  59 85.5  10 14.5  
 Not documented 20 9.9  2 10.0  18 90.0  
No. of spheroids generated         .000 
 Mean 6.34  7.18  4.55  
 Range 0-60  2-60  0-35  
 
Cellular characteristics in vitro  
Incubation of generated spheroids [h]         .853 
 Mean 50.22  49.97  50.86  
 Range 36-94  36-79  46-94  
No. of treatment options          .000 
 Mean 1.57  1.72  1.20  
 Range 1-9  1-9  1-6  
Metabolic activity solvent controls [cps/cell]         .023 
 Mean 0.235  0.306  0.0516  
 Range 0.000 – 6.648  0.000 – 6.648  0.000 – 0.620  
Readout method           .009 
 ATP 143 70.8  97 67.8  46 32.2  
 MTS 33 16.3  30 90.9  3 9.1  
 No readout 26 12.9        
No., number of, TM, transport medi um, d, days , h,  hours, min, minutes, cps, counts per second, ATP, adenosi ne triphosphate, M TS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium. 
 
Factors related to the logistics of the sample shipment (biopsy method, transporta-
tion medium, expiration thereof) as well as characteristics of the cell isolation proce-
dure (time difference between tissue excision, duration of mechanical, enzymatic, 
total duration of tissue isolation) did not show any significant impact on assay suc-
cess, see Table 2. The time difference between tissue excision and the beginning of 
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the laboratory procedure (cell isolation, p =.526), as well as the number of technical 
replicates also did not have an impact on assay outcome (p =.939).  
As described in the methods section above, spheroid formation was confirmed fo l-
lowing a mean of 50.22 h (range 36-94 h) incubation. Differences in incubation time 
were not significantly associated with assay success (49.97 vs 50.86 h, p =.853).  
Clinical factors were also tested in regard to assay success: only age was signifi-
cantly associated with assay success (p =.007). A higher percentage of patients over 
50 years were excluded due to metabolic activity below threshold (20 out of 32 e x-
cluded patients). However, an association with laboratory exclusion criteria was not 
found (p =.123). All other tested factors were not associated with assay success, as 
shown in Table 3. 
 
Table 3: Overview of association of clinical factors with successful assay outcome. 
                     Laboratory criteria fulfilled 
  
  
Yes 
 
 
No 
 
 
 
 
  
N 
 
% 
 
 
N 
 
% 
 
p-value 
All patients  
 
129 63.9  73 36.1 
 
 
Clinical characteristics 
        
Age at diagnosis [y]        .183 
 ≤50  62 69.7  27 30.3  
 >50  67 59.8  45 40.2  
Mean   53.2 
21-85 
 56.1 
32-82 
.123 
Range     
BMI        .604 
 Under/Normal w eight  56 67.5  27 32.5  
 Overweight/Adipose  55 72.4  21 27.6  
 Not documented  18 41.9  25 58.1  
Effected side        .083 
 Left  71 68.3  33 31.7  
 Right  47 57.3  35 42.7  
 Not documented  11 68.8  5 31.2  
Centricity/focality        .651 
 Mult ifocal  30 58.8  21 41.2  
 Mult icentric  14 70.0  6 30.0  
 Unicentric  75 64.1  42 35.9  
 Not documented  10 71.4  4 28.6  
Quadrant        .409 
 Central  7 70.0  3 30.0  
 Upper-inner   14 77.8  4 22.2  
 Low er-inner  2 33.3  4 66.7  
 Upper-outer  28 65.1  15 34.9  
 Low er-outer  7 77.8  2 22.2  
 Several overlapping quadrants effected  10 76.9  3 23.1  
 Caudal  1 50.0  1 50.0  
 Quadrant not specif ied  1 50.0  1 50.0  
 Not documented  -   1 100  
Tumor stage        1.000 
 cT1/T2  90 64.3  50 35.7  
 cT3/4  31 64.4  17 35.4  
 Not documented  8 57.1  6 42.9  
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Nodal status 
       .222 
 cN+  65 69.9  28 30.1  
 cN-  58 61.1  37 38.9  
 Not documented  6 42.9  8 57.1  
UICC          .251 
 IA  10 66.7  5 33.3  
 IIA  47 63.5  27 36.5  
 IIB  31 57.4  23 42.6  
 IIIA  19 86.4  3 13.6  
 IIIB  7 63.6  4 36.4  
 IIIC  0 -  1 100  
 IV  5 71.4  2 28.6  
 Not documented  10 55.6  8 44.4  
Clinical tumor size at diagnosis, 
largest diameter [cm] 
 
 
   
   
 MRI (N=69)        
 Mean  3.4  3.8 .361 
 Range  0.7-9.5  1.0-8.0  
 Mammography (N=137)        
 Mea  3.2  2.9 .238 
 Range  1.0-10.0  0.1-7.0  
 Sonography (N=169)        
 Mean  3.0  2.8 .273 
 Range  1.15-8.0  0.11-6.0  
 
Histopathological characteristics 
       
Grading        .123 
 G1/2  65 19.5  40 80.5  
 G3  56 37.1  29 62.9  
 Not documented  8 66.7  4 33.3  
Histologic type        .361 
 Ductal invasive  81 62.8  48 37.2  
 Ductal invasive + DCIS component  14 56.0  11 44.0  
 Lobular invasive  16 69.6  7 30.4  
 Invasive ductal/lobular  1 100  0 -  
 Medullary  2 100  0 -  
 Inflammatory  2 50.0  2 50.0  
 Other  10 90.9  1 9.1  
 Not documented  3 42.9  4 57.1  
ER status        .732 
 Negative  38 69.1  17 30.9  
 Positive  81 65.3  43 34.7  
 Not documented  10 43.5  13 56.5  
PR status        .428 
 Negative  52 70.3  22 29.7  
 Positive  69 64.5  38 35.5  
 Not documented  8 38.1  13 61.9  
HER2 status        .593 
 Negative  94 18.6  47 81.4  
 Positive  28 62.5  17 37.5  
 Not documented  7 43.8  9 56.2  
Triple negative        .432 
 Yes  27 73.0  10 27.0  
 No  85 64.4  47 35.6  
 Not documented  17 51.5  16 48.5  
Ki67 (biopsy)        .230 
 <=30% (median)  39 22.2  29 77.8  
 > 30%  31 42.3  13 57.7  
 Not documented  59 65.6  31 34.4  
Mean   37%  28% .084 
Range   3-99%  1-85%  
HR/HER2        .853 
 HR+/HER2+  20 66.7  10 33.3  
 HR+/HER2-   62 65.3  33 34.7  
 HR-/HER2+  7 63.6  4 36.4  
 HR-/HER2-   27 73.0  10 27.0  
 Not documented  13 44.8  16 55.2  
y, years, BMI, body mass index, UICC, Uni on for International Cancer Control,  MRI, magnetic resonance imaging, DCIS, ductal carcinoma i n situ, ER, es trogen receptor,  
PR, progesterone receptor, HER2, human epidermal growth factor receptor 2, HR, hormone r eceptor.  
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Laboratory baseline factors of the study cohort 
The laboratory baseline data is shown in  
Table 4. A mean of 4 biopsy cylinders were received per study sample with a range 
of 1-12. The weight per cylinder averaged at 22.71 mg, ranging between 3.28 to 
123.87 mg for the samples in the final analysis. The total weight of tumor tissue per 
received sample averaged to 114.1 mg (range 8.9 – 1568.0 mg). The majority of 
study samples were obtained through a core needle biopsy procedure (96.2%); 
however two samples were obtained through a vacuum-assisted biopsy and one 
through an excisional biopsy procedure.  
 
Table 4: Summary of laboratory baseline characteristics and correlation w ith the mean cell survival of the clinically relevant 
cytostatic treatment in vitro as measured in the breast cancer spheroid model.  
      
      
  N % % cell survival p-value 
All Study samples  78 100   
Cell survival     
 Mean 51.97   
 Range 3 – 103   
 
Tissue and logistic cri teria 
     
No. of biopsy cylinders received     .486 
 Mean 4   
 Range 1-12   
Weight study sample [mg]      .150 
 Mean 114.1   
 Range 8.9-1568.0   
Biopsy method     * 
 Core needle  75 96.2 53.8  
 Vacuum-assisted  2 2.6 7.3  
 Excision  1 1.3 4.1  
Transport in medium    * 
 Yes 74 94.9 53.0  
 No 3 3.8 35.3  
 Not documented 1 1.3 -  
Transport medium not expired    .208 
 Yes 61 78.2 54.6  
 No 12      15.4 42.7  
 Not documented 5 6.4 -  
No. of days TM expired [d]     .742 
 Mean 10   
 Range 1-61   
 
Characteristics cell isolation procedure 
 
  
Time diff. biopsy – begin lab procedure [h]   .526 
 Mean 26.3   
 Range 4.75-85.5   
Mechanical isolation [min]    .579 
 Mean 11.76   
 Range 3-45   
Enzymatic isolation [min]   .937 
 Mean 160.6   
 Range 103-275   
Total time isolation procedure [min]   .971 
 Mean 172.3   
 Range 112-287 
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Total enzyme added [units]     .520 
 Mean 1.4   
 Range 0.65-5.2   
Total no. of vital cells after filtration    .102 
 Mean 0.686 x106   
 Range 13200-34.092x106   
Cell viability [%]     .121 
 Mean 87.2   
 Range 26.2-97.6   
No. of cells per spheroid   .827 
 Mean 24646   
 Range 2841-187500   
No. of cells per spheroid grouped    .841 
 < 10 000 22 28.2 55.5  
 10 000 – 20 000 20 25.6 50.8  
 > 20 000 36 46.2 50.5  
No. of spheroids generated    .008 
 Mean 7   
 Range 2-60   
No. of technical replicates    .023 
 Mean 2   
 Range 1-6   
Incubation of generated spheroids [h]    .010 
 Mean 50   
 Range 36-75   
Metabolic activity [cps/cell]    .023 
 Mean 0.322   
 Range 0.000 – 6.648   
No. of treatment options    .002 
 Mean 2   
 Range 1-9   
Readout method     .000 
 ATP 62 79.5 42.2  
 MTS 16 20.5 89.9  
* No statistics availabl e due to sampl e size < 5 in the subgroup comparison. No.,  number of, TM, transport medium, d, days , h,  hours, min, minutes, 
cps, counts per second, ATP, adenosi ne triphosphate, MTS, 3-(4,5-di methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium.  
 
The time between biopsy harvesting and the start of the cell isolation was between 
4.75 and 85.5 h, with a mean of 26.3 h. Twelve samples (15.4%) were shipped in 
expired media with a range between 1 to 61 days past expiration date, however this 
was not associated with any differences in assay quality or outcome . Mechanical 
isolation varied with tissue consistency and percentage of included connective tis-
sue, a mean of 11.76 min was documented (range 3 – 45 min). The following enzy-
matic isolation continued for another 160.6 min (range 103 – 275 min) with a total of 
1.4 units of enzyme (range 0.65 – 5.2). The complete isolation procedure totaled to a 
mean of 172.3 min (range 112 – 287 min) until a single cell suspension was ob-
tained.  
A mean yield of 0.686 x 106 cells were obtained from the study samples (range 
13200 – 34.092 x 106 cells per sample) with a mean of 3330 cells per mg sample 
weight (range 131 – 22927 cells/mg).  
Mean overall cell viability was 87.2% (range 26.2 – 97.6%). A total of 7 spheroids 
were generated per sample (range 2 – 60) with a mean of 24646 cells per spheroid 
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(range 2841 – 187500 cells/spheroid). Seeded cells were subsequently kept in cul-
ture for a total of 50 h (range 36 – 75 h).  
Two separate assays measuring cell viability were used to assess cell survival fo l-
lowing cytostatic treatment in vitro; the majority of the samples (79.5%) samples 
were analyzed using the ATP assay. 
Baseline clinical characteristics of the patient cohort 
Baseline clinical characteristics of the patient cohort are shown in Table 5. A com-
parison of this cohort to other large trials in the neoadjuvant treatment setting 
showed that main characteristics such as age, clinical tumor stage, tumor histology 
and receptor status were representative [71, 339]. Comparison of the patients that 
were included in the final analysis to those excluded showed no significant differ-
ences in factor distribution with the exception of age. Older patients were more likely 
to be excluded (supplementary  
 
Table 14). Patients older than 50 were less likely to receive neoadjuvant chemothera-
py (19 out of 30 excluded patients) and treatment often varied from the initial rec-
ommendation due to existing medical conditions (14 out of 20 excluded patients).  
 
Table 5: Clinical and pathological characteristics of the analyzed cohort. Presented data was collected at the time of the init ial 
diagnosis. 
               pCR  
    
  
Yes 
 
 
No 
 
 
 
 
 
N 
 
% 
  
N 
 
% 
 
 
N 
 
% 
 
p-value 
All Patients  78 100 
 
22 28.2  56 71.8 
 
 
Clinical Characteristics 
          
Age at diagnosis [y]          .207 
 ≤50 43 55.1  15 34.9  28 65.1  
 >50 35 44.9  7 20.0  28 80.0  
Mean  51 
21 - 78 
 46 
21-65 
 53 
25-78 
.045 
Range     
BMI          .620 
 Under/Normal w eight 39 50.0  10 25.6  29 74.4  
 Overweight/Adipose 38 48.7  12 31.6  26 68.4  
 Not documented 1 1.3  -   1 -  
Effected side          .801 
 Left 46 58.9  13 28.3  33 71.7  
 Right 29 37.2  9 31.0  20 69.0  
 Not documented 3 3.9  -   3 -  
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Centricity/focality 
 
  
       
.067 
 Mult ifocal 19 24.4  6 31.6  13 68.4  
 Mult icentric 10 12.8  6 60.0  4 40.0  
 Unicentric 44 56.4  10 22.7  34 77.3  
 Not documented 5 6.4  -   5   
 
 
Quadrant 
 
 
        
 
.088 
 Central 5 6.4  0 -  5 100  
 Upper-inner  12 15.4  5 41.7  7 58.3  
 Upper-outer 20 25.6  8 40.0  12 60.0  
 Low er-outer 3 3.8  2 66.7  1 33.3  
 
Several overlapping 
quadrants effected 
6 7.7 
 
0 -  6 
100  
 Quadrant not specif ied 32 41.0  7 21.9  25 78.1  
Tumor stage          .779 
 cT1/T2 56 71.8  16 28.6  40 71.4  
 cT3/4 21 26.9  5 23.8  16 76.2  
 Not documented 1 1.3  1 4.5  -   
Nodal status          1.000 
 cN+ 42 53.8  12 28.6  30 71.4  
 cN- 35 44.9  10 28.6  25 71.4  
 Not documented 1 1.3  -   1 -  
UICC             .740 
 IA 6 7.7  1 16.7  5 83.3  
 IIA 30 38.5  8 26.7  22 73.3  
 IIB 21 26.9  8 38.1  13 61.9  
 IIIA 15 19.2  3 20.0  12 80.0  
 IIIB 4 5.1  1 25.0  3 75.0  
 IIIC -    -   -   
 IV -    -   -   
 Unknown 2 2.6  1 -  1 -  
Clinical Tumor Size at diagnosis, 
largest diameter [cm] 
 
  
 
   
   
 MRI (N=36)          
 Mean 3.6  3.4  3.3 .517 
 Range 0.7-9.5  1.8-6.60  0.70-9.50  
 Mammography (N=57)         
 Mea 3.2  2.9  3.3 .285 
 Range 1.0-8.0  1.0-4.6  1.3-8.0  
 Sonography (N=69)         
 Mean 3.0  3.0  3.0 .948 
 Range 1.15-8.0  1.3-6.0  1.15-8.0  
 
Histopathological characteristics 
         
Grading          .123 
 G1/2 41 52.6  8 19.5  33 80.5  
 G3 35 44.9  13 37.1  22 62.9  
 Not documented 2 2.6  1 4.5  1 -  
Histologic type          .498 
 Ductal invasive 53 67.9  17 32.1  36 67.9  
 
Ductal invasive + DCIS 
component 
7 9.0 
 1 14.3  6 85.7  
 Lobular invasive 8 10.3  1 12.5  7 87.5  
 Invasive ductal/lobular 1 1.3  - -  1 100.0  
 Medullary 1 1.3  1 100.0  -   
 Inflammatory 1 1.3  -   1 100.0  
 Other 7 9.0  2 28.6  5 71.4  
ER status          .180 
 Negative 26 33.3  10 38.5  16 61.5  
 Positive 49 62.8  11 22.4  38 77.6  
 Not documented 3 3.8  1 4.5  2 3.6  
PR status          .002 
 Negative 36 46.2  16 44.4  20 55.6  
 Positive 41 52.6  5 12.2  36 87.8  
 Not documented 1 1.3  1 -  - -  
           
HER2 status          .001 
 Negative 59 75.6  11 18.6  48 81.4  
 Positive 16 20.5  10 62.5  6 37.5  
 Not documented 3 3.8  1 -  2 -  
Triple negative          1.000 
 Yes 18 23.1  5 27.8  13 72.2  
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 No 52 66.7  14 26.9  38 73.1  
 Not documented 8 10.2  3 -  5 -  
Ki67 (biopsy)            
 <=30% (median) 27   6 22.2  21 77.8 .148 
 > 30% 26   11 42.3  15 57.7  
 Not documented 25   5 -  20 -  
 
Mean 
 
 
30% 
  
40% 
  
36% 
 
.644 
Range  5-95%  5-80%  5-95%  
HR/HER2              .001 
 HR+/HER2+ 10   6 60.0  4 40.0  
 HR+/HER2-  39   5 12.8  34 87.2  
 HR-/HER2+ 5   4 80.0  1 20.0  
 HR-/HER2-  18   5 27.8  13 72.2  
 Not documented 8 10.3  3 -  5 -  
 
Drug treatment 
          
Drug treatment          .001 
 AC -> T 57 73.1  11 19.3  46 80.7  
 AC -> TH 9 11.5  8 88.9  1 11.1  
 TCbH 7 9.0  2 28.6  5 71.4  
 AC -> TCb 3 3.8  1 33.3  2 66.7  
 AC 2 2.6  0 -  2 100.0  
Treatment adherence          .016 
 Yes 60 76.9  21 35.0  39 65.0  
 No 18 23.1  1 5.6  17 94.4  
 
Endpoints 
          
Residual tumor size          .000 
 ypT0 19 24.4  19 86.4  -   
 ypTis 4 5.1  -   4 7.3  
 ypT1 26 33.3  -   26 47.3  
 ypT2 16 20.5  -   16 29.1  
 ypT3 8 10.3  -   8 14.5  
 ypT4 1 1.3  -   1 1.8  
 Not documented/ ypTx 4 5.1  3 13.6  1 1.8  
Surgical therapy          .004 
 BCS Yes 54 69.2  20 90.9  34 60.7  
 No 22 28.2  1 4.5  21 37.5  
 Not documented 2 2.6  1 4.5  1 1.8  
Grade of regression          .000 
 0 3 3.8  -   3 5.9  
 1 38 48.7  -   38 74.5  
 2 7 9.0  -   7 13.7  
 3 3 3.8  -   3 5.9  
 4 22 28.2  22 100.0  -   
 Not documented 5   -   5 8.9  
y, years, BMI, body mass index, MRI, magnetic resonance i maging, DCIS, ductal carcinoma in situ, PR, progesterone receptor; ER, estrogen r eceptor, HER2, human 
epidermal  growth factor  receptor 2,  pCR, pathol ogic complete response,  A, anthracycline, T, paclitaxel or docetaxel,  C, cycl ophosphamide; C b, carboplatin, H, 
trastuzumab, BCS, breas t conser ving surgery. 
 
The mean age of the enrolled patients was 51 with a range of 21-78 years at initial 
diagnosis. A slightly higher percentage of patients were 50 or younger (55.1%). Age 
was significantly associated with pCR (p =.045), although a grouped comparison us-
ing the cutoff of 50 years was not (p =.207).  Assessment of body mass index (BMI) 
showed an even distribution of under/normal weight patients versus over-
weight/adipose patients (50.0% vs. 48.7%). The BMI did not have an impact on the 
outcome of the neoadjuvant therapy and pCR rates did not show a significant differ-
ence between the two groups under/normal weight and overweight/adipose patients. 
Regarding disease stage, the majority of the patients were stage UICC IIA (38.5%) 
with a slightly higher percentage of patients with a positive lymph node status 
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(53.8%) and a tumor size between 2-5 cm in diameter (cT2; 45 out of 77; 58.4%). 
These three factors however, had no impact on pCR in this group of patients. The 
tumor size, as measured through radiologic imaging either through magnetic reso-
nance imaging, mammography, or ultrasound, had a mean diameter of 3.6 (N=36), 
3.2 (N=57), and 3.0 cm (N=69) respectively. The diameter at initial diagnosis was not 
significantly associated with pCR, regardless of the applied imaging method. Study 
samples were mostly obtained from tumors of the left breast (58.9 %) located in the 
upper outer quadrant of the breast (25.6%). 19 cases of multifocal and 10 
multicentric tumor disease were included in the study but none of these factors had 
any impact on treatment outcome. 
Patient tumors were most frequently invasive ductal in their histology (N=53, 67.9%), 
7 tumors were identified as invasive ductal with included components of ductal carci-
noma in situ. Invasive lobular tumor histology was documented in a total of 8 pa-
tients. One patient exhibited a mixed invasive ductal/lobular histology. Medullary, 
inflammatory, metaplastic, neuroendocrine, squamous cell carcinoma histology was 
observed in one patient. Comparison of the pCR rates for the different types of his-
tology showed no observable differences. A two-group comparison of invasive ductal 
and/or other histologic types (N=70, 89.7%) and lobular histology did not reveal any 
difference in pCR rates (p =.429).  
An analysis of tumor biology revealed that 65.4% of tumors were HR+ with 62.8% 
(N=49) and 53.2% (N=42) positive for ER and PR respectively. A negative PR status 
(p =.002) was significantly associated with pCR, whereas the ER status was not (p 
=.180). HER2 overexpression was noted in 20.8% of the tumor samples. A positive 
HER2 status was also highly correlated with achieving pCR (p =.001). Classifying 
patients according to both HR and HER2 status showed that patients with a negative 
HR status as well as a positive HER2 status (N=4) were most likely to achieve pCR 
(80%) in this patient cohort, although a positive HR status only caused the percent-
age to drop to 60% (N=6). The combined HR/HER status was significantly related to 
pCR (p =.001), however group size was lower than 5 in three groups (HR-/HER2+, 
HR+/HER2+ and pCR no). A triple negative tumor biology was evident in 23.1% of 
the patients, the pCR rate for this group of patients was 27.8% and therefore slightly 
higher than the overall rate of pCR although not significantly so (p =1.000). 
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The observed mean rate of the Ki67 index was 30% positive cells with a range be-
tween 5-95%, correlation of the data did not reveal any difference in Ki67 for patients 
with pCR and those without (p =.644). Analysis of patient subgroups with values 
above and below the observed mean did not reveal any differences between the pa-
tients with pCR and those without, although more patients with pCR also had a Ki67 
value above 30%. However, data was only available for 53 (68%) of the study pa-
tients.  
Regarding chemotherapy regimen, all except two patients received taxane-based 
chemotherapy combined with either anthracycline or carboplatin. The mean duration 
of the complete treatment period starting from biopsy to histopathological analysis of 
the surgical specimen was 6.6 months (range 3.2 – 9.4 months) with a mean of 8.9 
received cycles (range 2 – 16) depending on choice of treatment regimen. All HER2+ 
patients received trastuzumab (H), combined with either carboplatin (6 cycles TCbH, 
N=7) or an anthracycline/taxane combination regimen: 4x Epirubicin + Cyclophos-
phamide (EC) followed by 4xDocetaxel (Doc, N=1)/12xPaclitaxel (Pac, N=8). HER2-
negative patients mainly received an anthracycline/taxane combination regimen of 4 
cycles EC followed by 4 cycles of Doc (N=39) or 12 weekly cycles of Pac (N=5). 
Carboplatin was added to the taxane treatment (Pac, N=2, Doc, N=1) in three cases 
following 4 cycles of anthracycline chemotherapy. Eight patients received the combi-
nation treatment consisting of Doc, doxorubicin, and cyclophosphamide (DocAC). 
Three patients were treated with three cycles of an anthracycline regimen containing 
5-FU followed by three cycles of Doc. Two patients received 2 or rather 4 cycles of 
EC without the addition of a taxane. One patient was simultaneously enrolled in the 
GeparQuinto Study (German Breast Group) studying the effect of Everolimus (Eve) 
on non-responders following 4 cycles of neoadjuvant anthracycline treatment and 
received this compound in combination with Pac [340]. Another patient switched to 
nanoparticle albumin-bound paclitaxel (nab-paclitaxel) following three cycles of 
paclitaxel therapy with prior anthracycline treatment due to an allergic reaction.  
Due to the small number of patients in each of the treatment regimen, patients re-
ceiving anthracycline/taxane combination therapy were combined in one group, e x-
cluding those patients also receiving carboplatin (N=59). In this subgroup of patients 
19.3% achieved pCR, compared to the other treatment combinations that showed a 
lower rate of successful treatment outcome (p =.009). Patients whose treatment in-
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cluded trastuzumab showed significantly higher rates of pCR: 9 out of 12, respective-
ly 8 out of 9 patients with anthracycline/taxane regimen combined with trastuzumab 
and 2 out of 7 receiving TCbH (p =.001). Treatment adherence defined as receiving 
all scheduled cycles and doses of the prescribed chemotherapy drugs was docu-
mented for 60, whereas a total of 18 patients received a reduced dose (N=9), ended 
chemotherapy prematurely (N=9), and/or switched drugs (N=5). Reasons for a 
change in treatment were either due to side effects or allergic reactions (N=8), pro-
gressive disease or no response (N=5), or patient preferences (N=2).  In three cases 
the reason for a change in the initially planned treatment was not documented. 
Treatment adherence was significantly associated with pCR (p =.016).   
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Predictive power of the breast cancer spheroid model for treatment outcome 
Following the completion of the clinical chemotherapy for all patients, a comparison 
was made between cell survival as measured in the breast cancer spheroid model in 
vitro and the documented clinical endpoints (pCR, grade of regression, ypT). Figure 
5A-B shows the individual values for the samples tested in the study grouped ac-
cording to pCR yes or no. A significant association between the two factors was 
found (p =.001). A mean cell survival of 21.8% was found in the breast cancer sphe-
roid model for patients with pCR versus 63.8% in non-pCR patients over all received 
clinical chemotherapy regimen. As can be seen in this figure a cutoff to correctly 
predict pCR using the assay was determined according to the 95th percentile of cell 
survival in patients achieving pCR at a value of 35% cell survival.  
 
Figure 5: Dot plot show ing the individual results of the analyzed sample plotted according to pCR Yes or No follow ing clinical treat-
ment. A) Patients receiving trastuzumab-based treatment are highlighted with grey triangles and in B) patients not adhering to the 
originally planned treatment regime are displayed as open circles. The dotted line represents the resulting cutoff at 35% cell survival 
in vitro. pCR, pathologic complete response 
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In Figure 5A the individual samples are highlighted to indicate patients receiving 
trastuzumab in addition to an anthracycline- or taxane-based regimen. For this sub-
group a mean of 21.9% versus 45.4% cell survival was seen in patients achieving or 
not achieving pCR respectively (see Table 6, p =.085). The HER2 status was also 
closely associated with the postulated cutoff (p =.000). A total of 28.8% (N=17) 
HER2 negative patients showed values below 35% cell survival in the breast cancer 
spheroid model, with the remaining 71.2% showed values above this cutoff. Patients 
with a HER2+ tumor predominantly showed results below 35% cell survival namely 
81.3% (N=13) out of the 16 HER2+ patients.  
Figure 5B highlights patients not adhering to the originally planned clinical treatment 
since this factor was also associated with the rate of observed pCR in this cohort as 
mentioned above. However, this factor was not related to the detected cell survival in 
vitro (p =.929) or cutoff in the model (p =.789).  
Hormone-receptor negative tumor samples showed a higher cytostatic treatment 
response compared to hormone-receptor-positive (p =.038). Refined subgroups ac-
cording to ER and PR status showed the lowest response to treatment in vitro for 
ER/PR-positive tumors (62.49%), followed by PR+/ER- or unknown samples 
(47.82%). The best response was observed for ER+/PR- or unknown samples 
(36.10%). A closer analysis of ER and PR status separately showed that PR+ was 
significantly correlated with higher observed cell survival in the assay (p =.007), 
whereas ER status was not (p =.084). PR negative samples showed a higher cyto-
static response (41.99%) compared to PR positive samples (61.77%). The distribu-
tion of the samples according to the cutoff value showed that the majority of samples 
with a negative PR status fell below the cutoff (N=20, p =.019). ER negative samples 
likewise responded better to treatment in vitro (43.40%), however the difference to 
ER positive samples was not significant (p =.097). Likewise, no significant associa-
tion was found for ER positive and negative samples and cell survival above or be-
low the cutoff (p =.224).  
No significant correlation was seen between other documented clinical factors and 
cell survival such as age at diagnosis (p =.877), tumor stage at diagnosis (p =.181), 
lymph node status (p =.813), grading (p =.339), or histologic type (p =.569). Similarly, 
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the number of patients with values below or above the cutoff also showed a similar 
distribution of values and no significant associations were found.  
 
Table 6: Correlation of cell survival cutoff w ith clinical and pathological factors 
     Cutoff 
      
   ≤35%  >35% 
           
 Mean cell survival [%] p-value  N %  N % p-value 
All Patients     32 41.0  46 59.0  
Age at diagnosis [y]   .877       1.000 
 ≤50 51.44   18 41.9  25 58.1  
 >50 52.61   14 40.0  21 60.0  
Mean    51 
21-76 
 51 
25-78 
.817 
Range     
Tumor stage   .181       .603 
 cT1/T2 49.40   24 42.9  32 57.1  
 cT3/4 60.66   7 33.3  14 66.7  
 Not documented -   1 100     
Nodal status   .813       1.000 
 cN+ 50.41   17 40.5  25 59.5  
 cN- 52.20   15 42.9  20 57.1  
 Not documented    -   1 100  
Grading   .339       .486 
 G1/2 55.34   15 36.6  26 63.4  
 G3 48.09   16 45.7  19 54.3  
 Not documented    1 50.0  1 50.0  
Histologic type   .569       .439 
 Ductal invasive/other 51.25   30 42.9  40 57.1  
 Lobular invasive 58.29   2 25.0  6 75.0  
ER status   .084       .224 
 Negative 43.40   13 50.0  13 50.0  
 Positive 57.10   17 34.7  32 65.3  
 Not documented    2 66.7  1 33.3  
PR status   .007       .019 
 Negative 41.99   20 62.5  16 34.8  
 Positive 61.77   11 34.4  30 65.2  
 Not documented    1 100  -   
HR status  .038       .042 
 ER+/PR+ 62.49   10 25.6  29 74.4  
 ER+/PR-/Unknow n 36.10   7 70.0  3 30.0  
 ER-/unknow n/PR+ 47.82   1 50.0  1 50.0  
 ER-/PR-  43.03   12 50.0  12 50.0  
HER2 status   .000       .000 
 Negative 58.34   17 28.8  42 71.2  
 Positive 30.70   13 81.3  3 18.7  
 Not documented    2 66.7  1 33.3  
Treatment adherence   .929       .789 
 Yes 51.79   24 40.0  36 60.0  
 No 52.58   8 44.4  10 55.6  
ypT-stadium   .000       .000 
 ypT0 23.49   18 94.7  1 5.3  
 ypTis 42.61   2 50.0  2 50.0  
 ypT1 59.65   5 19.2  21 80.8  
 ypT2 64.64   3 18.8  13 81.3  
 ypT3 88.52   0 -  8 100  
 ypT4 22.79   1 100  0 -  
 Not documented -         
Grade of regression   .000       .000 
 0 64.80   1 33.3  2 66.7  
 1 69.95   5 13.2  33 86.8  
 2 50.91   1 14.3  6 85.7  
 3 28.35   2 66.7  1 33.3  
 4 21.78   21 95.5  1 4.5  
 Not documented 5         
y, years, PR, pr ogesterone r eceptor; ER, estr ogen receptor; HER2, human epi dermal growth factor receptor  2, pCR, pathol ogic complete response. 
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Correlation of cell survival in the spheroid model with the ypT stage revealed that the 
breast cancer spheroid model was significantly related to the gradual response as 
seen in the surgical specimen after chemotherapy (Figure 6A; Spearman’s rho= .548  
p =.000). No residual tumor remaining in the surgical specimen (ypT0) or a remai n-
ing noninvasive component (ypTis) was associated with a lower cell survival in the 
assay (23.49% and 42.61% respectively) compared to mean cell survival for patients 
with remaining viable tumor cells following the completion of chemotherapy (ypT1, 
59.65%; ypT2, 64.64%; ypT3, 88.52%; ypT4, 22.79%). One patient was categorized 
as ypT4 due to a previously undiagnosed inflammatory component in the surgical 
sample, thus explaining the outlier found for the ypT4 category in Figure 6A. A simi-
lar results was seen for the comparison between grade of regression and cell survi v-
al in the breast cancer spheroid assay (Figure 6B; Spearman’s rho= -.611, p =.000), 
the higher the grade of regression the lower the recorded cell survival. Undetectable 
tumor cells in the surgical specimen (grade of regression = 4), as seen in 22 sam-
ples, was associated with a mean cell survival of 21.78%. An increasing amount of 
viable tumor tissue was highly associated with an increasing cell survival (grade of 
regression 3, 28.35%; grade of regression 2, 50.91%; grade of regression 1, 
69.95%; grade of regression 0, 64.80%).   
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The sensitivity and specificity of the determined cutoff value was calculated, and rel-
evant values are given in Table 7. Sensitivity or the rate of true positive treatment 
outcome prediction was calculated at 95.5% and specificity or the rate of the correct 
identification of non-pCR was determined at 80.4%.  The positive predictive value of 
the test, also referred to as the precision value of a test, was determined to be 21 out 
of 32 cases which equals to 65.6% while the negative predictive value was calcula t-
ed to be 45 out of 46 (97.8%). A calculation of the cutoff values according to the co l-
lected data using the Youden index resulted in the same value of 35% cell survival. 
The ratio between a true positive test result and false positive test results was de-
termined at 4.86 for the positive likelihood ratio. The corresponding negative likeli-
hood ratio was calculated to be 0.06. All six values can be used in this case, since 
the prevalence of pCR in this population is comparable to the rate of pCR in current 
literature and are therefore representative for the diagnostic accuracy of the assay.  
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Figure 6: Box plot diagram w ith overlaying dot plot of each individual study sample show ing mean cell survival in the breast cancer 
spheroid model after cytostatic treatment in comparison to the A) remaining tumor (ypT-stadium) and B) grade of regression as 
determined by the pathological assessment of the surgical specimen af ter chemotherapy. Cutoff of 35% is represented by the dotted 
line.  
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Table 7: Sensitivity and specif icity of the resulting cutoff, as well as 
other commonly used parameters used to assess the quality of di-
agnostic methods. 
  pCR [N]  
Cell survival [% solvent control]  Yes No Total 
≤ 35  21 11 32  
> 35   1 45 46 
Total  22 56 78 
Diagnostic accuracy     
Sensitivity  95.5 
Specificity  80.4 
Positive Predictive Value  65.6 
Negative Predictive Value  97.8 
Positive Likelihood  4.86 
Negativ Likelihood  0.06 
pCR, pathol ogic complete response. 
 
In order to further assess the predictive power of the breast cancer spheroid model 
the accumulated data was additionally analyzed in the context of established predic-
tors using a receiver operator characteristic curve (ROC). This graph summarizes 
the cost/benefit analysis of the assay, the benefit being the correct identification of 
patients likely to achieve pCR against the potential cost of incorrectly identifying pa-
tients who will not achieve pCR but are classified by the assay to do so. In this case 
the breast cancer spheroid model shows a high accuracy in predicting treatment out-
come (Figure 7A). The c statistic (area under the ROC curve) was calculated for the 
treatment results as well as for standard clinical parameters and the resulting value 
was compared. The c statistic is the probability of randomly selecting a set of pa-
tients from the pCR and non-pCR group and correctly classifying both. The values 
for the spheroid model are shown above the ROC curve in Figure 7A and Table 8. A 
comparable multivariate model using the clinical parameters age, ER, PR, as well as 
HER2 status resulted in a value of 0.7976. Combining the result obtained in the 
spheroid model with the factor of treatment adherence resulted in the highest AUC 
totaling to 0.9082, see Figure 7C. Calculating the sensitivity/specificity using only 
patients adhering to the initially planned protocol resulted in an improvement in the 
specificity of the assay to 89.7%, while the sensitivity remained the same. Several 
other factors were also analyzed in univariate and multivariate models, the corre-
sponding c statistics are given in Table 8.  
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Figure 7: Receiver operator curves (ROC) displaying the sensitivity and specif icity of  A) the breast cancer spheroid model, B) a 
mult ifactor model w ith baseline predictive factors (ER, PR, HER2, and age) impacting pCR , and C), a model combining the 
breast cancer spheroid model w ith the factor of treatment adherence defined as treatment discontinuation, dose-reduction or 
change of treatment. The resulting area under the curve (AUC) is displayed at the top of each graph  
 
Table 8: Corresponding c statistics from the ROC curve analysis 
Criteria AUC 
ER,PR, HER2, triple neg 0.7817 
ER, PR, HER2, Age 0.7976 
Breast cancer spheroid model plus clinic criteria (ER, PR, HER2, Age) 0.8587 
Lobular histology vs Others 0.8589 
HER2 status 0.8589 
PR status 0.8597 
cT1/2 vs. cT3/4 0.8605 
cN- vs. cN+ 0.8620 
HR status 0.8633 
ER status 0.8633 
Chemotherapy regimen containing anthracyclines 0.8636 
Medication groups 0.8636 
Age ≤50 vs. >50 years 0.8636 
Breast cancer spheroid model 0.8636 
Chemotherapy regimen containing  trastuzumab 0.8774 
Cutoff breast cancer spheroid model ≤35 vs. >35% 0.8791 
Ki67 ≤30% vs. > 30% 0.8807 
Breast cancer spheroid model + clinic criteria (ER,PR, HER2, Triple neg) 0.9058 
Change in tumor diameter TStart - TChange 0.9071 
Treatment adherence 0.9082 
Change in tumor diameter TChange - TEnd 0.9219 
ER, estr ogen receptor, PR, pr ogesterone receptor, H ER2, human epidermal growth factor receptor 2, HR, hormone 
receptor, triple neg, tripl e negati ve.  
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The odds ratios (OR) and confidence interval (CI) were determined as a byproduct of 
the backward regression analysis to calculate the ROC curves and showed similar 
results, namely that PR status, HER2 status, treatment adherence, and cutoff in the 
breast cancer spheroid model had the most significant impact on pCR (see Figure 
8). Other factors such as ER (OR 0.463, CI 0.164-1.306), HR status (OR 0.513, CI 
0.180-1.465), and anthracycline-taxane-based chemotherapy (OR 0.244, CI 0.084-
0.709) were not found to increase the probability of achieving pCR in this cohort of 
patients. 
 
Figure 8: Odds ratios for signif icant factors impacting pCR. Diamond shape indicates the determined odds ratio and bars left 
and right the corresponding 95% confidence interval. pCR, pathologic complete response, HER2, human epidermal grow th 
factor receptor 2, PR, progesterone receptor.  
 
Differences in treatment efficacy in vitro  
The spheroids in the assay were treated in vitro according to the national treatment 
recommendations relevant to the study recruitment period [341-343]. Figure 9 shows 
all individual study samples according to each in vitro treatment, patients with pCR 
are highlighted in black. The corresponding cell survival values are additionally spec-
ified in Table 9. 
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Figure 9: Dot plot show ing the individual cell survival values per utilized treatment compound or combinations. Red dots repre-
sent patients w ithout pCR follow ing chemotherapy; black dots show patients with complete response. The dotted line shows the 
cutoff value at 35% cell survival. pCR, pathologic complete response, EC, epirubicin + cyclophosphamide, Doc, docetaxel, 
FEC, 5-f luourouracil + epirubicin + cyclophosphamide, DocAC, docetaxel + doxorubicin + cyclophosphamide, TCbH, paclitaxel, 
carboplatin, trastuzumab, Pac, paclitaxel.  
 
Table 9: Overview of the cell survival for each tested compound or combination of compounds 
 
pCR, pathologic complete response,  Stdv, standard devi ation, EC, epirubicin + cyclophosphamide, Doc, docetaxel,  FEC, 5-fluourouracil + epirubicin + cyclophosphamide, 
DocAC, docetaxel + doxorubicin + cyclophosphamide, TCbH, paclitaxel, carboplatin, trastuzumab, Pac, paclitaxel.  
 
The majority of samples were treated in vitro with EC (N=50), which resulted in a 
mean cell survival of 46.0%. In these samples, cell survival was significantly lower in 
patients with pCR (N=17, mean 24.6% cell survival) compared to those with residual 
tumor at surgery (N=33, 57.0% cell survival, p =.000). The addition of a taxane, 
namely Doc, was not as effective and resulted in a mean cell survival of 92.7%, none 
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N 
Mean cell survival  
± Stdv [%]  N 
Mean cell survival  
± Stdv [%] p-value 
Tested compounds      
EC 50 46.0 ± 30.4  17 24.6 ± 22.5  33 57.0 ± 28.2 .000 
EC-Doc 9 92.7 ± 10.2  0 -  9 92.7 ± 10.2 - 
FEC 4 66.8 ± 40.4  0 -  4 66.8 ± 40.4 - 
DocAC 8 46.3 ± 34.7  3 10.0 ± 3.0  5 68.1 ± 23.0 .004 
TCbH 7 40.3 ± 28.1  2 15.2 ± 11.1  5 50.3 ± 26.6 .145 
Doc 16 88.9 ± 41.2  5 64.9 ± 21.2  11 99.9 ± 44.1 .118 
Pac 8 86.9 ± 23.9  6 86.6 ± 24.7   2 87.6 ± 31.3 .966 
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of whom achieved pCR. The addition of 5-FU resulted in a slightly better treatment 
efficacy with a mean cell survival of 66.8%. Again, none of these patients showed a 
full response, therefore, a comparison with cell survival in vitro could not be done. 
The combination treatment DocAC showed a mean cell survi val of 46.3%. Compari-
son with pCR status showed that treatment efficacy was significantly higher in pa-
tients with no residual tumor (N=3, 10.0%) versus 50.3% for all 5 patients with re-
maining residual tumor (p =.004). A similarly high difference in cell survival was seen 
following in vitro treatment with TCbH with a mean of 40.3% over all tested samples. 
A mean of 15.2% (N=2) and 50.3% (N=5) cell survival was observed for those with 
and without pCR respectively (p =.145).    
Table 10 shows the association between the tested compounds and the number of 
samples showing values above or below the cutoff of 35% cell survival.  
 
Table 10: Cross table showing the number of samples 
achieving values above and below the resulting threshold 
grouped according to the tested compounds 
 Cutoff [% cell survival] 
Tested compounds ≤ 35% > 35% p-value 
 N % N % 
.075 
EC 24 48.0 26 52.0 
EC-Doc 0 - 9 100.0 
FEC 1 25.0 3 75.0 
DocAC 3 37.5 5 62.5 
TCbH 4 57.1 3 42.9 
Doc 0 - 16 100  
Pac 0 - 8 100  
EC, epirubicin + cyclophosphami de, Doc , docetaxel, FEC, 5-fluourouracil + 
epirubicin + cyclophosphami de, DocAC, docetaxel + doxorubicin + cyclophospha-
mide, TCbH, paclitaxel, car bopl atin,  trastuzumab, Pac, paclitaxel.  
 
Analysis of laboratory factors influencing assay outcome were already discussed 
above (see Table 2). As shown in Table 11, additional testing using the determined 
cutoff showed that the number of spheroids (p =.009), but not the total number of 
isolated cells (p =.299) had a significant influence on whether or not cell survival was 
above or below 35%. Also impacting cell survival in this analysis was the number of 
tested treatment option in vitro (p =.011), the fewer spheroids generated or options 
tested in the assay, the higher the changes of values above 35% cell survival. This 
latter factor is, however, directly associated with the number of generated spheroids. 
The type of readout also had an impact on the outcome of the assay: all tested sam-
ples using the MTS assay resulted in values above the determined cutoff, while 
48.4% only of the samples tested in the ATP assay did (p =.000).  
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Table 11: Laboratory factors influencing calculated cutoff of 35% cell survival. 
  Cutoff  
  ≤35%  >35%  
  N %  N % p-value 
All Study samples  32 41.0  46 59.0 - 
No. of biopsy cylinders received       .547 
 Mean 4  4  
 Range 1-12  1-9  
Weight study sample [mg]       .631 
 Mean 148.9  89.4 
 Range 10.5-1568.0  8.9-288.3 
Biopsy method       .106 
 Core needle biopsy 29 38.7  46 61.3  
 Vacuum-assisted biopsy 2 100.0  - -  
 Excision biopsy 1 100.0  - -  
No. of technical replicates       .118 
 Mean       
 Range       
Transport in medium      .561 
 Yes 29 39.2  45 60.8  
 No 2 66.7  1 33.3  
 Not documented 1 100.0  - -  
Transport medium expired      .200 
 Yes 22 36.1  39 63.9  
 No 7 5.8  5 41.7  
 Not documented 3 60.0  2 40.0  
No. of days TM expired [d]       .561 
 Mean 13  7  
 Range 1-61  1-21  
Time diff. biopsy – begin lab procedure [h]     .646 
 Mean 25.6  26.8  
 Range 17.5-46.8  4.75-85.5  
Mechanical isolation [min]      .721 
 Mean 12.3  11.39  
 Range 4-45  3-40  
Enzymatic isolation [min]      .968 
 Mean 160.3  160.8  
 Range 103-225  107-275  
Total time isolation procedure      .959 
 Mean 172.6  172.2  
 Range 115-224  112-287  
Total enzyme added [units]       .856 
 Mean 1.4  1.3  
 Range 0.65-5.2  0.65-2.6  
Total No. of vital cells       .299 
 Mean 1.408 x106  0.173x106  
 Range 22950-34.092x106 13200-1.590 x106 
Cell viability [%]       .386 
 Mean 85.9  88.2  
 Range 26.2-96.1  60.6-97.6  
No. of cells per spheroid      .972 
 Mean 21732  26673  
 Range 4443-51000  2841-187500 
No. of cells per spheroid      .934 
 < 10 000 8 36.4  14 63.4  
 10 000 – 20 000 9 45.0  11 55.0  
 20 000 – 50 000 14 42.4  19 57.6  
 > 50 000 1 33.3  2 66.7  
No. of spheroids generated      .009 
 Mean 10  5  
 Range 4-60  2-25  
Incubation of generated spheroids [h]      .373 
 Mean 48.5  50.5  
 Range 36-59  36-75  
No. of treatment options      .011 
 Mean 2  1  
 Range 1-9  1-4  
Readout method       .000 
 ATP 32 51.6  30 48.4  
 MTS - -  16 100.0  
* N per group <5, No., number of, TM, tr ansport medium, d, days, h, hours, min, minutes, cps, counts per second, ATP, adenosi ne triphosphate, M TS, 3-(4,5-
dimethylthi azol-2- yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.  
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Correlation of clinical factors with treatment efficacy in vitro  
Since the group of samples tested with EC made up the largest number of cases, 
treatment outcome in the spheroid model was corre lated with different clinical sub-
groups to determine if any differences in treatment efficacy in vitro could be identi-
fied. Of all tested parameters a significant difference was only observed in a compar-
ison between tumors originating from the left or right breast (Figure 10A), as well as 
in regard to the HER2 status of the tumor (Figure 10B). Regarding sidedness, tumor 
originating in the right breast responded significantly better to EC treatment com-
pared to tumors originating in the left breast (right breast, N=19, 33.77% vs left 
breast, N=29, 54.95% mean cell survival, p =.011). Similarly tumors with a positive 
HER2 status showed a higher treatment efficacy compared to tumors with a negative 
HER2 status in regard to response to EC (HER2+, N=9, 23.24% vs HER2-, N=39, 
52.54% mean cell survival, p =.000). A similar result was seen in the comparison of 
the patient grouped according to HER2 status combined with HR status (Figure 10C, 
p =.010). In all cases HER2+ tumors responded significantly better to EC treatment 
compared to negative tumors, combined with a positive HR status treatment efficacy 
was improved further  (HER2+/HR+, N=6, 20.35%, HER2+/HR-, N=3, 29.01% cell 
survival). Triple negative tumors showed the highest heterogeneity in treatment re-
sponse to EC (N=13, mean 38.08%, range 3.00 – 101.00% cell survival). HR+, 
HER2 negative samples showed the lowest treatment efficacy to EC, with a mean 
well above the cutoff (N=25, 58.47% mean cell survival).  
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Figure 10: Subgroup of patients tested with EC combination treatment grouped according to resulting cell survival according to 
factors of tumor biology, such as A) tumor origin in left versus right breast, B) HER2 status, as well as C) combination of HR status 
with HER2 status. Dotted line represents the resulting cutoff at 35% cell survival. HR, hormone receptor, HER2, human epidermal 
growth factor receptor 2. 
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DISCUSSION 
The main results of the SpheroNEO Study indicate that the breast cancer spheroid 
model correctly identified treatment outcome for clinically applied chemotherapy reg-
imens on an individual patient basis with a high degree of sensitivity (95.5%) and 
specificity (80.4%). The primary endpoint pCR, and other clinical outcome variables 
such as residual tumor extent (ypT) and grade of regression, were all significantly 
associated with in vitro cell survival. A cutoff of 35% cell survival was calculated sep-
arating assay results according to higher or lower likelihood for pCR with a high de-
gree of diagnostic accuracy. Corresponding ROC analysis and odds ratios of the 
assay results and the proposed cutoff further strengthened these findings. Compari-
son of the collected data with similar patient cohorts showed that both clinical and 
histological patient characteristics were representative. Patient exclusion was mostly 
due to changes in the initially intended treatment scheme. Quality criteria regarding 
patient tissue samples and assay methodology were consistently high. The main 
limiting factor for successful assay readout was the number of cells isolated per pa-
tient sample. Results obtained in this exploratory study will be used in the design of 
an interventional study.
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Assay outcome and diagnostic accuracy   
The overall rate of pCR in this study was 28.2%, which corresponds to data found in 
other studies where similar neoadjuvant chemotherapy combinations were used in 
the treatment of breast cancer [344, 345]. This rate of positive response increased to 
65.6% (21 out of 32 patients) using the breast cancer spheroid assay. The addition 
of treatment adherence as co-factor caused this rate to increase to 83.3% (20 out of 
24 patients). This indicates that the results from the in vitro assay are highly associ-
ated with treatment outcome as measured via pCR, and are further improved when 
patients complete the full drug treatment as recommended by national guidelines.  
By comparison, many of the standard clinical parameters were much less effective in 
predicting treatment outcome. Age groups, cT stadium, LN status, tumor histology, 
as well as grading were all not associated with pCR. However, this was also found in 
a recent analysis of pooled neoadjuvant trials. Unlike in other neoadjuvant studies a 
higher odds ratio for pCR was not found for a HR- status, the main biomarker in 
breast cancer treatment [346, 347]. Also surprising was the significant association 
between pCR and the PR status, which was not evident for the ER status. However, 
it is highly likely that these finding are artifacts and mainly a result of the small sam-
ple size. As expected, HER2+ status significantly predicted treatment outcome. This 
can also be seen in the corresponding c statistics of the ROC analysis and odds rati-
os. A direct comparison of diagnostic accuracy of the breast cancer spheroid model 
to similar chemoresponse assays is difficult, since currently there are not many stud-
ies that are comparable in design and were conducted using a prospective ap-
proach. One such study by Singer et al showed parallels to the SpheroNEO study, 
such as a prospective approach and the use of the peak plasma concentration for 
the applied treatment in vitro. However, no association with pCR was reported, ra-
ther assay results are compared to the measured change in proliferative activity 
(Ki67) and clinical change in tumor size through imaging methods [348]. Using iso-
lated primary cells obtained from patient tumors embedded in collagen and studying 
treatment efficacy using imaging analysis, Takamura et al were able to obtain a 
comparable level of accuracy (positive predictive value = 83.3, negative predictive 
value = 100.0 to treatment with EC) using breast cancer biopsies, however, as with 
the previous publication, a 3D cell culture model was not used and patient numbers 
were not powered to the specified outcome of clinical response [349].  
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Multivariate analysis combining the in vitro assay data with ER, PR, and HER2 sta-
tus improved the diagnostic accuracy of the data to 0.908. This result was only sur-
passed by treatment adherence, which interestingly showed the highest level of sen-
sitivity/specificity. The overall specificity of the breast cancer spheroid model was 
lower than the observed sensitivity by approximately 10%, but no common charac-
teristics could be identified to explain this discrepancy. Treatment adherence was 
able to account for some but not all of the patients that were false positive in the as-
say. However, the overall accuracy of 84.6% was similar to other diagnostic methods 
such as mammography and ultrasound [350]. These factors, such as changes in tu-
mor diameter assessed through standard radiological examinations (i.e. sonography, 
mammography, MRI) did show a high correspondence as well, however this data 
was not collected under standardized circumstances, and factors such as inter-
examiner differences were not accounted for. Current reviews have shown that ultra-
sound examinations tend to underestimate tumor size while MRI examinations over-
estimate the actual tumor size [351, 352]. PET measurement of tumor metabolism 
would be the most appropriate clinical counterpart to an in vitro assay system. How-
ever, current data is inconclusive in regard to the sensitivity/specificity of this ap-
proach [353] and PET is expensive and not part of the routine clinical care for most 
breast cancer patients.  
In vitro treatment efficacy comparing standard treatment combinations in this study 
recapitulate clinical treatment options as outlined in current guidelines [330, 341, 
354, 355]. Mean cell survival was significantly lower for patients exhibiting pCR com-
pared to those that did not. This association was independent of the applied treat-
ment combination (compare Table 9), thereby strengthening the hypothesized rela-
tion between in vitro and clinical efficacy. The clinical treatment for the majority of 
patients consisted of an anthracycline/taxane-based combination chemotherapy 
analogous to current guideline recommendations, consisting of EC followed by either 
Doc or Pac with or without trastuzumab for the majority of patients (84.6%, 66 out of 
78 patients). In this study (pCR rate 28.8%, 16 out of 66 patients), and other large-
scale trials this treatment combination was found to be highly effective [356-359]. 
The same treatment in vitro was similarly effective, DocAC (mean 45.3% cell surviv-
al) and EC (mean 46.0% cell survival) achieving similar results. However, the TCbH 
combination (mean 40.3% cell survival) proved slightly more effective. These combi-
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nations all proved far superior to EC-Doc (mean 92.7% cell survival) and taxane sin-
gle compound treatment (Doc, mean 88.9% cell survival) or Pac (Pac, mean 86.9% 
cell survival). The addition of 5-FU to the anthracycline-based combination was 
somewhat more effective in vitro with a mean cell survival of 66.8%, although only a 
total of four cases were tested with this combination. This compound is currently un-
der discussion in the treatment against breast cancer due to the results of several 
clinical trials that showed the addition of the 5-FU in tablet form did not improve 
treatment outcome or long-term prognosis [93, 110, 360]. However, in each of the 
studies a small percentage did respond to this treatment, and out of the four tested 
cases one showed a high treatment efficacy to FEC in vitro. Given the proven effica-
cy of 5-FU and its continued use in other tumor diseases, this combination should 
still be considered for some patients. Potentially a comparison of individuals with a 
high treatment response may be useful in identifying smaller patient subgroups that 
profit from this treatment regimen. Outliers were also found for the other tested com-
binations, larger sample sizes could determine common clinical or tumor biological 
characteristics of these potentially individual patients. A similar approach is currently 
being used in clinical research across different tumor diseases, identifying super re-
sponders profiting from drugs initially thought to be ineffective [361]. 
Overall cell survival correlated with HER2 status with all nine study positive samples 
showing a treatment efficacy below 35%, all of which were treated with trastuzumab. 
This finding corresponds to data found in a large meta-analysis where the more ag-
gressive tumor biology found in HER2+ and triple negative tumors resulted in higher 
rates of pCR following anthracycline-based chemotherapy compared to hormone 
positive/HER2 negative tumors even without the addition of trastuzumab. This high 
chemosensitivity might be due to a higher proliferative activity, however correlation 
between Ki67, pCR, and survival have been inconclusive. Using smaller, molecular 
subgroups as a basis could potentially lead to a more definitive explanation [49, 
362]. The potential of the assay to predict the HER2 status through the response 
pattern found in vitro could aid in this process. In a review of current literature, there 
were only a small number of publications using a similar approach to investigate a 
potential association between treatment efficacy in vitro and HER2 status. In a study 
by Woo et al a similar difference in treatment efficacy was found, however the differ-
ence between the two groups was only significant for the antimetabolite gemcitabine 
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[363]. In a second study from Korea a trend was observed towards a higher re-
sponse for HER2+ patient samples in an ATP assay and a significant difference in 
the response to treatment with epirubicin was found [364]. Both studies were con-
ducted using small patient numbers, and the findings were not consistent even 
though similar cytostatic compounds were tested. In the data presented above, the 
mean cell survival of triple negative samples was also below 35%, although the 
range of treatment response was much greater.  In regard to the breast cancer sphe-
roid model, high sample numbers will be necessary to determine if the assay could 
be applied as a functional biomarker to discriminate triple negative and HER2+ tumor 
biology based on treatment efficacy results. 
High standard deviations were found regardless of the tested substance, reflecting  
the heterogeneity of the patient subgroups and the individual patient cancer tissue. A 
statistical comparison over all tested compounds was therefore not significant. It 
should be noted that except for EC treatment, the case number for all other treat-
ment combinations was small. This could explain, why the applied treatment in vitro 
only explained 14% of the variance found for cell survival. Similar results were re-
ported by other groups, heterogeneity in the cellular composition and the microenvi-
ronment observed in patient tumors were cited as the possible underlying cause 
[365, 366].  
A clinical subgroup analysis of the study samples tested with EC in vitro demonstrat-
ed a differential response in regard to HER2 status, combined hormone and HER2 
status, as well as the effected side. The finding that HER2 status as a single factor or 
combined with the HR status effects treatment in vitro was not surprising given that 
in general this tumor biology has shown higher rates of pCR as well as high 
chemosensitivity in vitro in other published studies, the underlying reasons for these 
findings were discussed above [49, 71, 367].  
Interestingly, tumors originating from the right side also responded significantly better 
to EC compared to tumors of the left breast, even though tumors originating on the 
right side were more often smaller in size at diagnosis (cT1/2).  The case numbers 
are small, however, other researchers have found a similar diversity between the left 
and the right mammary gland, both in regard to developmental markers as well as 
disease occurrence and progression [368, 369]. An asymmetry has also been re-
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ported in other solid tumors such as kidney, lung, testicular, melanoma, colorectal, 
and ovarian cancer [370]. Differences in the expression patterns of the developmen-
tal markers may offer an explanation for this finding, although there are few publica-
tions on asymmetrical carcinogenesis. In a study on breast patient-derived tissue 
samples Campoy et al compared the methylation profile in regard to sidedness and 
found inherent differences [371]. It could also be speculated that side-specific influ-
ences from the microenvironment may effect tumor development and growth une-
qually. Behavioral patterns as well as growth factors were also cited as an underlying 
cause for increased frequency of cancer in the left breast [372].  
On an individual patient basis, a total of six patients were identified where more than 
one treatment combination could be tested due to sufficient vital tumor tissue. The 
results of the breast cancer spheroid model correctly identified the efficacy of the 
clinical treatment combination by demonstrating lower cell survival with this drug 
combination over other treatments tested (data not shown). Interestingly at least two 
or more treatment combinations proved equally effective in vitro, implying that a de-
cision between approved anthracyclines (namely doxorubicin or epirubicin) or 
taxanes (namely paclitaxel or docetaxel) could be made according to each patient’s 
comorbidity or tolerability. In the study cohort a direct comparison was not possible 
due to small sample sizes. Two study samples were tested with 
anthracycline/taxane-based treatment combinations and one with trastuzumab-
based combinations. All demonstrated a low response in vitro, corresponding to the 
unfavorable histological outcome. In one patient not achieving pCR under EC fol-
lowed by Doc treatment (mean cell survival = 39%), a significantly more effective 
treatment result in the breast cancer spheroid model was seen with the addition of 5-
FU (mean cell survival = 18%; p =.004). Among the tumor samples tested in vitro 
with trastuzumab-based therapy, a selective effect was seen. When the in vitro 
treatment with trastuzumab showed no additional benefit as compared to chemo-
therapy alone, the patients were histologically confirmed HER2 negative (N=5). The-
se results indicate that the breast cancer spheroid model may be able to distinguish 
the efficacy of the treatment guideline directed anthracycline/taxane based regimen 
depending on the individual tumor biology. Low cell yield is currently the main limiting 
factor in determining the selective applicability of the assay. By maximizing the num-
ber of cells isolated from each study samples more treatment options can be tested 
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in the assay. Therefore, this represents a key factor in validating the ability of the 
breast cancer spheroid model to correctly identify the most efficient treatment com-
bination out of several equivalent treatment options.  
Study site and patient characteristics  
The final study cohort for our study consisted of 78 patients. Although the sample 
size was small in comparison to large-scale clinical trials, distribution of clinical char-
acteristics was comparable to the distribution of clinical and histological characteris-
tics found in current literature [373, 374]. The overall dropout rate for screened pa-
tients was 65.15%. Although the rate is high compared to other prospective trials, 
reason for exclusion due to laboratory criteria was only 26.2% of all cases (53 out of 
202). Patient exclusion due to clinical criteria was slightly higher with a total of 35.1% 
(71 out of 202). Comparison of the included and excluded patients showed that no 
specific clinical subgroup was selected, thereby limiting selection bias.  
Further analysis of the exclusion according to clinical criteria showed that the time-
line of the neoadjuvant protocol, more specifically, the timing of the biopsy procedure 
and the subsequent determination of the treatment regimen, were problematic for the 
parallel assay analysis. Even though there was a preference at each participating 
study site for one or two chemotherapy regimens as mentioned above, no final deci-
sion regarding the chemotherapy regimen had been made for the respective breast 
cancer patient at biopsy. This explains the number of patients switching to a different 
chemotherapy treatment combination (N=21), adjuvant treatment or surgery alone 
(N=30). However, obtaining biopsy samples at a later time-point, such as during port 
implantation or sentinel node biopsy, was ruled out, since no information is currently 
available how the tumor biology is altered by this additional intervention and thereby 
possibly effecting subsequent assay results [375].  
Age of study participants also played an important factor in patient screening, since 
older patients were more likely to discontinue treatment or even refuse chemothera-
py. Non-adherence was most frequent in older patients (median age treatment 
non-adherence 56.5 years at diagnosis vs 48 median age patients receiving treat-
ment as planned). Reasons were, in part, side effects (N=8) but also patient prefer-
ences (N=2). Similarly, these reasons have previously been reported with non-
adherence most often linked to side effects such as alopecia and fatigue [376].  For 
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example, in a study on patient preferences and treatment adherence by 
DiBonaventura in 2014, 34.8% of metastatic breast cancer patients did not fully ad-
here to the prescribed oral treatment. The decision for one clinical treatment combi-
nation is ultimately made in collaboration between patient and doctor, and many fac-
tors should be involved in this shared decision-making process. Existing comorbidi-
ties, medical conditions and also patient preferences are all considered alongside 
tumor stage and biology [377, 378]. Potentially a predictive tests such as the one 
studied here could motivate patients to adhere to the full treatment as planned by 
visualizing efficacy before treatment start.  
Surprisingly, not many patients were excluded due to metastatic disease (N=7, 3.8% 
of all screened patients), especially considering the state of disease was often un-
clear at the time of biopsy. Similarly, only two patients were excluded due to benign 
neoplasia. Current data cites a rate of 10% of patients with breast cancer that are 
advanced or stage IV at initial diagnosis [379, 380]. This fact shows that current rou-
tine screening and staging methods, mainly mammography and ultrasound examina-
tions are fairly accurate in determining the extent and malignancy of suspicious find-
ings with a sensitivity ranging from 48-96% [351, 381].  
A comparison across all study sites showed a similar distribution of baseline patient 
characteristics. Although the patients screened for study inclusion in Starnberg were 
slightly older (median 68 years at diagnosis, N=8) than those screened at the other 
study sites (overall median 52 years at diagnosis), however, no patient from this 
study site was included in the final analysis making this difference in age insignificant 
to the study outcome (exclusion criteria for all patients: no neoadjuvant chemothera-
py). Another finding was the clinical tumor size at diagnosis; screened patients from 
the coordinating study site (University Hospital LMU) were more frequently cT3/4 (12 
out of 19 patients, 63.2%) compared to the other sites (overall 48 out of 188, 25.5%). 
The main reason is that patients with more extensive disease are more likely to be 
referred to a university hospital rather than a smaller clinic. This finding was further 
corroborated by the fact that patients from Munich’s other university hospital, “Rechts 
der Isar”, were more frequently diagnosed with metastatic disease (4 out of all 9 pa-
tients diagnosed cM1, 44.4%). However, these minor differences that were found in 
the patient population showed no associations to laboratory results and were there-
fore not considered to have any influence on the analysis of the final study data.  
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Factors influencing assay methodology 
Current biobanking standards recommend several steps in optimizing tissue quality 
for the isolation of cells from fresh tissue samples such as: 1) An initial examination 
by a qualified pathologist, 2) transportation of the tissue sample in culture medium 
immediately after excision 3) subsequent transportation at 4˚C to the processing la-
boratory, 4) storage of the sample upon arrival in an incubator at 37˚C and 4% CO2 
until further processing. All tissue samples should also be 5) identified through a dis-
tinct code to prevent any incorrect allocation to patient demographics [382] .   
All these recommendations were supported by the study synopsis, and subsequently 
documented, and complied with in the course of the SpheroNEO Study. The time 
difference between tissue excision and the start of the cell isolation procedure was 
kept at a minimum with a mean of 26.3 h, only slightly surpassing the recommended 
ischemic time of 24 h [383, 384]. 
Tissue availability remained a key issue. The limiting factor was the minimal number 
of cells that are required for a valid assay outcome. As described in the results sec-
tion, all factors influencing successful assay outcome were either directly or indirectly 
related to the number of cells isolated from the study samples. Quality of the study 
sample also played a major role in the success of the assay, as was evident in the 
wide range of isolated cell number per total sample weight. Some samples weighed 
less but yielded a higher number of vital cells, while others weighed more but con-
sisted almost completely of fatty or connective tissue. The spheroid methodology 
used in this study had previously been established using surgical specimen from 
colorectal carcinoma patients, which were relatively homogenous in tissue composi-
tion and consistently yielded greater numbers of cells per study sample [299]. Adapt-
ing this method to the much smaller core needle biopsy samples from breast cancer 
patients proved difficult, especially since the anatomy of the breast is much more 
diverse in its tissue components. For this reason it is essential to determine the cellu-
lar composition of the study sample, for example using immunohistochemistry or flu-
orescent staining methods either following tissue excision and/or after cell isolation. 
Genetic analysis or next-generation sequencing may be considered as well [385, 
386]. This would sort out unfit samples at an early stage thus reducing time and cost.  
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Since a specified tissue amount in mg is an impractical measure in clinical routine, a 
minimum requirement of four biopsy cylinders could be considered optimal. If surgi-
cal bulk specimens are analyzed in the assay on the other hand, a weight require-
ment is more pragmatic, since the pathological analysis requires the dissection of the 
tumor for a microscopic analysis. A minimum requirement for surgical tissues was 
previously published [387]. Results obtained in this study showed that a minimum of 
four biopsy cylinders with a mean total weight of 89.6 mg (range 10.5 – 353.4 mg), 
were required to test a minimum of three treatment combinations. This would cover 
the in vitro analysis of one exemplary compound from each treatment combination, 
i.e. 1) Anthracycline-taxane, 2) anti-HER2 treatment combination, as well as 3) a 
platinum-containing regimen. The specific compounds included in the treatment 
combination for example Doc vs Pac or epirubicin vs doxorubicin would need to be 
narrowed down by the physician beforehand; otherwise the number of combinations 
would exceed the potentially available amount of tissue. Since at the time of the ini-
tial biopsy the HER2 status was not yet available, an anti-HER2 treatment combina-
tion should be included in case of a potentially HER2+ tumor. If the final treatment 
decision has already been made, for example due to preexisting comorbidities, tes t-
ing in the breast cancer spheroid model would only require a minimum amount of 
tissue. The likelihood of treatment efficacy or resistance to the pre-specified drugs 
can be tested; however the comparison of treatment efficacy to other compounds will 
be limited. 
Anti-hormonal compounds were not tested in the current study, and more research is 
required to optimize the assay for anti-hormonal treatment in vitro. These lipophilic 
compounds are often only available in solid form, making their application in vitro 
difficult. Although adding endocrine treatment to the list of compounds, would be of 
great value. Other drugs such as bevacizumab cannot be applied in the in vitro 
treatment setting due to the lack of a functioning blood vessel system in the spheroid 
model. However, not just these types of compounds but also other targeted drugs, 
such as immune modulators and signal transduction inhibitors, are the main focus of 
current drug development and a growing number of patients will receive these drugs 
as part of their treatment. An individual evaluation of in vitro drug efficacy will deter-
mine the validity of each new drug in the model, thereby ruling out any confounding 
issues. Patients receiving these types of compounds should currently not be includ-
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ed in the study population, since the clinical results cannot be fully compared to the 
laboratory data. Especially since only a small fraction of patients may receive the 
drug and lessen the effect size of the primary endpoint. The association between 
clinical and laboratory outcome should first be verified using a homogenous study 
population with similar drug treatment, subsequently the laboratory data may be as-
sumed as a surrogate for clinical outcome.  
All other laboratory factors documented during the assay procedure were consistent 
and had little impact on assay success or outcome. The only exception was the 
choice of readout method, ATP or MTS. In retrospect, the ATP proved to be the sub-
stantially more sensitive readout method compared to MTS. Individual differences in 
cell survival between treatment options in vitro were much more distinguishable us-
ing ATP, while results obtained using MTS showed a much smaller range in values. 
It appears that an ATP readout is the method of choice in this model and should be 
used for all future study samples to ensure comparability both between patients and 
applied treatment combinations in vitro.  
Other than the above specified limitations, the breast cancer spheroid assay was 
very efficient. This was reflected by the high viability seen overall study samples and 
the low rate of contamination. Outside factors such as tissue logistics appeared to 
play only a minor role in both the success of the assay and outcome. The time inter-
val from sample excision to beginning of cell isolation was slightly higher in samples 
not fulfilling laboratory criteria, however the difference was not significant. Based on 
prior experience and published data a limitation to 48 h total transportation time is 
essential considering tissue and enzymatic degradation, as well as possible changes 
in gene and protein expression profi les [388-392]. Considering the types of logistics 
available today, this time limitation is feasible for fresh tumor study samples. In this 
study, nine study samples exceeded this time span, however, of these four were i n-
cluded in the main analysis and of the other five only three were excluded according 
to laboratory criteria. The four samples were included despite protocol deviation 
since all documented factors such as viability and baseline metabolic activity were 
within the normal range.  
The uti lized transportation medium did have an effect as can be seen in the 7 sam-
ples that were shipped in isotonic sodium chloride solution (0.9% NaCl). Out of these 
Discussion 
 
 
  
 
Page 88 of 120 
 
 
 
samples, only two could be tested in the assay and mean viability was 78.17% dur-
ing cell isolation, compared to an overall mean of 86.06% for samples arriving in 
shipping medium.  
Current and previous chemosensitivity testing 
A tumor spheroid model, such as the one tested here, is able to replicate the hetero-
geneity of cell types, cell-cell interactions, and the microenvironment of the patient 
tumor more closely as compared to cell-based monolayer assays and other 3D as-
says [393-395]. In addition, through the 3D structure a penetration barrier is formed 
allowing different amounts of cytostatic agent to reach each tumor cell  [396]. Compa-
rable chemoresponse assays were either not validated in a prospective trial with ad-
equately powered endpoints, did not achieve the high sensitivity/specificity as seen 
here, and/or do not resemble the original 3D structure of the patient tumor. Thus, this 
assay represents a model, which may improve treatment selection uti lizing the tumor 
heterogeneity of breast cancer present in individual patients. This is based upon re-
sults obtained in a prospective study conducted according to high quality standards 
with a homogenous patient cohort. The current expert opinion should be reconsid-
ered regarding the application of chemoresponse assays in clinical diagnostics.  
Chemosensitivity/chemoresistence assays, collectively referred to as 
chemoresponse assays using patient tissue-derived cells have been tested since the 
early 1970s, and the results obtained from the first type, clonogenic assays, initially 
seemed promising [291, 295, 397, 398]. Although re-evaluation of the data led to the 
discredit of the method due to the failed association with clinical outcome [399]. Var-
ious approaches and laboratory methods, such as differential staining/dye exclusion, 
incorporation of radioactive precursors by macromolecules, colorimetric assays, 
chemoluminescence, and measurement of differential optical density, have been 
used not only for breast cancer patients but other solid tumors as well [295, 398, 
400-404]. The methodological approaches for all of these assays are similar; initially 
the patient tumor sample is disassociated into a single-cell suspension with subse-
quent culture of the isolated cells. The length of this culture period depends on 
whether or not the cells are intended to proliferate or not, longer cell culture may pre-
fer specific cell types such as fibroblasts and result in changes in cellular physiology 
[405]. A drug or combination of drugs is applied and the resulting change in cell sur-
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vival is quantified and interpreted after a period of incubation. Results are analyzed 
in comparison to individual patient outcome, mainly survival endpoints. Currently 
there are several assays which are commercially available. Among them are the di f-
ferential staining cytoxicity assay (Weisenthal Cancer Group, Huntington Beach, CA, 
USA), the EVA/PCD™ assay (Rational Therapeutics, Long Beach CA, USA), the 
fluorometric microculture cytoxicity assay, thymidine incorporation assay, the 
histoculture drug resistance assay (HDRA, AntiCancer Inc., San Diego, CA, USA, 
SRL Inc., Tokyo, JP), the adenosine triphosphate bioluminescence assay, 
ChemoFX® (Helomics Corp., Pittsburgh, PA, USA), CorrectChemo® (Diatech On-
cology, Franklin, TN, USA), extreme drug resistance assay (EDR®, Exiqon Diagnos-
tics, Tustin, CA, USA, TherapySelect, Heidelberg, DE), Oncogramm (Oncomedics, 
Limoges, FR) to name a few.  
Only a limited number have been tested in a randomized prospective trial, such as 
the tritiated thymidine incorporation assay testing extreme drug resistance [406]. Us-
ing cells in monolayer or clusters, tritiated thymidine is added to the tumor cells and 
the radioactivity incorporated into the DNA is quantified to determine drug resistance 
in vitro. Drug resistance or sensitivity is quantified through a direct or inverse meas-
urement of the incorporated radioactivity that is generated from viable cells that i n-
corporate the compound into their DNA following cytostatic treatment in vitro. Analy-
sis in several prospective randomized trials with ovarian cancer patients did not 
show any significant difference in overall response of the assay group compared to 
the control group, which received treatment according to standard clinical criteria 
[407]. In a similar retrospective analysis using breast cancer tissue, between patients 
with low drug resistance in the assay compared to those with intermediate/high drug 
resistance significant differences in prognosis were found. However, the identified 
patient subgroups showed initial differences in disease stage and nodal status which 
may be the underlying cause for the observed differences in survival. The grouping 
of the patients into drug resistance profiles is also unclear and may have been a re-
sult of an otherwise small sample size. Also no randomization procedure was includ-
ed in the trial [408].  
Using the ATP assay to measures luminescence of intracellular ATP as a surrogate 
marker for cell survival following cytostatic treatment, a randomized controlled study 
was conducted using cells in monolayer isolated from recurrent platinum-resistant 
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ovarian cancer patients [409]. In this study no significant differences in prognosis 
were seen in the assay-directed versus the control treatment group. However, an-
other study including patients with metastatic melanoma did find significant differ-
ences in progression-free survival with patients receiving in vitro sensitive treatment 
[410]. The ChemoFX assay also utilizes an ATP readout system. Currently there are 
several published studies, which showed an increase in OS of 14 months using as-
say-directed treatment for ovarian cancer patients [411]. In a study using breast can-
cer biopsies, pCR correlated with assay outcome in vitro and was found to achieve a 
sensitivity of 83.3% and 71.4% specificity [291]. However, the patient sample size 
was 34 in this analysis and only conducted as a sub study; the main objective of the 
article was a general assessment of the validity of the assay methodology. It is un-
clear if the analysis is sufficiently powered to obtain a valid statistical result for this 
secondary endpoint. Although several prospective trials have been conducted using 
this assay, mainly in ovarian cancer with mixed results, health care providers have 
criticized the lack of a randomization procedure in the conducted studies.  Without 
randomization any observed effect may be attributed to known or unknown co n-
founding factors, therefore skewing results in one direction or another.  
For the other listed assays, no randomized prospective trials are available, for e x-
ample the differential staining cytotoxicity assay, which uses a counterstaining meth-
od using Fast Green Dye (dead cells) and hematoxylin-eosin (viable cells). The ratio 
of dead to viable cells is quantified following cytostatic treatment in vitro. The idea 
behind the approach is relatively simple. However, the methodology is complex and 
utilizes a difficult scoring system. The interpretation of the results should only be 
conducted by trained professionals. In a small study by Cortazar et al on small cell 
lung cancer patients, a significant improvement in patient survival was seen (38.5 
assay-directed vs 19 mths standard chemotherapy selection). However, due to the 
methodological complexity, an implementation of this assay in the clinical routine is 
not feasible. This method is currently successfully used in hematologic malignancies 
where it is being used for in vitro drug assessment [412, 413]. 
The EVA/PCD™ assay is also based on a hematoxylin-eosin counterstaining meth-
od with Nigrosin and Fast Green Dye to quantify apoptotic cells in microspheroids 
(50-100 cells per spheroid). A study from 2012 showed an overall response rate of 
64.5%, which was greater than twice the response rate (complete and partial re-
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sponse) observed for historic controls [414]. Positive aspects included the use of a 
3D cell culture model and the application of guideline recommended compounds in 
several concentrations.  Limitations in the study design are a comparison to historic 
controls and no report of the examination that was used to determine clinical re-
sponse to treatment.  
A slightly different differential staining technique is used in the fluorometric 
microculture cytotoxicity assay, which associates higher levels of fluorescence - pro-
duced through the hydrolysis of fluorescein diacetate - with increased drug re-
sistance [415]. A newer procedure was offered by the company Oncomedics (Li-
moges, FR), which is referred to as Oncogramm. Using patient cells and a triple 
staining procedure following treatment in vitro, live and dead cells are counted using 
a fluorescent microscope. Preliminary studies in metastasized colorectal cancer 
specimen reported a good sensitivity (84.6%) for the assay, although specificity was 
low at 33.3% [416]. This type of assay has not been analyzed in a prospective ran-
domized study.  
The histoculture drug resistance assay [417] grows small tissue particles in a 3D col-
lagen matrix. The inhibition rate was determined using the MTT readout following 
treatment in vitro with applicable drugs. Although the 3D architecture of the patient 
tumor was preserved in this assay, the trials used a retrospective design. In more 
recent trials, no control group was included for this assay. In a recent publication us-
ing tissue from anaplastic thyroid cancer patients, the assay outcome (inhibition rate) 
was associated with prolonged patient survival, although the results are based on a n 
individual patient comparison, and the patient cohort is very heterogeneous both in 
extent of disease and tissue excision site, making a direct correlation to clinical out-
come potentially biased [418].  
The colorimetric MTT readout method measures mitochondrial activity through the 
enzymes involved in the reduction of NADP(H) and has previously been used to 
study cytostatic efficacy. One such example is a retrospective study analyzing the 
benefit of assay-based chemotherapy in gastric cancer patients by Wu et al. [419]. 
The study included a control group which received chemotherapy according to the 
physician’s choice and compared the documented toxicities in both arms. No benefit 
in OS was seen for the patients tested with this assay. Also the number of adverse 
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events was the same in both groups. A similar study was conducted on advanced 
breast cancer patients, which showed more favorable results in patients receiving 
assay-directed treatment, however no significant differences were observed in the 
median survival in a comparison to the control arm [420].  
The Microculture-Kinetic (MiCK) assay (CorrectChemo®, Diatech Oncology, Frank-
lin, TN) uses optical density measurement over a time span of 48 h to determine in-
duced cell death following treatment in vitro [421, 422]. Data from randomized trials 
using this assay are not available and prospective data is only available for acute 
myeolocytic leukemia or a patient cohort diagnosed with a variety of solid tumor 
types [423]. 
Generally problematic in many of these studies are the inhomogeneous patient 
and/or tissue populations. Patients with prior treatment were oftentimes part of the 
study cohort, and in a few cases tissue samples were obtained from the solid tumor 
site or metastatic ascites/pleural effusions. These factors make overall data regard-
ing treatment outcome or prognosis difficult to interpret and a direct association be-
tween in vitro assay results and clinical outcome potentially confounded. In some 
older studies, patients suffering from different solid tumors were included in the study 
and differences in patient prognosis and endpoint measurements (disease-free vs 
progression-free vs OS) were not adjusted according to baseline differences in prog-
nosis. 
Based on the described obstacles, implementation of these assays into the clinical 
routine has proven difficult, and so far none of these assays are used on a routine 
basis. The reason behind this as voiced by current guidelines and reviews are that in 
general chemosensitivity- and chemoresistence assays have not shown conclusive 
evidence obtained through prospective randomized clinical trials [295, 414, 424], 
which represent the gold standard in clinical research today. Currently the opinion 
voiced by many treating physicians is that results from in vitro chemoresponse as-
says are promising and interesting but the data remain inconclusive especially re-
garding a benefit in survival. This is why many doctors are reluctant to recommend 
such a test to their patients [72, 115].  
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Current evaluation of the validity of chemosensitivity testing 
In light of the fact that the latest review dates from 2011 (ASCO) and the guidelines 
regarding the validation of potential biomarkers have been updated, the current posi-
tion toward these assays should be reconsidered [295, 425-428]. Currently, national 
(AGO, DKFZ) and international professional organizations (ASCO, NCCN, NCI), as 
well as major healthcare providers do not recommend chemoresponse assays for 
routine clinical application outside of clinical trials [295, 341, 354, 429, 430]. Approval 
from regulatory authorities is not required since the test does not fall under the a u-
thorities’ jurisdiction. In Germany, for example, this type of assay falls under the reg-
ulations covering in vitro diagnostics (IVD-Richtlinie 98/79/EG) and medical devices. 
A high level of evidence through randomized clinical trials is however required by 
healthcare providers, in order to subsidize the cost of such a test.  
Other concerns, often listed by physicians, are the inability to include systematic ef-
fects, such as pharmacodynamics and pharmacokinetics, as well as blood supply to 
and from the tumor, all of which are difficult if not impossible to mimic in vitro. Some 
of these concerns may be resolved using simultaneous in vitro and in vivo testing, 
although the addition of a murine component brings a potentially confounding varia-
ble into the equation. The ideal decision-aiding tool should predict the most favorable 
balance of tolerability and efficacy for each patient while limiting confounding effects 
by the assay itself, however there is currently no assay available that addresses all 
these aspects simultaneously [431].  
Several aspects should be considered in the search for the ideal model or assay, 
such as the type of material used in the assay, as well as the potential feasibility for 
clinical translation. Using patient cancer tissue obtained in routine diagnostic proce-
dure or surgical tumor removal for in vitro analysis seems to be a logical step to 
treatment selection for individual patients. Current ethical considerations, as well as 
the continuous improvement in biobanking standards make this a feasible approach 
and a framework most representative of the heterogeneity found in patient tumors 
[432, 433]. Other options are animal models, mainly murine, as well as immortalized 
cell lines. The drawback to in vivo models using immunodeficient mice is the murine 
microenvironment which may have a confounding effect on tumor biology and treat-
ment efficacy. Tumors often take weeks to develop, making this model setup ques-
Discussion 
 
 
  
 
Page 94 of 120 
 
 
 
tionable for clinical implementation due to the time delay until assay data is available. 
Experiments using knock-out models or xenograft transplants offer insight into the 
underlying disease pathways and are valuable preclinical models, but have not been 
able to predict patient treatment outcome in a prospective study [434, 435]. The 
subrenal capsule assay is a model system using immunocompromised or other 
mouse breeds where small amounts of tumor tissue or tumor cell lines was implant-
ed in the subrenal capsule and subsequently studied for differential growth following 
treatment [436]. This model has been tested as a potential assay system to predict 
clinical outcome in ovarian cancer, however, there no improvement in patient survi v-
al has been demonstrated [437, 438]. A similar approach was developed by the Na-
tional Cancer Institute using implantable biocompatible hollow fibers where tumor 
cells can grow in vivo [439]. Tumor efficacy can also be tested using this method, 
however there are no studies, where this approach was used in predicting clinical 
outcome using patient tumor tissue [440].  
Cell lines in comparison are much more cost-efficient and less care-intensive while 
offering little information into the effects from the tumor microenvironment due to the 
limited cellular heterogeneity. Data obtained through genetic profiling and extensive 
characterization of established cell lines already allow mathematical modeling of po-
tential treatment outcome, aiding in the preclinical drug testing process [441, 442]. 
Current research is mainly done using gene-based assays, which have shown to 
accurately predict the necessity of systemic therapy +/- endocrine maintenance ther-
apy, although results are not applicable to all patient subgroups equally [443]. This 
aspect also applies to the newly developed immunohistochemistry assay as well as 
to the next generation sequencing approaches: both rely on breas t cancer subtyping 
(luminal A, luminal B, HER2-like, basal-like) to determine the treatment strategy i.e. 
combination of endocrine treatment and chemotherapy with the most favorable 
prognosis [444]. Next generation sequencing by analyzing the genomic and proteo-
mic characteristics of individual patient tumors may also identify new targets for more 
effective treatment strategies and targeted drugs [445]. However, these assays do 
not address the issue of which compounds should be included in the drug treatment 
and which would yield the most effective treatment outcome. An ideal assay would 
potentially combine in vitro testing with genomic subtyping. Also promising are the 
findings from studies on the immune profi le of patient tumors, however several fac-
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tors will still have to be investigated further, such as the contribution of the individual 
cell types and the contributing mechanisms [216, 446].  
Interventional study using the breast cancer spheroid model 
The data presented in this thesis indicates that the breast cancer spheroid model 
may not only be predictive of treatment outcome, but also potentially selective in dis-
cerning ineffective from effective treatment options.  Additional data will need to be 
obtained to strengthen these findings in a larger, randomized trial with an endpoint 
measuring survival. In an interventional study this and other factors such as im-
proved patient and tissue screening using in- and exclusion criteria based on data 
obtained in the SpheroNEO study. In addition to the information gathered already, an 
analysis of the health economics of this assay could provide further evidence for ap-
proval of the assay by health insurance providers. 
Survival data is especially important for assay validation considering the scientific 
discussion concerning pCR as a surrogate endpoint on a trial-level for long-term 
treatment success [447]. Some argue that pCR only acts as a surrogate marker for 
HER2+ and triple negative disease and maintain the position that survival is the em-
pirically strongest endpoint and should be used as a primary objective in clinical trials 
[71, 448, 449]. However, others consider pCR a valid marker for prognosis in all 
breast cancer subtypes [447, 450] and the drug approving agency in the United 
States (FDA) has approved the use of pCR as a surrogate marker in drug approval 
trials [451]. Proponents argue that this will enable drugs to be brought onto the mar-
ket more quickly than waiting for survival data. Opponents cite the example of the 
anti-angiogenesis drug bevacizumab which was approved using a fast track ap-
proach. Later, the approval was revoked in the treatment for primary breast cancer 
due to insufficient evidence for treatment efficacy and potentially serious side effects 
in some patients [452].  
Depending on the extent of the treatment, follow-up would be a minimum of five 
years following surgery, however guideline recommendations regarding this time 
span differ [355, 453]. According to current data the rate of recurrence has continua l-
ly dropped due to improved treatment options with most cases being observed in the 
first two years following initial treatment. The OS after 5 years lies between 80-90%. 
However, a small percentage of patients have shown disease recurrence after up to 
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20 years following the initial diagnosis [454, 455]. Even patients with pCR have a 
small percentage of developing recurrent disease [456].  
In order to validate the results from this explorative study an interventional random-
ized controlled study is essential to determine the independent predictive power of 
the spheroid model and such a confirmatory phase III study is planned. In addition 
an interventional study is required by German health insurance providers for the 
compensation assessment of this assay. The cutoff of 35% cell survival differentiat-
ing between complete pathological response and not, will be analyzed in regard to its 
validity and reliability in a larger cohort of patients. A total sample size of 318 pa-
tients with 1:1 randomization procedure (159 per arm) has already been determined. 
These numbers are based on the assumption of 70% assay success rate and an 
improved pCR rate through assay-directed chemotherapy selection of 44%, power 
and α are 0.80 and 0.05 respectively.  
The study design incorporates both the treating physicians, as well as the local tu-
mor board in the treatment decision-making process. Study samples will again be 
accrued during the initial diagnosis examination, following pathological examination 
and extraneous tissue (minimum 4 biopsy cylinders) will be shipped to the central 
laboratory for cell isolation and spheroid preparation. The in- and exclusion criteria 
will remain largely the same as for the SpheroNEO study, however in order to im-
prove patient screening the minimum number of biopsy cylinders will be included 
(N=4). Patients will also be required to have an ECOG of 0 or 1 to maximize treat-
ment adherence, similarly patients taking concurrent medication or suffering from a 
serious medical condition that would contraindicate chemotherapy or put the patient 
at an increased risk are excluded from study participation. By excluding patients with 
contralateral or inflammatory breast cancer the study population will be more ho-
mogenous in regard to outcome and recommended drug treatment.  
Following successful screening, patients will be randomized to the assay-directed or 
the control arm. Patients in the control arm will be treated as determined by the tu-
mor board, and data from the spheroid assay will not be forwarded to study site per-
sonnel. Patients in the assay-directed arm will also be discussed in the local tumor 
board, however the treating physicians will have access to the data obtained from 
the spheroid assay and may base their treatment decision on these results. If the 
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treatment is not applied according to the results of the spheroid assay, the reason 
must be stated by the physician such as patient preferences. This questionnaire was 
suggested by the ruling ethics committee and will be required for the interventional 
study. Following the completion of chemotherapy by all study patients, a comparison 
will be made between the control and study arm to determine if the data from the 
spheroid assay has led to an increase in successful treatment outcome. The study 
will again use patients eligible for neoadjuvant chemotherapy and the primary end-
point will progression-free survival. As became evident during the SpheroNEO study, 
the assistance of a contract research organization (CRO) would be highly advisable 
in the site feasibility and management, as well as data collection. The number of 
sites would also need to be increased to accrue the necessary number of patients in 
a sufficient time span, the addition of other countries beside Germany should be 
considered such as Austria and the Netherlands, the Netherlands currently rank 3rd 
among European countries in the age-standardized breast cancer incidence rate 
[457]. Given the patient numbers successfully included in the current study per 
month, an estimated number of 53 study sites would need to be initiated to obtain 
the patients needed in a time span of two years.  
A cost-benefit analysis will be conducted as a secondary endpoint to examine the 
potential benefit of an assay-directed treatment compared to standard clinical based 
treatment decision-making. Health economics are becoming increasingly important 
for health insurance providers and pharmaceutical companies due to the enormous 
costs of targeted oncology drugs. Treatment-related costs for oncology drugs rank 
fifth in overall health care expenditures. For instance, the cost of one year of targeted 
anti-HER2 medication lies around 35 000 - 55 000 € for a single patient [458]. This 
illustrates the importance of distinguishing non-efficacious drugs early on in preclini-
cal drug development and identifies patients who will be incorrectly treated. Thereby 
harmful toxicities may be avoided for the patient, as well as unnecessary costs for 
the insurance provider. Additional secondary endpoints are assessment of adher-
ence to the assay results by the decision-making physician(s) and comparison of 
quality of life in the study and the control arm.  
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Conclusion 
In the treatment of breast cancer, there are an abundance of drugs and targeted 
therapies available today, yet, not all patients respond equally well. The rate of pCR 
remains stable at 22%, with percentages varying according to disease subtypes (lu-
minal A 6.4%, luminal B/HER2- 11.2%, basal-like 31.0%, HER2-like 32.9% [49, 459, 
460]. The introduction of targeted therapy nearly two decades ago has vastly im-
proved the prognosis for a subset (15-20%) of patients with HER2+ tumor biology, 
yet the remaining majority of patients lacking this trait continue to receive standard 
chemotherapy which is selected using empirical decision algorithms. Since time is of 
the essence in cancer treatment, the current trial and error selection of anti -cancer 
treatment mainly based on lengthy and costly clinical drug trials should be expanded 
to include preclinical in vitro models. Using a 3D cell culture technique on patient-
derived cells, the breast cancer spheroid model reflects many aspects of the patient 
tumor biology. The data described in this manuscript show that the assay has 
achieved high levels of sensitivity and specificity regarding clinical outcome in a pro-
spective study. Further research is warranted to validate this assay for the individual 
patient treatment selection and clinical implementation. A consolidation of laboratory 
and clinical data would not only speed up the process of preclinical drug testing but 
would also aid in identifying the treatment with the most favorable prognosis for indi-
vidual breast cancer patients [461, 462].  
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LIST OF ABBREVIATIONS 
 
2D  2-Dimensional  
3D  3-Dimensional  
5-FU  5-Fluorouracil  
ABC  ATP-binding cassette 
AC  Anthracycline + Cyclophosphamide 
AC -> T  Anthracycline + Cyclophosphamide -> Taxane 
AC -> TCb Anthracycline + Cyclophosphamide -> Taxane + Carboplatin 
AC -> TH Anthracycline + Cyclophosphamide -> Taxane + Trastuzumab 
Akt  Protein kinase B 
AUC  Area under curve 
BCS  Breast conserving surgery  
BMI  Body mass index  
CA 15-3 Carcinoma Antigen 15-3 
CAF  Cancer associated fibroblast 
CEA  Carcinoembryonic antigen 
cps  Counts per second 
CRF  Case report form 
DAPI  4', 6-Diamidino-2-phenylindole 
DCIS  Ductal carcinoma in situ 
DFS  Disease-free survival  
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DMBA  7, 12-Dimethylbenzo [a] anthracene  
DMEM  Dulbecco/Vogt modified Eagle's minimal essential medium  
Doc  Docetaxel  
DocAC  Docetaxel + Doxorubicin + Cyclophosphamide  
EC  Epirubicin + Cyclophosphamide 
EDR  Extreme drug resistance 
ER  Estrogen receptor   
EGFR  Epidermal growth factor receptor 
EtOH  Ethanol  
Eve  Everolimus  
FBS  Fetal bovine serum 
FEC  5-Fluorouracil + Epirubicin + Cyclophosphamide 
FISH  Fluorescence in situ hybridization 
HDRA  Histoculture drug resistance assay  
HER2  Human epidermal growth factor receptor 2 
H  Trastuzumab  
HR  Hormone receptor 
IGFR1  Insulin-like growth factor 1 receptor 
IHC  Immunohistochemistry 
ISO  International Organization for Standardization   
IVD  In vitro diagnostics 
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MAPK  Mitogen-activated protein kinase 
MCTS  Multicellular tumor spheroids  
MDR  Multi drug resistance 
MDSC  Myeloid-derived suppressor cell  
MEM  Minimum Essential Medium 
MiCK  Microculture Kinetic 
MRI  Magnetic resonance imaging 
MS  Mass spectrometry  
MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
mTOR  Mammalian target of rapamycin 
mTORC1 Mammalian target of rapamycin complex 1 
NADP  Nicotinamide adenine dinucleotide phosphate  
NEAA  Non-essential amino acids 
NMR  Nuclear magnetic resonance 
OS  Overall survival  
Pac  Paclitaxel 
PAI-1  Plasminogen activator inhibitor-1 
PARP  Poly (ADP-ribose) polymerase 
PBS  Phosphate buffered saline 
pCR  Pathological complete response 
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PET  Positron emission tomography 
PFS  Progression-free survival 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
ppc  Peak plasma concentration 
PR  Progesterone receptor 
PTEN  Phosphatase and tensin homolog 
ROC  Receiver operating characteristic 
SERM  Selective estrogen receptor modulator 
STAT  Signal transducer and activator of transcription 
TAM  Tumor-associated macrophages 
TCbH  Docetaxel + Carboplatin + Trastuzumab 
TDM-1  Trastuzumab emtansine 
TNBC  Triple negative breast cancer 
TM  Transport medium 
TME  Tumor microenvironment 
uPA  urokinase-type plasminogen activator 
VEGF-A Vascular endothelial growth factor A  
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Table 12: List of participating breast cancer centers 
Site 
number 
Study site 
Samples 
received 
Eligible patients 
Patients 
enrolled per 
month 
Drop-out rate 
(%) 
01 Klinikum Landshut 26 18 0.94 45.45 
03 Klinikum Starnberg 8 0 0.28 100.00 
04 Frauenklinik KUM 22 9 0.69 64.00 
05 Frauenklinik TUM 21 4 0.79 81.82 
05 Radiologie TUM 4 1 0.17 75.00 
07 Klinikum Harlaching 17 7 0.65 58.82 
14 Klinikum St. Marien Amberg  15 8 1.67 46.67 
15 Leopoldina Krankenhaus der Stadt Schweinfurt gGmbH 9 5 0.90 44.44 
16 Klinikum Nürnberg  5 0 0.63 100.00 
17 Städtisches Klinikum Karlsruhe  5 2 0.63 60.00 
18 Markus Krankenhaus Frankfurt 15 1 1.67 93.33 
19 Marienhospital Bottrop gGmbH 30 9 3.33 70.00 
20 Evangelische Kliniken Gelsenkirchen 21 11 2.10 47.62 
21 Klinikum Dritter Orden 4 3 0.80 25.00 
  Total 202 78 15.25 65.15 
 
Table 13: List of screened participants with reason for exclusion 
Patient-ID 
Year of 
Birth 
Sample received Comment 
Included in final 
analysis 
Reason for 
exclusion 
A-008 1942 15.06.2010 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
A-009 1963 30.06.2010 - Yes  
A-010 1962 02.07.2010 - Yes  
A-011 1954 02.07.2010 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
A-013 1953 21.07.2010 cM1 (liver) No Metastatic disease 
A-014 1968 26.08.2010 - Yes  
A-015 1949 30.08.2010 - No 
Insuff icient number of 
epithelial cells 
A-016 1961 21.09.2010 - Yes  
A-017 1967 27.10.2010 - Yes  
A-018 1972 25.11.2010  Yes  
A-019 1972 15.12.2010 - No Technical diff iculties 
A-020 1979 16.02.2011 - Yes  
A-021 1949 10.03.2011 - Yes  
A-022 1986 24.05.2011 - Yes  
A-023 1969 22.06.2011 - Yes  
A-024 1967 30.06.2011 - Yes  
A-025 1956 08.09.2011 - Yes  
A-026 1951 11.10.2011 - Yes  
A-027 1973 28.10.2011 - Yes  
A-028 1938 15.12.2011 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
A-029 1969 29.12.2011 Bilateral tumor  Yes  
A-030 Unknown 09.03.2012 - No 
Clinical data not 
available 
A-031 1964 02.08.2012 - Yes  
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A-032 1969 22.08.2012 - No 
Cellular metabolic 
activity under 
threshold 
A-033 1948 02.10.2012 - Yes  
A-034 1948 21.11.2012 - Yes  
B-002 1956 23.11.2010 cM1 (liver) No Metastatic disease 
B-003 1939 30.11.2010 - No 
No neoadjuvant drug 
treatment 
B-004 1946 21.01.2011 
cM1 (bone), 
simultaneous renal cell 
carcinoma 
No 
No neoadjuvant drug 
treatment 
B-005 1964 23.05.2011 - No 
No neoadjuvant drug 
treatment 
B-006 1937 16.06.2011 - No 
No neoadjuvant drug 
treatment 
B-007 1934 25.08.2011 - No 
Insuff icient number of 
epithelial cells 
B-008 1960 13.10.2011 - No 
No neoadjuvant drug 
treatment 
B-009 1927 08.03.2012 - No 
No neoadjuvant drug 
treatment 
C-004 1956 25.01.2011 Bilateral tumor  Yes  
C-005 1973 01.02.2011 Histologically no tumor No No malignant tumor 
C-006 1953 09.02.2011 Loss to follow-up No 
Clinical data not 
available 
C-007 1953 25.08.2011 - No 
No neoadjuvant drug 
treatment 
C-008 1970 26.08.2011 - No 
Previous malignant 
disease 
C-009 1935 30.08.2011 - No 
No neoadjuvant drug 
treatment 
C-010 1937 02.09.2011 - No 
Previous malignant 
disease 
C-011 1932 23.09.2011 - No 
No neoadjuvant drug 
treatment 
C-012 1965 07.10.2011 Bilateral tumor  No 
Previous malignant 
disease 
C-013 1948 07.10.2011 - No 
Insuff icient number of 
epithelial cells 
C-016 1990 14.11.2011 - Yes  
C-017 1949 17.11.2011 - No 
No neoadjuvant drug 
treatment 
C-018 1950 20.12.2011 - Yes  
C-019 1939 25.01.2012 
End of chemotherapy 
after 4 cycles 
Yes  
C-020 1937 17.02.2012 - No 
No neoadjuvant drug 
treatment 
C-021 1947 27.03.2012 - Yes  
C-022 1968 29.03.2012 - Yes  
C-023 1948 05.04.2012 
End of chemotherapy 
after 2 cycles due to 
side effects 
Yes  
C-024 1969 13.04.2012 - No 
No neoadjuvant drug 
treatment 
C-025 1974 21.06.2012 - Yes  
C-026 1957 28.06.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
C-027 1983 08.08.2012 - Yes  
D-002 1970 08.06.2010 - Yes  
D-003 1958 17.06.2010 - No 
No neoadjuvant drug 
treatment 
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D-004 1961 18.06.2010 
End of chemotherapy 
after 7 cycles due to 
progressive disease 
Yes  
D-005 1959 25.06.2010 
Bilateral tumor; 
M1(liver) 
No 
Previous malignant 
disease 
D-006 1944 01.07.2010 
Previous diagnosis of 
breast cancer in 2003 
No 
Previous malignant 
disease 
D-007 1939 05.07.2010 
Previous diagnosis of 
breast cancer in 1991 
No 
Previous malignant 
disease 
D-008 1965 14.07.2010 - No 
No neoadjuvant drug 
treatment 
D-009 1960 20.07.2010 - No 
No neoadjuvant drug 
treatment 
D-010 1972 16.09.2010 - No 
No neoadjuvant drug 
treatment 
D-011 1955 27.12.2010 Bilateral tumor  No 
No neoadjuvant drug 
treatment 
D-012 1966 01.09.2011 - No 
Insuff icient number of 
epithelial cells 
D-013 1955 05.09.2011 - No 
No neoadjuvant drug 
treatment 
D-014 1968 08.09.2011 - No 
No neoadjuvant drug 
treatment 
D-019 1951 23.12.2011 Bilateral tumor  No 
No neoadjuvant drug 
treatment 
D-020 1969 20.01.2012 
M1 (central nervous 
system) 
No Metastatic disease 
D-021 1969 15.02.2012 - No 
No neoadjuvant drug 
treatment 
D-022 1938 06.03.2012 - Yes  
D-023 1960 07.03.2012 - Yes  
D-024 1971 25.04.2012 
Treatment in Russia, 
loss to follow up 
No 
Clinical data not 
available 
D-025 1969 26.04.2012 - No 
No neoadjuvant drug 
treatment 
D-027 1948 18.06.2012 
Bilateral tumor; M1 
(Spleen, lung, liver, 
adrenal gland, bone) 
No Metastatic disease 
D-015 1927 14.10.2011 - No, 
No neoadjuvant drug 
treatment 
D-016 1959 14.10.2011 - No 
Clinical data not 
available 
D-017 1938 28.10.2011 - Yes  
D-018 1946 22.11.2011 cM1 No Metastatic disease 
E-001 Unknown 26.07.2010 Histologically no tumor No 
Clinical data not 
available 
E-002 1964 29.10.2010 - No 
Insuff icient number of 
epithelial cells 
E-003 1941 10.11.2010 - No Yeast contamination 
E-004 1966 08.12.2010 - No Cell viability < 50% 
E-005 1965 15.12.2010 - Yes  
E-006 1980 11.02.2011 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
E-007 1965 11.03.2011 - Yes  
E-008 1948 23.03.2011 - No Yeast contamination 
E-009 1958 30.08.2011 - Yes  
E-010 1954 04.01.2012 - Yes  
E-011 1968 31.01.2012 - No 
Insuff icient number of 
epithelial cells 
E-012 1953 21.03.2012 - No 
Cellular metabolic 
activity under 
threshold 
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E-013 1952 30.03.2012 - Yes  
E-014 1954 19.06.2012 - No 
Cellular metabolic 
activity under 
threshold 
E-015 1947 01.08.2012 - Yes  
E-016 1962 17.10.2012 - No 
Insuff icient number of 
epithelial cells 
E-017 1948 20.12.2012 - Yes  
F-001 1970 17.12.2011 - Yes  
F-002 1964 28.01.2012 - No 
Insuff icient number of 
epithelial cells 
F-003 1957 18.02.2012 - Yes  
F-004 1980 18.02.2012 - No 
Cellular metabolic 
activity under 
threshold 
F-005 1965 03.03.2012 - Yes  
F-006 1956 08.03.2012 - No  
F-007 1959 24.04.2012 - No 
Cellular metabolic 
activity under 
threshold 
F-009 1965 14.06.2012 cM1 No 
No neoadjuvant drug 
treatment 
F-008 1981 15.06.2012 - Yes  
F-010 1961 12.07.2012 - Yes  
F-011 1961 26.07.2012 - No 
Cellular metabolic 
activity under 
threshold 
F-012 1963 18.08.2012 - Yes  
F-013 1956 18.08.2012 - No 
Cellular metabolic 
activity under 
threshold 
F-014 1975 30.08.2012 - Yes  
F-015 1970 07.09.2012 - Yes  
G-001 1962 22.12.2011 - Yes  
G-002 Unknown 29.12.2011 - No 
Cellular metabolic 
activity under 
threshold 
G-003 1950 11.01.2012 - Yes  
G-004 1964 28.01.2012 - Yes  
G-005 1958 08.02.2012 
Bilateral tumor; end of 
chemotherapy after 4 
cycles 
No 
Clinical treatment 
does not correspond 
to in vitro treatment 
G-006 1967 04.04.2012 - Yes  
G-007 1955 18.04.2012 - No 
Cellular metabolic 
activity under 
threshold 
G-008 1966 12.05.2012 - No 
Cellular metabolic 
activity under 
threshold 
G-009 1948 05.07.2012 - Yes  
H-001 1969 11.01.2012 - No 
No neoadjuvant drug 
treatment 
H-002 1961 12.05.2012 - No 
Insuff icient number of 
epithelial cells 
H-003 1947 29.06.2012 - No 
Insuff icient number of 
epithelial cells 
H-004 1950 22.08.2012 - No 
Insuff icient number of 
epithelial cells 
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H-005 1954 05.09.2012 - No 
Cellular metabolic 
activity under 
threshold 
I-001 1948 10.05.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
I-002 1961 28.08.2012 - Yes  
I-003 1950 29.08.2012 - Yes  
I-004 1952 08.09.2012 - No 
Cellular metabolic 
activity under 
threshold 
I-005 1965 15.09.2012 - No 
Cellular metabolic 
activity under 
threshold 
J-001 1966 10.12.2011 - No 
No neoadjuvant drug 
treatment 
J-002 1968 14.01.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
J-003 1954 14.01.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
J-004 1966 17.01.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
J-005 1931 07.02.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
J-006 1951 08.02.2012 - No 
No neoadjuvant drug 
treatment 
J-007 1942 01.03.2012 - No 
Cellular metabolic 
activity under 
threshold 
J-008 1944 06.03.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
J-009 1971 14.03.2012 - No 
Clinical data not 
available 
J-010 1967 15.03.2012 - No 
Cellular metabolic 
activity under 
threshold 
J-011 1932 29.03.2012 - No 
No neoadjuvant drug 
treatment 
J-012 1970 04.04.2012 - Yes  
J-013 1976 13.06.2012 - No 
Insuff icient number of 
epithelial cells 
J-014 1950 20.06.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
J-015 1928 01.09.2012 - No 
No neoadjuvant drug 
treatment 
K-001 1930 17.12.2011 - No 
No neoadjuvant drug 
treatment 
K-002 1974 04.01.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-003 1957 13.01.2012 - No 
Previous malignant 
disease 
K-004 1941 10.02.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
K-005 1966 16.02.2012 - No 
Cellular metabolic 
activity under 
threshold 
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K-006 1960 21.02.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
K-007 1930 22.02.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-008 1966 31.03.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-009 1937 03.04.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
K-010 1958 05.04.2012 - No 
Insuff icient number of 
epithelial cells 
K-011 1966 20.04.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
K-012 1968 24.04.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-013 le 1936 27.04.2012 Bilateral tumor  No 
Cellular metabolic 
activity under 
threshold 
K-013 re 1936 27.04.2012 Bilateral tumor  Yes  
K-014 1944 01.05.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-015 1959 09.05.2012 - No Cell viability < 50% 
K-016 1969 12.06.2012 - Yes  
K-017 1972 20.06.2012 - Yes  
K-018 1945 23.06.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
K-019 1966 06.07.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
K-020 1935 14.07.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-021 1956 19.07.2012 - Yes  
K-022 1931 27.07.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-023 1942 17.08.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-024 1972 22.08.2012 - No 
Cellular metabolic 
activity under 
threshold 
K-025 1934 05.09.2012 - Yes  
K-026 1940 12.09.2012 - Yes  
K-027 1936 15.09.2012 - Yes  
K-028 1968 15.09.2012 - Yes  
K-029 1971 19.09.2012 - Yes  
L-001 1975 09.12.2011 Histologically no tumor No No malignant tumor 
L-002 1963 22.12.2011 - Yes  
L-003 1949 23.12.2011 - No Technical diff iculties 
L-004 1974 27.01.2012 - Yes  
L-005 1966 07.03.2012 
Sw itch of 
chemotherapy regimen 
after 4 cycles 
No Technical diff iculties 
L-006 1951 08.03.2012 - No Cell viability < 50% 
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L-007 1969 27.03.2012 - Yes  
L-008 1967 04.04.2012 - No 
Cellular metabolic 
activity under 
threshold 
L-009 1970 14.04.2012 - Yes  
L-010 1953 19.04.2012 - No 
Cellular metabolic 
activity under 
threshold 
L-011 1954 21.04.2012 - Yes  
L-012 1958 25.05.2012 - No 
Cellular metabolic 
activity under 
threshold 
L-013 1965 05.06.2012 - Yes  
L-014 1955 19.06.2012 - No 
Cellular metabolic 
activity under 
threshold 
L-015 1963 19.06.2012 - No 
Cellular metabolic 
activity under 
threshold 
L-016 1956 19.06.2012 - Yes  
L-017 1974 11.07.2012 - Yes  
L-018 1968 20.07.2012 - Yes  
L-019 1960 30.08.2012 - Yes  
L-020 1964 31.08.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
L-021 1964 31.08.2012 - Yes  
M-001 1956 15.05.2012 - Yes  
M-002 1946 23.06.2012 - Yes  
M-003 1949 12.07.2012 - Yes  
M-004 1960 19.07.2012 - No 
Clinical treatment 
does not correspond 
to in vitro treatment 
 
 
Table 14: Comparison of clinical criteria for included, enrolled, and excluded patient cohorts   
 Enrolled Excluded All Patients 
Characteristic N % Mean N % Mean N % Mean 
Age at diagnosis 78  51 124  56 202  54 
<= 40 13 16.7  9 7.3  22 10.90  
40 - 55 38 48.7  55 44.7  93 46.30  
> 55 27 34.6  59 48.0  86 42.80  
No data available 0 -  1 -  1 -  
Age grouped by median          
<= 50 43 55.1  46 37.4  89 44.30  
> 50 35 44.9  77 62.6  112 55.70  
No data available 0 -  1 -  1 -  
Grading at biopsy          
1 2 2.6  3 2.6  5 2.60  
2 39 50  61 53.5  100 52.60  
3 35 44.9  50 43.9  85 44.70  
No data available 2 2.6  10 -  12 -  
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T-Stadium          
cT1a 0 -  2 1.8  2 1.10  
cT1b 0 -  1 0.9  1 0.50  
cT1c 11 14.1  14 12.6  25 13.30  
cT2 45 57.7  68 61.3  113 60.10  
cT3 17 21.8  17 15.3  34 18.10  
cT4 4 5.1  9 8.1  13 6.90  
No data available 1 1.3  13   9   
Nodal status          
cN+ 42 53.8  51 45.9  93 49.50  
cN- 35 44.9  60 54.1  95 50.50  
No data available 1 1.3  13   14   
UICC           
IA 6 7.7  9 8.3  15 8.20  
IIA 30 38.5  44 40.7  74 40.20  
IIB 21 26.9  33 30.6  54 29.30  
IIIA 15 19.2  7 6.5  22 12.00  
IIIB 4 5.1  7 6.5  11 6.00  
IIIC 0 -  1 0.9  1 0.50  
IV 0 -  7 6.5  7 3.80  
No data available 2 2.6  16   18   
Estrogen receptor (ER)           
Pos 49 62.8  75 72.1  124 69.30  
Neg 26 33.3  29 27.9  55 30.70  
No data available 3 3.8  20   23   
Progesterone receptor (PR)          
Pos 41 52.6  66 63.5  107 59.10  
Neg 36 46.2  38 30.6  74 40.90  
No data available 1 1.3  20   21   
HER2          
Pos 16 20.5  29 26.1  45 24.20  
Neg 59 75.6  82 73.9  141 75.80  
Unknown 3 3.8  13   16   
ER/PR Status Biopsy          
ER+/PR+ 39 50  64 61.5  103 57.50  
ER+/PR-/Unknow n 10 12.8  11 10.6  21 11.70  
ER-/unknow n/PR+ 2 2.6  2 1.6  4 2.20  
ER-/PR-  24 30.8  27 26.0  51 28.50  
No data available 3 3.8  20   23   
Histology          
Invasive ductal 53 67.9  76 65  129 66.20  
Invasive ductal + DCIS 7 9.0  18 15.4  25 12.80  
Invasive lobular 8 10.3  15 12.8  23 11.80  
Invasive ductal/invasive lobular 1 1.3  0 -  1 0.50  
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Medullary 1 1.3  1 0.9  2 1.00  
Inflammatory 1 1.3  3 2.6  4 2.10  
Other 7 9.0  4 3.4  11 5.60  
No data available 0   7   7   
Ki67 Biopsy [%] 53  38.0      33.61 
<14% 10 12.8  15 25.4 29.97 25 22.30  
>= 14% 43 55.1  44 74.6  87 77.70  
Unknown 25 32.1  65   90   
Clinical Tumor Size at Presentation, largest 
diameter [cm] 
         
MRI 36  3.62   3.5   3.56 
Mammography 57  3.19   3.1   3.13 
Sonography 69  3.01   2.94   2.97 
Molecular Subtype Biopsy          
Luminal A 28 35.9  42 42.4  70 41.40  
Luminal B/HER2 neg 9 11.5  12 12.1  21 12.40  
Luminal B/HER pos 10 12.8  20 20.2  30 14.90  
HER2 enriched 5 6.4  6 6.1  11 5.40  
Triple neg 18 23.1  19 19.2  37 18.30  
Unknown 8 10.3  25   33   
Drug treatment          
Anthracycline -> Taxane 48 61.5     61 72.60  
TAC 8 10.3        
TCH 7 9.0     7 8.30  
Anthracycline -> Taxane + Other drug (Eve, H) 10 12.8     1 1.20  
Anthracycline -> Taxane + Carboplatin 3 3.9     3 3.60  
EC only 2 2.6     2 2.40  
pCR (ypT0/ypN0)    28.2        
Yes 22 28.2        
No 56 71.8        
Unknown 0 -        
Grade of regression          
0 2 2.6        
1 38 48.7        
2 6 7.7        
3 3 3.8        
4 21 26.9        
Unknown 8 10.3        
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Surgical Therapy          
BCS Yes 54 69.2        
No 22 28.2        
Unknown 2 2.6        
Residual Tumor Size          
ypT0 19 24.4        
ypTis 4 5.1        
ypT1 26 33.3        
ypT2 16 20.5        
ypT3 8 10.3        
ypT4 1 1.3        
Unknown/ ypTx 4 5.1        
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Anthracycline/taxane-based chemotherapy
Anthracycline-based chemotherapy
Trastuzumab-based drug therapy
Treatment adherence
Reduced dose
Premature discontinuation of drug therapy
Change in drug regimen
Clinical tumor size midway chemotherapy, US
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Clinical response
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Change in CEA, beginning - end chemotherapy
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No. of biopsy cylinders received
Weight tissue sample 
Weight per biopsy cylinder 
No. of cells per mg tissue received
No. of days TM expired
Time difference biopsy - begin lab procedure 
Mechanical isolation 
Enzymatic isolation 
Total time isolation procedure 
Total enzyme added 
Total No. of vital cells after filtration
Cell viability 
No. of cells per spheroid
No. of cells per spheroid groups 
No. of spheroids generated
No. of technical replicates
Incubation of generated spheroids [h]
Mucous exterior lining [Yes vs No]
Cell density before treatment
Same-day preparation cytostatic compounds 
Time between compounds preparation and in vitro 
treatment 
No. of treatment options
Visible morphological changes after treatment 
Mucous exterior lining following treatment 
Readout method 
Incubation with MTS reagent 
Incubation with ATP reagent 
Metabolic activity mean solvent control 
Metabolic activity mean solvent control per cell 
Cell survival 
Cutoff cell survival 
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Age at diagnosis
Age groups
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Clinical tumor size at diagnosis, CT-Thorax
Clinical tumor size at diagnosis, MRT 
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Clinical tumor size at diagnosis, Ultrasound
Tumor stage 
Tumor stage groups
Nodal status
UICC
Effected side
Centricity/focality
Histologic type
Grading
ER 
PR 
ER status 
PR status 
Hormone receptor status 
HER2 score 
HER2 status 
HR/HER2
Ki67
Ki67  cutoff
CEA
CA 15-3
CEA status
CA 15-3 status
M
e
a
n
 c
e
ll s
u
rv
iv
a
l E
C
0
.5
8
2
0
.7
2
4
0
.0
3
1
0
.2
6
4
0
.0
4
5
0
.4
8
7
0
.7
2
7
0
.5
4
1
0
.5
5
5
0
.2
4
8
0
.8
08
0
.2
7
4
0
.0
0
7
0
.1
5
8
0
.5
8
8
0
.3
2
7
0
.1
7
2
0
.1
1
4
0
.3
0
4
0
.0
1
4
0
.3
0
4
0
.0
0
8
0
.0
0
0
0
.0
1
9
0
.2
5
6
0
.1
0
5
0
.4
4
1
0
.1
4
8
0
.0
0
4
0
.3
68
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l E
C
0
.0
4
9
0
.0
4
7
0
.8
3
9
0
.7
8
1
0
.1
0
1
0
.0
0
7
0
.2
5
8
0
.4
5
8
0
.9
3
1
0
.6
6
6
0
.0
81
0
.6
8
7
0
.8
3
4
0
.7
2
8
0
.4
4
0
0
.0
6
5
0
.8
6
8
0
.3
6
5
0
.7
0
3
0
.5
9
7
0
.7
0
3
0
.3
6
5
0
.4
8
6
0
.7
3
1
0
.9
3
4
0
.4
3
0
0
.7
0
3
0
.6
9
1
0
.4
7
4
0
.8
21
M
e
a
n
 c
e
ll s
u
rv
iv
a
l E
C
D
0
.1
6
2
0
.3
3
3
0
.3
2
4
N
A
N
A
0
.3
5
7
0
.3
5
3
0
.5
8
1
0
.5
7
2
0
.5
1
3
0
.2
23
0
.4
7
3
0
.6
4
1
0
.6
1
3
N
A
0
.5
2
0
0
.3
1
7
0
.2
8
6
0
.6
8
4
0
.5
2
0
N
A
0
.3
3
3
N
A
0
.5
6
2
0
.2
0
5
0
.5
9
0
0
.8
9
3
0
.5
8
3
0
.5
2
4
0
.9
02
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l E
C
D
0
.6
4
4
0
.8
9
9
0
.2
3
6
N
A
N
A
0
.4
2
6
0
.8
6
9
0
.6
5
7
0
.3
1
0
N
A
0
.6
66
0
.1
1
6
0
.8
4
4
N
A
N
A
N
A
0
.4
3
4
0
.8
5
9
N
A
N
A
N
A
0
.4
1
6
N
A
N
A
0
.1
0
3
N
A
0
.0
9
2
0
.0
9
3
N
A
0
.1
33
M
e
a
n
 c
e
ll s
u
rv
iv
a
l E
C
-T
ra
s
tu
z
u
m
a
b
0
.8
3
7
0
.8
3
9
0
.2
4
2
0
.3
6
5
N
A
0
.6
3
6
0
.4
4
4
0
.1
7
3
0
.7
6
7
N
A
0
.1
0
.2
6
2
0
.3
2
7
0
.6
9
4
N
A
0
.2
2
3
0
.5
3
9
0
.5
0
9
0
.7
1
4
0
.4
4
6
0
.7
1
4
0
.4
3
3
N
A
0
.9
9
9
0
.7
9
2
N
A
0
.3
1
7
0
.0
0
4
N
A
N
A
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l E
C
-T
ra
s
tu
z
u
m
a
b
0
.3
5
6
0
.5
9
4
0
.9
5
2
0
.5
2
6
N
A
0
.1
0
3
0
.5
2
3
0
.0
6
7
0
.5
3
7
N
A
0
.1
74
0
.4
4
3
0
.1
4
4
0
.4
9
8
N
A
0
.3
6
0
0
.1
5
7
0
.1
6
8
0
.2
3
9
0
.1
4
6
0
.5
7
2
0
.8
9
4
N
A
0
.5
1
0
1
.0
0
0
N
A
0
.3
5
2
0
.0
1
7
N
A
N
A
M
e
a
n
 c
e
ll s
u
rv
iv
a
l F
E
C
0
.0
6
1
0
.0
7
4
0
.7
4
0
0
.8
5
2
0
.9
5
9
0
.6
2
2
0
.4
7
6
0
.5
1
4
0
.0
5
2
0
.0
8
4
0
.0
2
0
.0
9
2
0
.8
6
0
0
.8
6
3
N
A
0
.7
5
8
0
.5
5
5
0
.2
4
5
0
.4
4
4
0
.1
9
7
0
.4
4
4
0
.8
1
2
N
A
0
.5
8
8
0
.8
5
3
0
.4
9
9
0
.7
2
5
0
.0
3
1
N
A
N
A
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l F
E
C
0
.9
0
3
0
.4
0
7
0
.8
0
2
0
.6
5
2
0
.6
6
5
0
.1
6
8
0
.0
4
2
0
.0
1
1
0
.0
0
4
0
.0
0
0
0
.2
32
0
.0
0
9
0
.6
8
7
0
.9
8
9
N
A
0
.3
1
3
0
.9
7
3
0
.7
7
9
0
.7
0
2
0
.9
5
4
0
.7
0
2
0
.8
0
5
N
A
0
.8
6
1
0
.7
6
6
0
.6
7
0
0
.6
4
9
0
.6
1
6
N
A
N
A
M
e
a
n
 c
e
ll s
u
rv
iv
a
l D
o
c
A
C
0
.5
0
5
0
.5
0
7
0
.6
5
2
0
.9
2
5
N
A
0
.2
8
6
0
.8
0
7
0
.9
9
0
0
.5
9
1
0
.6
8
5
0
.3
24
0
.4
9
4
0
.9
8
3
0
.0
4
4
N
A
N
A
0
.1
9
2
0
.2
4
1
0
.0
2
5
0
.2
3
4
0
.2
3
4
0
.3
1
0
N
A
0
.1
1
1
0
.1
9
2
N
A
N
A
N
A
N
A
N
A
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l D
o
c
A
C
0
.1
9
4
0
.1
4
1
0
.3
7
4
0
.5
3
6
N
A
0
.7
7
6
0
.1
9
8
0
.1
4
9
0
.4
0
5
0
.5
7
4
0
.7
62
0
.5
7
3
0
.6
5
0
0
.4
9
8
N
A
N
A
0
.0
0
2
0
.0
0
3
0
.5
0
6
0
.4
0
0
0
.4
0
0
0
.0
0
1
N
A
0
.2
1
6
0
.8
3
3
N
A
N
A
N
A
N
A
N
A
M
e
a
n
 c
e
ll s
u
rv
iv
a
l T
C
b
H
0
.7
2
0
0
.9
8
4
0
.6
7
9
0
.9
0
1
N
A
0
.5
9
3
0
.2
8
1
0
.2
6
8
0
.4
4
9
N
A
0
.9
67
0
.0
7
4
0
.3
3
2
0
.4
5
3
N
A
0
.6
6
1
0
.2
7
5
0
.4
0
2
0
.3
7
1
0
.3
5
9
0
.3
7
1
0
.4
5
2
0
.2
1
7
0
.4
8
3
0
.1
2
4
N
A
0
.2
4
0
0
.1
7
4
N
A
N
A
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l T
C
b
H
0
.0
7
7
0
.2
2
4
0
.6
9
8
0
.7
0
6
N
A
0
.4
3
1
0
.0
0
7
0
.2
8
3
0
.3
3
5
N
A
0
.2
55
0
.8
6
8
0
.5
1
8
0
.5
8
3
N
A
0
.1
6
2
0
.4
9
1
0
.5
4
2
0
.4
8
7
0
.5
1
0
0
.4
8
7
0
.5
6
3
0
.2
7
0
0
.6
2
5
0
.5
8
2
N
A
0
.0
5
4
0
.4
6
7
N
A
N
A
M
e
a
n
 c
e
ll s
u
rv
iv
a
l D
o
c
 
0
.6
6
4
0
.8
1
2
0
.8
8
8
0
.1
4
5
0
.8
3
0
0
.7
0
8
0
.5
5
8
0
.7
0
3
0
.0
3
5
0
.0
9
0
0
.3
4
0
.0
4
9
0
.3
6
6
0
.9
4
2
0
.4
3
4
0
.5
0
6
0
.9
2
6
0
.9
4
9
0
.5
3
8
0
.8
4
3
0
.5
3
8
0
.5
3
3
N
A
0
.9
2
1
0
.2
1
1
0
.2
4
6
0
.7
7
0
0
.3
3
4
N
A
0
.1
98
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l D
o
c
 
0
.1
6
3
0
.2
0
3
0
.6
5
2
0
.6
6
8
0
.9
7
9
0
.4
5
2
0
.8
1
1
0
.4
7
7
0
.0
3
6
0
.1
5
4
0
.5
24
0
.0
7
2
0
.9
7
6
0
.4
0
5
0
.8
4
3
0
.6
9
4
0
.2
7
5
0
.2
1
2
0
.2
3
5
0
.2
5
9
0
.2
3
5
0
.4
8
8
N
A
0
.2
5
0
0
.4
3
4
0
.4
9
4
0
.2
8
7
0
.5
0
1
N
A
0
.5
96
M
e
a
n
 c
e
ll s
u
rv
iv
a
l P
a
c
0
.6
7
2
0
.4
5
6
0
.8
6
9
0
.5
6
2
N
A
0
.3
7
0
0
.0
1
2
0
.4
1
4
0
.3
8
1
0
.2
4
0
0
.7
96
0
.6
3
4
0
.5
3
2
0
.9
9
6
N
A
0
.6
7
0
0
.8
8
7
0
.3
4
7
0
.5
5
2
0
.6
3
5
0
.5
5
2
0
.2
2
8
0
.0
3
4
0
.0
9
7
0
.3
4
0
0
.5
0
8
0
.3
0
6
0
.3
4
6
N
A
N
A
S
td
v
 m
e
a
n
 c
e
ll s
u
rv
iv
a
l P
a
c
0
.3
7
0
0
.0
7
2
0
.2
0
9
0
.2
0
6
N
A
0
.9
1
8
0
.6
7
7
0
.5
8
0
0
.8
9
8
0
.7
0
4
0
.6
4
0
.9
2
9
0
.8
2
1
0
.1
2
5
N
A
0
.3
5
4
0
.1
6
6
0
.1
0
9
0
.6
0
6
0
.0
0
4
0
.6
0
6
0
.4
3
3
0
.2
7
7
0
.6
7
6
0
.2
8
1
0
.0
2
7
0
.7
6
1
0
.2
3
2
N
A
N
A
B
a
s
e
lin
e
 c
lin
ic
a
l d
a
ta
In vitro treatment cont.
Appendix 
 
  
Page xxvi of xxvi 
 
 
 
Anthracycline/taxane-based chemotherapy
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In vitro treatment cont.
